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Soft tissue tumors are one of the most commonly observed tumors, which is mostly due 
to the high incidence of benign soft tissue tumors [1]. On the contrary, malignant or locally 
aggressive soft tissue tumors, also called soft tissue sarcomas (STS), are rare and account 
only for approximately 1% of all adult cancers, which is equivalent to 650-700 new patients 
annually in the Netherlands [2, 3]. STS is a heterogeneous disease of mesenchymal origin, 
consisting of over 50 different subtypes with each subtype harboring its own biological 
and clinical features [1]. The most common subtypes are gastrointestinal stromal tumors 
(GISTs), leiomyosarcomas and liposarcomas. Since STS can originate from all types of soft 
tissue, such as muscles, fat, tendons, blood vessels and nerve sheaths, they can arise at 
any site of the body, but the most common localizations are the extremity, the abdomen/
retroperitoneum and the trunk. It is mainly a disease of the elderly, with a median age of 
65 years at time of diagnosis, although some STS subtypes have a peak incidence during 
childhood (rhabdomyosarcoma) or adolescence (synovial sarcoma) [1]. 
Etiology
Most STS arise de novo and have an unknown etiology. Only in rare cases a genetic or 
environmental cause can be found. Examples include radiation-associated (angio)sarcoma, 
human herpes virus 8-induced or HIV/AIDS-associated Kaposi sarcoma, neurofibromatosis-
type 1-associated malignant peripheral nerve sheath tumors and the Li-Fraumeni syndrome 
(TP53 germline mutation) [1, 4-8].
Diagnostic work-up
Most patients present with a painless and slowly growing mass, and therefore undergo 
imaging, depending on the tumor localization an MRI and/or CT scan. Given the importance 
of a correct diagnosis regarding treatment and prognosis, usually an imaging-guided biopsy is 
taken and examined by an expert pathologist, who uses morphology, immunohistochemistry 
and/or additional molecular diagnostic tests. The STS subtype will be categorized according 
the classification of the World Health Organization [1] and graded according to the French 
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system, based on 
tumor differentiation, mitotic count and tumor necrosis [9]. Additionally, a staging CT scan 
will be performed to check for metastatic disease. 
Treatment of soft tissue sarcoma
Currently, the treatment of STS is uniform for most of the different STS subtypes. Patients 
with localized disease are usually treated with surgery, optionally preceded or followed by 
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radiotherapy, isolated limb perfusion or systemic therapy [10]. Indications for neoadjuvant/
adjuvant treatment include a large tumor size, high tumor grade, inconvenient tumor 
localization and/or positive resection margins amongst others [10]. For certain STS 
subtypes, effective systemic therapy is available. For example imatinib for GIST patients and 
chemotherapy regimens for patients with small blue round cell sarcomas (e.g. embryonal 
rhabdomyosarcoma), but for most STS subtypes systemic treatment is not indicated in case 
of localized disease. 
With respect to the non-GIST, non-small blue cell sarcomas, approximately 10-15% 
of the patients present with metastatic disease at time of diagnosis [11] and up to 40% of 
the patients with initially localized disease will develop metastases over time [12]. For these 
patients cure is generally not possible anymore, and treatment with palliative intent remains. 
Only in selected cases with oligometastatic disease, for example in patients with a solitary 
(lung) metastasis, long-term survival can be achieved [13-16]. Despite the heterogeneity 
amongst the different STS subtypes in terms of biology and sensitivity to chemotherapy, first-
line treatment is similar for most STS subtypes, consisting of doxorubicin-based regimens 
[10]. Most patients receive doxorubicin monotherapy with a response rate of 10-15% and 
a median overall survival of 12-18 months [17-21]. For fit patients in need of a response, 
combination therapy with doxorubicin plus ifosfamide can be considered, prolonging 
the progression-free survival but not overall survival [17]. Recently, the combination of 
doxorubicin plus olaratumab was conditionally approved as first-line treatment, based on a 
phase II trial showing an improvement of 2.5 months in progression-free survival and almost 
a year in overall survival [18]. However, the phase III ANNOUNCE trial has failed to confirm 
the beneficial effect of the combination therapy compared to doxorubicin monotherapy 
[22]. As a consequence, the European Medicines Agency (EMA) has withdrawn its conditional 
marketing authorization.
In second-line treatment and beyond, a histology-driven/STS subtype-specific choice of 
treatment is becoming much more common. Examples include trabectedin in leiomyosarcoma 
and liposarcoma subtypes other than well-differentiated liposarcoma [23-25], eribulin in 
liposarcoma [26], pazopanib in non-adipocytic STS [27, 28], gemcitabine-based regimens 
in leiomyosarcoma [29, 30] or taxanes in angiosarcoma [31]. Additionally, a few promising 
agents in the pipeline are being explored in early phase clinical trials, such as regorafenib 
in non-adipocytic STS [32, 33] and therapies directed against the NY-ESO-1 antigen in 
synovial sarcoma and myxoid liposarcoma [34, 35]. Also immune checkpoint inhibitors are 
being investigated for their efficacy in various STS subtypes, including pembrolizumab [36], 





Liposarcoma is one of the most common STS subtypes, representing approximately 20% of 
all STS. These tumors are derived from lipoblasts/adipocytes, and can be divided into four 
major subtypes based on distinct morphological and genetic features: well-differentiated 
liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS) 
and pleomorphic liposarcoma (PLPS). A small part of liposarcomas cannot be further 
defined, resulting in a residual group of liposarcomas not otherwise specified (LPS NOS). 
The most common liposarcoma subtype is WDLPS, accounting for approximately 50% of 
all liposarcomas. It is a low-grade tumor with no metastatic potential, and – depending on 
tumor localization – is sometimes also called an atypical lipomatous tumor. It is molecularly 
characterized by amplification of 12q14-15, including the gene MDM2. In approximately 10% 
of the WDLPS, dedifferentiation into the more aggressive and high-grade DDLPS subtype 
occurs, thereby gaining the ability to metastasize. The remaining 90% of DDLPS arise de 
novo, are also characterized by amplification of 12q14-15 and are most frequently localized 
in the retroperitoneum. The third subtype, MLPS, accounts for approximately a third of all 
liposarcomas and is characterized by a translocation of t(12;16)(q13;p11), resulting in the FUS-
CHOP (also called FUS-DDIT3) fusion protein. Approximately a third of the MLPS patients will 
develop metastatic disease, which is related to the presence of a round cell component and 
thereby the grade of the tumor. PLPS is the rarest but also the most aggressive liposarcoma 
subtype, harboring complex karyotypic aberrations. Up to 50% of the patients with PLPS will 
develop metastases, resulting in a poor prognosis [1].
Outline of this thesis
Because of the rarity, complexity and heterogeneity of the disease, not only diagnosing and 
treating these patients can be difficult, but also conducting research is challenging. Items 
that have been investigated for other more common cancers are still unexplored in STS and 
knowledge of these tumors is lagging behind, resulting in many ‘gaps’ in the STS biology, 
pathophysiology, diagnosis and treatment. This thesis contains research on a variety of 
subjects on multiple aspects of STS; from translational basic research to clinical research, 
from localized STS to advanced/metastatic STS, from diagnosis to evaluation of the current 
treatment, and from one specific STS subtype to all STS subtypes.
The first part of this thesis concentrates on the molecular biology of different STS 
subtypes. A better understanding of the tumor biology and pathophysiology is key in the 
identification and development of new treatment strategies. In chapter 2, the genomic 
landscape of metastatic STS, and more specifically GIST and leiomyosarcomas, was unraveled 
by using whole genome sequencing, along with the identification of targetable features for 
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systemic treatment. In addition to genomic alterations, also microRNAs can greatly impact 
the behavior of tumors. In chapter 3, the role of two specific microRNAs, miR-26a and miR-
3913, and their effect on proliferation in liposarcoma (WDLPS and DDLPS) was explored. In 
the last chapter of this part, chapter 4, the biology of recurrent WDLPS was investigated 
on a microRNA and genome-wide DNA methylation level by comparing paired primary and 
recurrent WDLPS tumor samples.
The second part of this thesis focuses specifically on liposarcomas, one of the largest 
sarcoma subgroups, and the heterogeneity amongst these lipomatous tumors. Although 
clear differences in tumor size, depth and heterogeneity between benign lipomas and 
malignant WDLPS have been described in literature, in daily clinical practice there is a 
considerable overlap in these features. It can be difficult to distinguish between these two 
tumor types based on imaging, or even after biopsy based on morphology. In chapter 5, we 
developed a more objective and less invasive method to differentiate WDLPS from lipomas 
using a radiomics approach. Liposarcomas can arise at any site of the body, but are mainly 
localized in the extremity or retroperitoneum. In chapter 6, the impact of primary tumor 
location on recurrence and survival of patients with liposarcoma was assessed. The last 
chapter of part two, chapter 7, focuses on one specific liposarcoma location, the extremity, 
and investigated the differences in treatment, recurrence and survival between the different 
liposarcoma subtypes on this location.
In the third part of the thesis, the surgical treatment of localized STS is evaluated. 
Chapter 8 assessed the treatment of WDLPS in the extremity, suggesting that there might 
be overtreatment of these patients and introducing the concept of active surveillance in 
this patient subgroup. Because of the rarity and complexity, more evidence is becoming 
available indicating that centralization has beneficial effects on the outcomes of STS patients 
in the last two decades. In chapter 9, the centralization of STS surgery in the Netherlands 
was evaluated on a nationwide level, together with its effect on surgical outcomes and the 
survival of Dutch STS patients. In chapter 10, one of these surgical outcomes, the unplanned 
resections or so called 'whoops' resections, was further examined for its effect on other 
surgical outcomes, such as the status of the resection margins, number of re-resections, use 
of adjuvant radiotherapy and plastic surgery. 
In the last and fourth part of this thesis, the systemic treatment for advanced/
metastatic STS is evaluated. Chapter 11 gives a concise overview of the current systemic 
treatment and the promising developments in the pipeline for locally advanced or metastatic 
STS. In the last decade, two new agents have become available for patients with advanced 
STS who had failed on first-line doxorubicin-based treatment; pazopanib and trabectedin. In 
chapter 12, the impact of these changes in the treatment for STS patients with synchronous 




pazopanib-induced toxicity and survival in patients with advanced STS was investigated in 
chapter 13. This study was performed based on the hypothesis that the occurrence of 
toxicity is related to the anti-tumor activity of the drug, and that toxicity therefore can be 
used as a biomarker of efficacy.
As outlined by this introduction, the mosaic theme reflects on multiple aspects of 
this thesis: the heterogeneity within the STS spectrum, the diversity of the subjects in this 
thesis and the variety of outcomes of the different chapters. Furthermore, the mosaic is still 
incomplete and the gaps have to be filled in further, which is — hopefully — partly done by 
this thesis.
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Approximately one-third of the patients with well-differentiated liposarcoma (WDLPS) will 
develop a local recurrence. Not much is known about the molecular relationship between 
the primary tumor and the recurrent tumor, which is important to reveal potential drivers of 
recurrence. Here we investigated the biology of recurrent WDLPS by comparing paired primary 
and recurrent WDLPS using microRNA profiling and genome-wide DNA methylation analyses. 
In total, 27 paired primary and recurrent WDLPS formalin-fixed and paraffin-embedded 
tumor samples were collected. MicroRNA expression profiles were determined using 
TaqMan® Low Density Array (TLDA) cards. Genome-wide DNA methylation and differentially 
methylated regions (DMRs) were assessed by methylated DNA sequencing (MeD-seq). A 
supervised cluster analysis based on differentially expressed microRNAs between paired 
primary and recurrent WDLPS did not reveal a clear cluster pattern separating the primary 
from the recurrent tumors. The clustering was also not based on tumor localization, time to 
recurrence, age or status of the resection margins. Changes in DNA methylation between 
primary and recurrent tumors were extremely variable, and no consistent DNA methylation 
changes were found. As a result, a supervised clustering analysis based on DMRs between 
primary and recurrent tumors did not show a distinct cluster pattern based on any of the 
features. Subgroup analysis for tumors localized in the extremity or the retroperitoneum 
also did not yield a clear distinction between primary and recurrent WDLPS samples. In 
conclusion, microRNA expression profiles and DNA methylation profiles do not distinguish 
between primary and recurrent WDLPS and no putative common drivers could be identified.




Soft tissue sarcomas form a heterogeneous group of rare, mesenchymal tumors, of 
which liposarcomas comprise one of the largest subgroups [1]. Of all 100-120 patients 
diagnosed annually with liposarcoma in the Netherlands [2], the most common subtype 
is well-differentiated liposarcoma (WDLPS). WDLPS are mostly localized in the extremities 
and the retroperitoneum, and the prognosis of these patients is significantly better than 
those of patients with dedifferentiated liposarcoma [2]. However, WDLPS have a risk 
of dedifferentiation, potentially leading to metastatic disease with concurrent dismal 
prognosis. The rate of dedifferentiation in WDLPS in the extremities is extremely low, while 
in the retroperitoneum the risk of dedifferentiation is higher [1]. Molecularly, WDLPS are 
characterized by amplification – on a neochromosome – of the 12q14-15 region, which 
includes the genes MDM2 and CDK4 [1]. Treatment of WDLPS consists of complete surgical 
resection of the tumor, occasionally combined with neoadjuvant/adjuvant radiotherapy for 
tumors localized in the retroperitoneum. Unfortunately, approximately one-third of the 
patients will develop a local recurrence. Whereas the biology and behavior of primary WDLPS 
has been widely studied, there is a lack of insight in changes in microRNA expression and 
DNA methylation profiles between primary and recurrent WDLPS.
MicroRNAs have been proven to play a significant role in tumorigenesis [3-5], including 
in soft tissue sarcomas and more specifically liposarcomas [6-11]. So far, microRNA 
expression profiles have been used to differentiate between different liposarcoma subtypes 
[6-9, 12, 13] or to predict patient outcome [10, 11, 14, 15]. However, it is unclear whether 
primary WDLPS and their recurrent tumors can be distinguished by their microRNA profiles, 
which would suggest that microRNAs may be involved in the process of recurrence.
DNA methylation is an epigenetic process that fulfils an essential role in physiological and 
biological processes [16], and can be an important pathological driver in cancer [17, 18]. DNA 
methylation patterns can be utilized as biomarker [19, 20], to classify cancer (sub)types [21, 22] 
or to predict outcome [20, 23]. Genome-wide DNA methylation analysis used to be technically 
challenging and costly, but recently a new method was developed showing accurate genome-
wide analysis of CpG-methylation by using the DNA methylation-dependent restriction enzyme 
LpnPI and subsequent DNA sequencing of the restriction fragments [24]. This methylated 
DNA sequencing (MeD-seq) technology is cost-effective, accurate and reproducible with 
high coverage, suitable for high-throughput epigenetic profiling, even on FFPE material. For 
liposarcoma in general and recurrent WDLPS specifically, the knowledge of epigenetics is 
limited. Only a few studies report on the role of DNA methylation in liposarcomas, but mostly 
focus on one specific DNA region in more aggressive liposarcomas subtypes [25, 26]. Some 




induced silencing of miR-193b in dedifferentiated liposarcoma but not in WDLPS [27] and 
low expression of miR-193b, due to downregulation by promoter methylation, resulting at 
least partly from an increased expression of DNA methyltransferase-1 [28].
In this study, we molecularly compared primary and recurrent WDLPS at microRNA and 
DNA methylation level aiming to discover differences and/or similarities that give insight in 
the biology of recurrent WDLPS.
Materials and methods
Patients and samples
Patients with available tumor samples of a primary and matching first recurrent WDLPS who 
were treated with surgery only were included. The formalin-fixed and paraffin-embedded 
(FFPE) tissue blocks were obtained through PALGA, the Dutch nationwide pathology registry, 
and the pathology department of the Maria Skłodowska-Curie Institute-Oncology Center 
together with anonymized clinicopathological information. The resection margins were 
defined as R0 (microscopically negative margins), R1 (microscopically positive margins), R2 
(macroscopically positive margins) or Rx (unknown/not assessed). Although recurrence after 
R1/R2 resections can be considered as progressed WDLPS rather than truly recurrent WDLPS, 
these will be referred to as recurrent WDLPS as well. To calculate time to recurrence, the 
resection dates stated in the pathology reports were used. Each pair received an individual 
number with index numbers designating the primary tumor (.1) or recurrent tumor (.2).
The experimental protocol was reviewed and approved by the Medical Ethics 
Committee of the Erasmus MC (MEC-2016-213). All experimental procedures were 
performed in accordance with the relevant guidelines and regulations, including the Helsinki 
Declaration. The use of anonymous or coded left-over material for scientific purposes is 
part of the standard treatment agreement with patients and therefore additional informed 
consent was not asked.
RNA and DNA isolation
The archival tumor samples were examined by an expert pathologist to confirm the initial 
histopathological diagnosis and to determine the percentage of tumor cells. The diagnosis 
of WDLPS was based either on the presence of lipomatous cells with fibrous septa and 
spindle cells with hyperchromatic irregular nuclei, or on the amplification of the MDM2 gene 
using FISH in case morphological atypia was less conspicuous. Only sections containing 
approximately 100% tumor cells were used for isolation. Total RNA was isolated using the 
RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion/Life Technologies) and total DNA was 
isolated using the AllPrep® DNA/RNA FFPE kit (Qiagen), both according to manufacturer’s 
instructions.




MicroRNA expression was determined using TaqMan® Low Density Array (TLDA) cards (A 
card v2.0, B card v3.0, Applied Biosystems/Thermo Fisher Scientific). Megaplex™ RT Primers 
(Human Pool, pool A v2.1, pool B v3.0, Applied Biosystems/Thermo Fisher Scientific) were 
used for cDNA synthesis, followed by a standard pre-amplification protocol using Megaplex™ 
PreAmp Primers (Human Pool, pool A v2.1, pool B v3.0, Applied Biosystems/Thermo Fisher 
Scientific). The TLDA cards were analyzed using a 7900HT Real-Time PCR system (Applied 
Biosystems). The paired samples were processed in three batches for logistical and technical 
reasons, with each primary and its matching recurrent tumor being placed within the same 
batch.
Statistical analysis of microRNA profiling data
The expression of each microRNA in a sample was normalized to the median Ct-value of all 
detectable microRNAs in that sample. The normalized relative expression was subsequently 
calculated for each microRNA and log-transformed. Since the samples were processed in 
multiple batches, potential batch-effects were investigated using PCA-plots in R (S1 Fig). To 
correct for the observed batch-effects, ComBat was used [29]. Only microRNAs detected 
in at least 50% of the samples were included in the statistical analyses. A paired t-test was 
performed to identify microRNAs that were differentially expressed between paired primary 
and recurrent WDLPS samples. A two-sided p-value <0.05 was considered statistically 
significant. To adjust for multiple testing, a false discovery rate (FDR) of 0.25 was used. For 
all microRNA clustering analyses, the software program Cluster 3.0 was used followed by 
Java TreeView for visualization of the clustering results. The microRNA expression datasets 
generated and analyzed during the current study have been deposited to the Gene 
Expression Omnibus (GEO) data repository under submission number GSE137722.
MeD-seq sample preparations
MeD-seq analyses were essentially carried out as previously described [24]. DNA samples 
were digested by LpnPI (New England Biolabs). Stem-loop adapters were blunt-end ligated 
to repaired input DNA and amplified to include dual indexed barcodes using a high fidelity 
polymerase to generate an indexed Illumina NGS library. The amplified end product was 
purified on a Pippin HT system with 3% agarose gel cassettes (Sage Science). Multiplexed 
samples were sequenced on Illumina HiSeq2500 systems for single reads of 50bp according 






Data processing was carried out using specifically created scripts in Python. Raw fastq 
files were subjected to Illumina adaptor trimming and reads were filtered based on LpnPI 
restriction site occurrence between 13-17bp from either 5’ or 3’ end of the read and mapped 
to hg38 using bowtie2. Genome-wide individual LpnPI site scores were used to generate 
read count scores for the following annotated regions (www.ensembl.org): transcription start 
sites (TSS, 1 kb before and 1 kb after), CpG-islands and gene bodies (1kb after TSS till TES). 
Detection of differentially methylated regions (DMRs) was performed between two datasets 
using the χ2-test on read counts. Significance was called by either Bonferroni or FDR using 
the Benjamini-Hochberg procedure.
In addition, a genome-wide sliding window was used to detect sequentially 
differentially methylated LpnPI sites. Statistical significance was called between LpnPI sites 
in predetermined groups using the χ2-test. Neighboring significantly called LpnPI sites were 
binned and reported. Annotation of the overlap was reported for TSS, CpG-islands and gene 
body regions. DMR thresholds were based on LpnPI site count, DMR sizes (in bp) and fold 
changes of read counts as mentioned in the figure legends before performing hierarchical 
clustering. The differentially methylated datasets generated and analyzed during the current 




In total 27 pairs of patient samples were collected: 16 from the Erasmus MC Cancer Institute, 
9 from the Netherlands Cancer Institute, and 2 from the Maria Skłodowska-Curie Institute- 
Oncology Center. The extremity was the most common localization (N = 15), followed by the 
retroperitoneum (N = 8). Fourteen patients were female, 13 patients were male. The median 
age at time of diagnosis of the primary tumor was 59 years (interquartile range [IQR] 50–64) 
and the median time to recurrence was 3.7 years (IQR 1.9–6.5). In a number of patients (N = 8, 
29.6%), the status of the resection margins of the primary tumor was unknown, not assessed 
or not specified (Rx) in the pathology report. Of those patients of whom the status of the 
resection margins was reported, all primary resections were R0 or R1 resections, except for 
one patient (no. 17) with tumor localization in the esophagus, who underwent a R2 resection. 
Resections of the recurrent tumors resulted in 4 patients in R2 resections (Table 1).
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Table 1. Patient and tumor characteristics.




















































































































































DMR, differentially methylated region. †Age at time of surgery. ‡in years. 
MicroRNA profiling of paired primary–recurrent WDLPS samples
After correction for batch effect, samples 10.1 and 10.2 were excluded from further microRNA 
analyses (S1 Fig). First, an unsupervised hierarchical clustering analysis was performed to 
group the samples based on their microRNA expression profiles without prior knowledge of 
the origin of the sample (primary or recurrent). This clustering did not show a clear distinction 
between primary and recurrent WDLPS samples, neither a discriminative pattern based on 
tumor localization, time to recurrence, age nor the status of the resection margins could be 
observed (Fig 1A). In 9 of the 26 pairs, the primary and recurrent tumor samples clustered 
together (indicated by the red squares in the bottom row of the figure). All of these pairs had 
a short time to recurrence (before the median time to recurrence of 3.7 years), except one 
pair with a time to recurrence of 3.9 years and one pair with a time to recurrence of 6.1 years.
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▲Fig 1. Hierarchical clustering based on the microRNA expression levels of 26 paired primary 
and recurrent WDLPS tumor samples.
(A) Results of an unsupervised clustering analysis, depicted with time to recurrence, tumor localization, 
age and the$ status of the resection margins. Tumor pairs that cluster together in the same branch of 
the cluster tree are indicated with red boxes in the bottom line of the figure. (B) Results of a supervised 
clustering analysis based on the expression of 28 significant differentially expressed microRNAs (p<0.05, 
FDR<0.25), together with time to recurrence, tumor localization, age, the status of the resection margins 





Next, a supervised analysis was performed based on the expression levels of the 28 
significant differentially expressed microRNAs (p<0.05, FDR<0.25)(Fig 1B, S1 Table). The heat 
map indicated no clear discriminative pattern between primary and recurrent WDLPS, nor a 
distinction based on tumor localization, time to recurrence, age or the status of the resection 
margins. Five pairs clustered together, but clustering of these pairs also did not seem to be 
driven by one of the clinicopathological parameters.
Since microRNA expression is reported to be (partially) tissue specific [30], it may be 
influenced by the localization of the tumor. Therefore, additional sub-analyses for the two 
largest subgroups regarding tumor localization were performed: the extremity (N = 15 pairs, 
Fig 2A) and the retroperitoneum (N = 8 pairs, Fig 2B). For the tumor samples localized in 
the extremity, 68 microRNAs were significantly differentially expressed between primary and 
recurrent WDLPS of which 9 had an FDR<0.25 (Fig 2A, S2 Table). A cluster analysis based on 
the expression of these microRNAs did not seem to depend on primary/recurrence, time to 
recurrence, age or status of the resection margins. For the retroperitoneal WDLPS, only 14 
microRNAs were significantly differentially expressed, of which none had an FDR<0.25 (S2 
Table). Therefore, the microRNAs with p<0.05 without FDR correction were used to generate 
a heat map for this subgroup (Fig 2B). Again, no distinction between primary and recurrent 
samples was observed.
DNA methylation patterns of paired primary and recurrent WDLPS 
samples
When comparing differentially methylated DNA regions (DMRs) between individual primary 
and recurrent WDLPS pairs, it was noted that the DNA methylation differences were 
extremely variable between pairs (Table 1), although most of the pairs with a short time to 
recurrence (before median time to recurrence of 3.7 years) tended to have a lower number 
of DMRs. However, samples with a longer time to recurrence, for example sample pairs 23 
and 28, also displayed relative low numbers of DMRs, and sample pair 1, which had a short 
time to recurrence, exhibited the largest number of DMRs (Table 1). These DNA methylation 
differences seemed to be inconsistent among the individual pairs and could not be identified 
when comparing primary tumors versus recurrent tumors as a group. In the total group, only 
a relatively small number of 470 DMRs were identified, located on various chromosomes 
(S3 Table). When these DMRs were used for a supervised hierarchical clustering analysis, 
no clear clustering of the 27 primary and recurrent samples was observed (Fig 3). Likewise, 
no distinction was detected based on the clinicopathological parameters (Fig 3). Five of the 
pairs clustered together, but again across these samples no similarities in terms of time to 
recurrence, localization, or the status of the resection margins could be identified.
A relatively high number of the observed 470 DMRs was located at chromosome 12 (S3 













▲Fig 2. Hierarchical clustering based on the microRNA expression levels of paired primary 
and recurrent WDLPS tumor samples of the two main tumor localizations. Grey designates 
missing expression values. (A) Results of a supervised clustering analysis based on nine differentially 
expressed microRNAs (p<0.05, FDR<0.25; N = 15 pairs) between primary and recurrent WDLPS of the 
extremity. (B) Results of a supervised clustering analysis based on 14 differentially expressed microRNAs 
(p<0.05; N = 8 pairs) between primary and recurrent WDLPS of the retroperitoneum.
Table), including DMRs linked to the genes MDM2, CDK4 and MIR26A (S4 Table). These DMRs 
might indicate a possible difference in methylation of (regions of) chromosome 12 between 
primary and recurrent WDLPS, albeit the fold changes between the groups are relatively 




relatively unknown gene located on chr12q15, the same region as MDM2, encoding a non-
coding RNA. For MDM2, which is amplified in WDLPS, eight DMRs were found, with a fold 














≤ 3.7 years (median)
> 3.7 years
Age at time of diagnosis/surgery
≤ 50 years
51-60 years












































































































▲Fig 3. Hierarchical clustering based on differentially methylated DNA regions (DMRs) 
between primary and recurrent WDLPS samples. The heat map depicts a supervised clustering 
of the 27 paired WDLPS samples based on 455 differentially methylated regions (DMRs), excluding sex 
chromosomal regions (N = 15 DMRs), together with the clinicopathological features time to recurrence, 
tumor localization, age and the status of the resection margins.
Since DNA methylation patterns are also tissue-specific [24, 31, 32] and may be affected 
by tumor localization, subgroup analyses for the two main localizations were performed: 
the extremity (N = 15 pairs) and the retroperitoneum (N = 8 pairs). For the tumor samples 
located in the extremity, 631 DMRs were identified between primary and recurrent samples. 
Also here, no clear clustering pattern could be identified based on primary/recurrent WDLPS, 
time to recurrence or the status of the resection margins (Fig 4A). For the tumor samples 
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localized in the retroperitoneum, 1,071 DMRs were identified. To prevent the clustering 
from being blurred by background noise due to the higher number of DMRs, the clustering 
analysis for the retroperitoneal tumors was based on the DMRs with a fold change >2 (N = 53 
DMRs). Again, this did not lead to a clear distinction between primary and recurrent WDLPS 
samples (Fig 4B).
Discussion
To the best of our knowledge, this is the first paper comparing paired primary WDLPS 
samples to recurrent WDLPS samples at a molecular level. We aimed to gain more insight 
into the biology of (recurrent) WDLPS and thereby the process of recurrence. The finding 
that no clear distinction could be made between primary and recurrent WDPLS based on 
differentially expressed microRNAs or differentially methylated DNA regions suggests that 
there are no common alterations or that the alterations in microRNA expression and DNA 
methylation are very heterogeneous and variable between individual patients.
In the unsupervised microRNA clustering analysis, 7 of the 13 pairs (54%) with a short 
time to recurrence (before median time to recurrence) clustered together, compared to 2 of 
the 13 pairs (15%) with a longer time to recurrence. This might point towards a recurrence 
through the outgrowth of a residue in these patients, rather than a recurrence that originates 
from a single tumor cell. Alternatively, it might suggest that early recurrent tumors resemble 
each other more closely than late recurrent tumors, because they have had less time to 
change.
Of the 28 differentially expressed microRNAs, miR-1263 was the most significant 
differentially expressed microRNA, a relatively unknown microRNA whose role in cancer 
has not been established yet, followed by miR-885-5p. Upregulation of this microRNA has 
been linked to enhanced proliferation and migration [33], and the development of liver and 
lung metastases in colorectal cancer [34]. In contrast, miR-885-5p suppressed proliferation, 
migration and invasion in vitro in osteosarcoma cells, and was downregulated in osteosarcoma 
patients with low expression levels being associated with a poor prognosis [35]. In our study, 
miR-885-5p was downregulated in the recurrent tumors, possibly matching the findings in 
osteosarcoma with low levels of miR-885-5p being associated with more proliferation and 
a poorer prognosis. Lastly, in our comparison of primary and recurrent WDLPS we did not 
detect differential expression of the microRNAs that were previously found to be important 
for sarcomagenesis in WDLPS, such as miR-628 [6], miR-675 [6], miR-26a [8], miR-451 [8] or 




























































































▲Fig 4. Hierarchical clustering based on differentially methylated DNA regions (DMRs) 
between paired WDLPS tumor samples for the two main localizations. (A) Results of the 
hierarchical supervised clustering, excluding sex chromosomal regions (N = 27), based on 604 DMRs 
of the 15 paired WDLPS samples localized in the extremity. (B) Results of the hierarchical supervised 
clustering analysis based on the 51 DMRs with a fold change ≥2, excluding sex chromosomal regions (N 
= 2), of the 8 paired retroperitoneal WDLPS samples.
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Remarkably, only 470 DMRs with relatively low fold changes were identified between 
primary and recurrent WDLPS, which is a relatively small number considering the thousands 
of potential DNA methylation sites in the genome. Possibly, this can be explained by the low-
grade nature of this tumor type [1]. Furthermore, there was large variability in the number of 
DMRs between the pairs, ranging from 294 to 32,854 DMRs. Given our extensive efforts to 
compose a homogenous dataset by selecting only WDLPS without any neoadjuvant/adjuvant 
treatment and using only sections almost entirely consisting of tumor tissue, it seems that 
the inter-tumor heterogeneity is abundant. This heterogeneity – in DNA methylation as well 
as in microRNA expression – could also be due to intra-tumor heterogeneity, such as exists 
in other cancers. The concept of intra-tumor heterogeneity describes the observation that 
a tumor may exist of different tumor cells with distinct molecular and genomic profiles. If 
the used primary tumor sample was taken of one part of the tumor, but the recurrence 
mainly consists of cells from another part of the tumor or of cells that had a relatively small 
contribution to the primary tumor, this might explain the differences in microRNA expression 
profiles and DNA methylation patterns, even in case of a short time to recurrence (Fig 5). 
However, currently it is unknown whether such an intra-tumor heterogeneity is present in 
WDLPS.
Primary tumor with intra-tumor heterogeneity
leaving residual cells behind after surgery
Recurrent tumor consisting
of only one clone 
Sample used for
profiling experiments
▲Fig 5. Schematic overview of the concept of intra-tumor heterogeneity in the context of 
the current study. If the primary tumor sample that was used for the experiments mainly consists 
of one specific cancer cell subtype, but the recurrent tumor is a recurrence of mainly other cancer cell 
subtypes, this might explain the large variability in DNA methylation and microRNA expression, even in 




A relatively high number of DMRs occurred in chromosome 12, including DMRs linked 
to MDM2, suggesting that hypermethylation of chromosome 12 plays a role in recurrence. 
However, with the MeD-seq method one cannot reliably discriminate copy-number variations 
from actual differences in DNA methylation. Since WDLPS is characterized by amplification of 
a specific region on chromosome 12 (12q14-15) [1, 36], including MDM2 and CDK4 amongst 
others, we cannot reliably distinguish between additional amplification or actual changes in 
DNA methylation.
A limitation of the study was that in approximately a third of the patients the status 
of the resection margins of the primary surgery was not specified in the pathology report. 
Unfortunately, due to the retrospective nature of the study, which is inevitable when 
studying extremely rare diseases like WDLPS, we were not able to retrieve these. However, 
this percentage (29.6%) of missing resection margins is not unusual and in line with the 
number (24.0%) of pathology reports lacking information on the resection margins in a 
nationwide study on sarcoma care in the Netherlands [37]. The strengths of this study were 
the relatively large sample size and the use of paired samples collected from multiple centers. 
Both microRNAs and DNA methylation are known to vary – to a certain extent – between 
individuals [38, 39], and by using paired samples, we aimed to eliminate or minimize this 
inter-individual variability, so that only microRNAs and DMRs involved in sarcomagenesis 
would remain in the analyses.
The results of this study suggest that there are no common alterations on microRNA or 
DNA methylation level that are possibly involved as drivers in the process of recurrence. The 
next question is whether recurrent WDLPS has different molecular abnormalities upfront, i.e. 
in the primary tumor, than those who do not recur. Therefore, for a future research project 
we would recommend to compare primary WDLPS samples of patients who did not develop 
a recurrence to primary WDLPS tumor samples of patients who did develop a recurrence.
Conclusion
Primary and recurrent WDLPS cannot be distinguished based on microRNA expression 
profiles and DNA methylation patterns. Although no common alterations for recurrence 
could be revealed, a role for microRNAs and DNA methylation in the process of recurrence 
cannot be ruled out completely, since the aberrations contributing to recurrence might be 
very heterogeneous and variable between individuals. Alternatively, other molecular events 
may underlie WDLPS recurrence.
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▲S1 Fig. Visualization of principal component analyses (PCA) using the microRNA expression 
data as input. The panels depict the PCA before (A) and after (B) correction for batch effects. Based on 
the analyses shown in panel B, data from sample 10.1 and 10.2 were excluded from further microRNA 
analyses, resulting in the PCA analysis in the third panel (C).
A B C
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S1 Table. Differentially expressed microRNAs. All differentially expressed microRNAs (p<0.05, FDR<0.25, 
N = 28 microRNAs) between primary and recurrent WDLPS of 26 paired tumor samples.
microRNA Upregulated  in Fold change % detection p-value FDR
hsa-miR-1263 Primary 1.209 73% 0.0001 0.041
hsa-miR-885-5p Primary 1.987 100% 0.0006 0.132
hsa-miR-885-3p Primary 4.699 87% 0.0010 0.132
hsa-miR-656 Primary 1.493 100% 0.0013 0.132
hsa-miR-450b-3p Primary 2.205 88% 0.0014 0.132
hsa-miR-330-5p Primary 2.167 85% 0.0016 0.132
hsa-miR-492 Primary 1.802 73% 0.0017 0.132
hsa-miR-452 Primary 2.541 98% 0.0018 0.132
hsa-miR-383 Primary 2.850 98% 0.0026 0.164
hsa-miR-548b Recurrence 4.178 69% 0.0032 0.168
hsa-miR-382 Primary 1.842 100% 0.0033 0.168
hsa-miR-378 Primary 2.460 85% 0.0035 0.168
hsa-miR-450a Primary 2.347 98% 0.0040 0.168
hsa-miR-1236 Primary 3.319 75% 0.0041 0.168
hsa-miR-505# Primary 1.412 96% 0.0045 0.171
hsa-miR-181a-2# Primary 2.224 96% 0.0060 0.216
hsa-miR-1 Primary 2.416 98% 0.0071 0.232
hsa-miR-625 Primary 1.724 100% 0.0073 0.232
hsa-miR-1253 Primary 1.135 85% 0.0079 0.240
hsa-miR-450b-5p Primary 1.966 100% 0.0096 0.248
hsa-miR-674 Primary 4.721 83% 0.0096 0.248
hsa-miR-154 Primary 3.068 83% 0.0107 0.248
hsa-miR-185 Primary 1.659 100% 0.0108 0.248
hsa-miR-339-5p Primary 3.076 96% 0.0109 0.248
hsa-miR-518d-5p Recurrence 3.008 50% 0.0112 0.248
hsa-let-7a Primary 1.695 94% 0.0114 0.248
hsa-miR-24-1# Recurrence 79.356 62% 0.0116 0.248




S2 Table. Differentially expressed microRNAs in subgroup analyses of the extremity and retroperitoneum. 
All differentially expressed microRNAs between 15 paired primary and recurrent WDLPS tumor samples 
of the extremity (p<0.05, FDR<0.25, N = 9 microRNAs) (A) and of the 8 paired primary and recurrent 
WDLPS tumor samples of the retroperitoneum (p<0.05, no FDR, N = 14 microRNAs)(B).
(A) Extremity          
microRNA Upregulated in Fold change % detection p-value FDR
hsa-miR-532-3p Primary 1.731 100% 0.0001 0.024
hsa-miR-1263 Primary 2.248 63% 0.0001 0.024
hsa-miR-145# Primary 1.731 100% 0.0008 0.155
hsa-miR-452 Primary 2.609 97% 0.0015 0.221
hsa-miR-100 Primary 1.303 100% 0.0028 0.221
hsa-miR-30d Primary 1.895 100% 0.0029 0.221
hsa-miR-26b# Primary 1.422 100% 0.0029 0.221
hsa-miR-33a Recurrence 1.128 83% 0.0031 0.221
hsa-miR-330-5p Primary 2.029 80% 0.0034 0.221
(B) Retroperitoneum        
microRNA Upregulated in Fold change % detection p-value FDR
hsa-miR-30b Recurrence 1.632 63% 0.0036 0.955
hsa-miR-130b Recurrence 1.524 88% 0.0051 0.955
hsa-miR-512-3p Primary 2.444 50% 0.0090 0.955
hsa-miR-340 Recurrence 5.300 88% 0.0090 0.955
hsa-miR-302b# Recurrence 3.381 69% 0.0144 0.955
hsa-miR-552 Recurrence 1.612 88% 0.0162 0.955
hsa-miR-1304 Recurrence 1.585 81% 0.0201 0.955
hsa-miR-129 Recurrence 1.085 94% 0.0214 0.955
hsa-miR-24-1# Recurrence 4.316 63% 0.0221 0.955
hsa-miR-130b# Recurrence 1.476 81% 0.0235 0.955
hsa-miR-136# Recurrence 1.808 100% 0.0378 0.955
hsa-let-7f Recurrence 1.884 94% 0.0382 0.955
hsa-miR-885-5p Primary 2.717 100% 0.0400 0.955
hsa-miR-16-1# Primary 1.710 81% 0.0483 0.955
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No accurate location* 70
Total 470
*DMRs found in repetitive genomic locations that lack an 




S4 Table. Top 100 genes with a DMR. Top 100 genes that contain at least one differentially methylated 
DNA region (DMR) after Bonferroni correction, excluding genes/DMRs located on the sex chromosomes, 
found by MeD-seq on 27 paired primary and recurrent WDLPS tumor samples.
No. Gene No. of DMRs Fold Change* Hypermethylated in Location
1 RP11-611E13.2 3 2.033 Recurrence chr12
2 CENPIP1 1 1.661 Primary chr13
3 FLG-AS1 3 1.590 Primary chr1
4 HRNR 3 1.590 Primary chr1
5 MYRFL 3 1.526 Recurrence chr12
6 RP11-571M6.17 1 1.512 Recurrence chr12
7 TSFM 2 1.512 Recurrence chr12
8 AVIL 3 1.512 Recurrence chr12
9 LYRM4 1 1.376 Recurrence chr6
10 SLC35E3 5 1.350 Recurrence chr12
11 OS9 2 1.298 Recurrence chr12
12 RP11-571M6.7 3 1.298 Recurrence chr12
13 NOC4L 1 1.293 Primary chr12
14 MDM2 8 1.293 Recurrence chr12
15 AC133749.1 1 1.289 Primary chr12
16 CPM 5 1.289 Primary chr12
17 CYP27B1 2 1.279 Recurrence chr12
18 AL671532.6 1 1.278 Recurrence chr14
19 AC025263.3 3 1.278 Recurrence chr12
20 MIR26A2 2 1.276 Recurrence chr12
21 CTDSP2 1 1.276 Recurrence chr12
22 RP11-159A18.1 1 1.244 Recurrence chr12
23 AC126281.1 7 1.239 Primary chr4
24 DUX4L8 6 1.239 Primary chr4
25 AL671532.5 1 1.239 Recurrence chr14
26 SHC2 2 1.234 Recurrence chr19
27 TBC1D22A 1 1.233 Recurrence chr22
28 RP11-571M6.18 1 1.227 Recurrence chr12
29 EXOC2 1 1.227 Primary chr6
30 LRP8 1 1.225 Recurrence chr1
31 LINC00854 6 1.225 Primary chr17
32 RP3-470B24.5 1 1.215 Recurrence chr6
33 AL671532.1 4 1.209 Recurrence chr14
34 RNA5S9 3 1.203 Primary chr1
35 AL713899.1 3 1.203 Primary chr 1
36 GRTP1 1 1.192 Recurrence chr13
37 SCNN1D 1 1.191 Primary chr1
38 EXD3 1 1.190 Primary chr9
39 DUX4L2 6 1.182 Primary chr4
40 AC126281.4 3 1.182 Primary chr4
41 AGAP2-AS1 2 1.182 Recurrence chr12
42 AGAP2 3 1.182 Recurrence chr12
43 AL845259.5 4 1.178 Primary chr10
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No. Gene No. of DMRs Fold Change* Hypermethylated in Location
44 DUX4L20 2 1.178 Primary chr10
45 TSPAN31 3 1.170 Recurrence chr12
46 CFAP46 1 1.164 Primary chr10
47 ABCC5 3 1.160 Recurrence chr3
48 RAB3IP 1 1.157 Recurrence chr12
49 TCEB3CL2 2 1.153 Recurrence chr18
50 KATNAL2 3 1.153 Recurrence chr18
51 AL732375.7 3 1.151 Primary chr10
52 DIP2C 1 1.150 Primary chr10
53 PCNT 1 1.146 Primary chr21
54 DUX4L4 4 1.144 Primary chr4
55 AC126281.5 3 1.144 Primary chr4
56 CDK4 2 1.144 Recurrence chr12
57 RNA5S17 2 1.140 Primary chr1
58 BEST3 2 1.138 Recurrence chr12
59 NLRP4 2 1.135 Recurrence chr19
60 TCEB3CL 3 1.133 Recurrence chr18
61 TCEB3C 2 1.133 Recurrence chr18
62 MIR8078 1 1.132 Recurrence chr18
63 ROCK1P1 1 1.132 Recurrence chr18
64 ANKRD33B 1 1.114 Recurrence chr5
65 MARCH9 2 1.114 Primary chr12
66 CTD-3220F14.1 7 1.113 Primary chr19
67 METTL21B 2 1.109 Recurrence chr12
68 RP11-571M6.15 2 1.109 Recurrence chr12
69 RP11-49K24.9 2 1.109 Recurrence chr18
70 HMGA2 2 1.109 Recurrence chr12
71 LMF1 1 1.105 Primary chr16
72 RP11-611O2.1 1 1.102 Primary chr12
73 SLC16A3 1 1.102 Recurrence chr17
74 CSNK1D 1 1.102 Recurrence chr17
75 RP13-638C3.3 2 1.101 Primary chr17
76 FOXK2 1 1.101 Primary chr17
77 YBEY 1 1.100 Primary chr21
78 AL845259.7 3 1.100 Recurrence chr10
79 LRRC10 2 1.097 Recurrence chr12
80 EHMT1 1 1.097 Primary chr9
81 TMTC2 1 1.092 Primary chr12
82 TERT 1 1.092 Recurrence chr5
83 PLEKHG4B 2 1.090 Primary chr5
84 RP11-620J15.2 1 1.088 Primary chr12
85 DBET 3 1.087 Primary chr4
86 RNA5S10 2 1.085 Primary chr1
87 RNA5S11 2 1.085 Primary chr1
88 RNA5S12 2 1.085 Primary chr1




No. Gene No. of DMRs Fold Change* Hypermethylated in Location
90 RNA5SP162 1 1.082 Primary chr1
91 DUX4L23 1 1.082 Primary chr10
92 CTD-3162L10.1 5 1.080 Primary chr19
93 TMEM242 2 1.078 Recurrence chr6
94 AL671532.2 1 1.076 Recurrence chr14
95 DLGAP2 1 1.076 Recurrence chr8
96 CPSF6 1 1.074 Primary chr12
97 RNA5S1 2 1.072 Primary chr1
98 RNA5S2 2 1.072 Primary chr1
99 RNA5S3 2 1.072 Primary chr1
100 RNA5S4 3 1.072 Primary chr1
*Fold change of first/top DMR of the relevant gene
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Background: Well differentiated liposarcoma (WDLPS) can be difficult to distinguish from 
lipoma. Currently, this distinction is made by testing for MDM2 amplification, which requires 
a biopsy. The aim of this study was to develop a non-invasive method to predict the MDM2 
amplification status using radiomics features derived from MRI.
Methods: Patients with an MDM2-negative lipoma or MDM2-positive WDLPS and a pre-
treatment T1-weighted MRI scan who were referred to Erasmus MC between 2009 and 
2018 were included. When available, other MRI sequences were included in the radiomics 
analysis. Features describing intensity, shape and texture were extracted from the tumour 
region. Classification was performed using various machine learning approaches. Evaluation 
was performed through a 100 times random-split cross-validation. The performance of the 
models was compared with the performance of three expert radiologists.
Results: The data set included 116 tumours (58 patients with lipoma, 58 with WDLPS) and 
originated from 41 different MRI scanners, resulting in wide heterogeneity in imaging 
hardware and acquisition protocols. The radiomics model based on T1 imaging features 
alone resulted in a mean area under the curve (AUC) of 0.83, sensitivity of 0.68 and specificity 
of 0.84. Adding the T2-weighted imaging features in an explorative analysis improved the 
model to a mean AUC of 0.89, sensitivity of 0.74 and specificity of 0.88. The three radiologists 
scored an AUC of 0.74 and 0.72 and 0.61 respectively; a sensitivity of 0.74, 0.91 and 0.64; and 
a specificity of 0.55, 0.36 and 0.59.
Conclusion: Radiomics is a promising, non-invasive method for differentiating between 
WDLPS and lipoma, outperforming the scores of the radiologists. Further optimization and 
validation is needed before introduction into clinical practice.




Lipomatous tumours are the most commonly observed soft tissue tumours, mostly owing 
to the high incidence of benign lipomas. Also within the malignant spectrum of soft tissue 
tumours (soft tissue sarcomas), liposarcoma is among the most frequently observed 
subtypes [1]. Well differentiated liposarcoma (WDLPS) represents the largest subgroup of 
liposarcomas; these low-grade, locally aggressive tumours are characterized by amplification 
of the MDM2 gene [1]. In rare cases, WDLPS can progress into a more aggressive subtype: 
dedifferentiated liposarcoma (DDLPS), which has a poorer prognosis [1].
Several differences between lipoma and WDLPS on MRI have been described in the 
literature: size, location, tumour depth and intra-tumour heterogeneity. However, as there 
can be considerable overlap between these features, distinguishing between the two tumour 
types remains difficult, even for trained radiologists [2-6]. As the differences between lipoma/
WDLPS and DDLPS are more obvious, this distinction can accurately be made solely by eye 
[5, 7-10].
An accurate diagnosis is needed to provide patients with the correct treatment and 
follow-up. Whereas lipomas do not necessarily need to be excised, patients with WDLPS 
are generally considered candidates for surgery [11]. Currently, the standard way to 
differentiate lipoma from WDLPS is through a biopsy, which is tested for MDM2 amplification 
using fluorescence in situ hybridization (FISH). Amplification of the MDM2 gene is present in 
WDLPS, but absent in lipoma [1, 12, 13]. Taking a biopsy is an invasive and painful procedure 
for the patient, and is associated with risks, depending on tumour location, and potential 
sampling error.
The field of radiomics is based on the hypothesis that there is a relationship between 
medical imaging features and the underlying biological information, such as genetic 
aberrations [14]. Radiomics approaches have already been used in soft tissue sarcomas to 
predict other outcomes, such as differentiating between benign and malignant soft tissue 
tumours in general (not specifically lipomatous tumours) [15], between intermediate- and 
high-grade soft tissue sarcomas [16], and predicting the risk of lung metastases from soft 
tissue sarcoma of the extremities [17]. Based on these results, it was hypothesized that 
radiomics might also be able to differentiate WDLPS from lipoma.
The aim of this study was to develop a model that predicts the MDM2 amplification 
status using a radiomics approach, thereby differentiating WDLPS from lipoma. MRI scans 
obtained during routine diagnostic evaluation were used. Additionally, the performance of 
this model was compared with that of three trained radiologists reading the images. Finally, 
patients with DDLPS were included and classified by the radiologists to confirm that these 






Patients with a pathologically confirmed diagnosis of lipoma, WDLPS or DDLPS, a known 
MDM2 amplification status tested by FISH, and with at least a T1-weighted MRI sequence 
available before treatment (if applicable) were included. All patients were either referred 
to/discussed at, or diagnosed/treated at the Erasmus MC Cancer Institute, Rotterdam, 
the Netherlands, between December 2009 and August 2018. As a result, some of the MRI 
scans were made in the referring hospitals. The study was reviewed and approved by the 
local medical ethics review committee (MEC-2016-339), and performed in accordance with 
national and international legislation. Need for informed consent was waived owing to the 
retrospective and anonymized nature of the study.
To explore the potential predictive value of different MRI sequences, several additional 
sequences were included, when available. Based on their use in clinical practice, the sequences 
were grouped into: plain T1 (T1); T1 with fat saturation (T1-FS) including T1 inversion recovery 
(IR) approaches (T1-IR; a combination of Spectral Presaturation with Inversion Recovery 
(SPIR), Short-TI Inversion Recovery (STIR), Spectral Attenuated Inversion Recovery (SPAIR) and 
Turbo Inversion Recovery Magnitude (TIRM)); T1 with gadolinium contrast (T1-GD); T1 with 
fat saturation and gadolinium contrast (T1-FS-GD) including T1-IR with GD; T2 imaging (T2) 
including T2-Fast Field Echo (T2-FFE) and T2*; and T2-FS including T2-IR.
Segmentation
The lipoma and WDLPS lesions were segmented semi-automatically on the T1 images 
to indicate the regions of interest (ROIs) [18]. All images were segmented independently 
by either a medical masters student or a PhD candidate with an MD degree. Both were 
blinded to the type of lipomatous tumour. To validate segmentation accuracy, a sample set 
was verified by a musculoskeletal radiologist, specialized in soft tissue sarcomas. Median 
tumour size, defined as the maximum diameter in centimetres, and tumour volume, with 
corresponding i.q.r. values, were extracted from the segmentations. The DDLPS images were 
used only for visual classification by the radiologists, and therefore not segmented.
To transfer the segmentations to the other sequences, all sequences were spatially 
aligned to the T1 sequence using automated image registration (elastix software [19]), 
thereby compensating for patient movement between scans. Quality assurance was done 
by visual inspection.
Radiomics feature extraction
Quantitative imaging features related to intensity, shape and texture were extracted from 
the ROIs using PyRadiomics software [20, 21]. More details can be found in Appendix S1 
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(supporting information). The shape features quantified were morphological properties 
such as volume and similarity to a circle. Intensity features were quantified using first-
order statistics such as the mean and standard deviation. Texture features quantified more 
complex properties, such as the presence of heterogeneity and speckle patterns. When a 
scan type was missing for a patient, the feature values for the missing image type were 
imputed.
Additional features
Several additional features were selected based on the available literature and clinical 
relevance, including patient characteristics (age, sex and tumour location (extremity, trunk, 
head and neck or pelvis)) and manually scored features (tumour depth (superficial or deep), 
unilobular or multilobular tumour, atypical appearance on T1 image (yes or no)). These are 
referred to as patient and manually scored features respectively. Tumours were considered 
superficial when entirely located above the fascia, or as deep-seated when located beneath 
the fascia, or with invasion of the fascia.
Decision model creation
To create a decision model from the features, the Workflow for Optimal Radiomics Classification 
(WORC) toolbox [22] was used. A schematic overview of the radiomics methodology is shown 
in Fig. 1. In WORC, decision model creation is divided into several steps. These steps include, 
for example, selection of features that offer the highest predictive value and machine 
learning to discover the patterns in these features that distinguish between WDLPS and 
lipoma. For each of these steps, numerous algorithms have been proposed in the literature. 
WORC performs an exhaustive search amongst these algorithms, in a fully automated way, 
and establishes the combination of algorithms that maximizes the prediction accuracy. As 
the single best solution may be a coincidental finding, the 50 best performing solutions 
were combined into a single model, with the purpose of creating a more robust model and 
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▲Fig. 1 Schematic overview of the radiomics approach. Inputs to the algorithm are T1- and T2-
weighted magnetic resonance images of well differentiated liposarcoma (WDLPS) and lipoma.
(1). Processing steps include segmentation of the tumour on the T1 image (2), registration of the T1 to 
the T2 image to transform this segmentation to the T2 image (3), feature extraction from both the T1 and 
T2 images (4) and the creation of a decision model from the features (5), using an ensemble of the best 
50 workflows from 100 000 candidate workflows; workflows are different combinations of the different 
processing and analysis steps (for example the classifier used).
Experimental set-up
To assess the predictive value of the T1 imaging features, and the additional patient and 
manually scored features, five models were trained and tested based on: imaging features 
only (model 1); patient features only (model 2); manually scored features only (model 3); a 
combination of imaging features and manually scored features (model 4); and volume only 
(model 5). The fifth model was included because WDLPS is generally larger than lipoma [3]. 
Additionally, to investigate the potential of the features independent of volume, these five 
models were evaluated on a volume-matched cohort, that is a subset of the data in which the 
distribution of tumour volume was similar among WDLPS and lipoma. These models were 
trained on the full data set, but tested only on patients from the volume-matched cohort.
Next, the potential value of other MRI sequences was explored by training and testing 
multiple imaging-based radiomics models using combinations of the various MRI sequences. 
When a model showed more potential than the T1 imaging-only model, it was evaluated on 
the volume-matched cohort as well.
Evaluation
Model evaluation was performed through cross-validation. The data were randomly split for 
100 iterations, using 80 per cent for training and 20 per cent for testing. In each iteration, 
automatic workflow optimization was performed on the training set in an internal ten times 
random split cross-validation (Fig. S1, supporting information). Thus, the models were 
optimized solely on the training set; the test set was used only for evaluation of the final 
model. All splitting was done in a stratified manner to keep the balance between WDLPS and 
lipoma similar in all data sets.
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Performance was evaluated using the area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve, accuracy, sensitivity, specificity, negative predictive 
value and positive predictive value, averaged over the 100 cross-validation iterations. 
Positive MDM2 amplification status (WDLPS) was defined as the positive class. Ninety-five 
per cent confidence intervals for the mean performance measures were constructed using 
the corrected resampled t test based on all 100 cross-validation iterations, thereby taking 
into account that the samples in the cross-validation splits were not statistically independent 
[23].
Model insights
Insight into the model was gained by ranking the patients from typical to atypical for both 
lipoma and WDLPS, based on the consistency of the model predictions. This was determined 
by the number of times (percentage) that a patient was classified correctly when included in 
the test set. Typical examples were patients who were always classified correctly; and atypical 
vice versa. In addition, to identify the individual imaging features included in the radiomics 
model and to assess their respective contribution to the model, univariable statistical testing 
of the imaging features was undertaken using the Mann–Whitney U test. P values were 
corrected for multiple testing using the Bonferroni correction.
Classification by radiologists
Three radiologists with expertise in soft tissue tumours classified the lipomatous tumours; 
radiologists 1, 2 and 3 had 3, 10 and 5 years of experience respectively. First, the radiologists 
had to classify the tumours as either DDLPS or WDLPS/lipoma (non-DDLPS), to confirm that 
DDLPS can be recognized visually. Regardless of whether a tumour was classified as DDLPS 
or not, the tumours subsequently had to be classified as MDM2-negative (lipoma) or MDM2-
positive (WDLPS/DDLPS). The classification was done using a ten-point scale to indicate the 
certainty of the radiologists. The radiologists had access to all sequences that were available 
for each patient, as well as the age and sex.
Results
In total, 138 tumours were included: 58 patients had an MDM2-negative lipoma, 58 had an 
MDM2-positive WDLPS and 22 had an MDM2-positive DDLPS. Most patients were men (60.1 
per cent) and had a deep-seated tumour located in a leg. Median WDLPS size was 20.4 
cm and median volume was 36.3 cl, compared with 12.3 cm and 12.9 cl for lipoma (Table 
1). Most of the patients underwent surgery: 32 with a lipoma, 50 with a WDLPS and 19 of 




conservatively with an active surveillance approach, whereas the three with a DDLPS who did 
not have surgery had an inoperable tumour.
The 116 lipoma and WDLPS scans came from 41 different MRI scanners; there was wide 
heterogeneity in imaging hardware and acquisition protocols used, reflected in differences 
in magnetic field strength (1.5T, 98 scans; 1T, 10 scans; 3T, 8 scans), manufacturer (Siemens, 
Munich, Germany, 45 scans; Philips, Amsterdam, the Netherlands, 45 scans; GE, Chicago, 
Illinois, USA, 26 scans), scanner model (19 different ones), slice thickness, repetition time and 
echo time. Additional sequences besides T1 were available in subsets of patients: T1-FS in 55 
patients (47.4 per cent), T1-GD in 42 patients (36.2 per cent), T1-FS-GD in 80 patients (69.0 
per cent), T2 in 76 patients (65.5 per cent) and T2-FS in 92 patients (79.3 per cent) (Table S1, 
supporting information).
Table 1. Characteristics of the patients with lipomatous tumours
No. of patients*(n =138)
Age (years)† 64 (54–71)
Sex ratio (M: F) 83 : 55
Diagnosis
   Lipoma 58 (42.0)
   WDLPS 58 (42.0)
   DDLPS 22 (15.9)
Tumour location
   Upper extremity 14 (10.1)
   Lower extremity 71 (51.4)
   Trunk 37 (26.8)
   Head and neck 6 (4.3)
   Retroperitoneum and pelvis 6 (4.3)
   Paratesticular 4 (2.9)
Tumour depth
   Superficial 20 (14.5)
   Deep 118 (85.5)
Tumour size (cm)†
   Lipoma 12.3 (9.3–15.5)
   WDLPS 20.4 (15.9–26.3)
Tumour volume (cl)†
   Lipoma 12.9 (4.6–25.0)
   WDLPS 36.3 (22.9–85.5)
*With percentages in parentheses unless indicated otherwise; †values are median (i.q.r.). WDLPS, well 
differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma. 
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Evaluation of radiomics models based on T1 imaging and additional 
features
The performances of models 1–5 are shown in Fig. 2 and Table S2 (supporting information). 
Model 1, based on the T1 imaging features, resulted in an AUC of 0.83, sensitivity of 0.68 
and specificity of 0.84. Model 2, based on patient features, had a lower AUC (0.75), higher 
sensitivity (0.77), but lower specificity (0.59). Similarly, model 3, based on manually scored 
features, also had a lower AUC (0.72), higher sensitivity (0.76) and lower specificity (0.57). 
Model 4, combining the imaging and manually scored features, performed worse than model 
1, implying that imaging features are sufficient as input. Finally, model 5, based on volume 
alone, performed similarly to model 1 with an AUC of 0.83, sensitivity of 0.67 and specificity of 
0.84. Although the performance metrics were similar for models 1 and 5, the ROC curves in 
Fig. 2 show some differences. The ROC curve for the volume model (Fig. 2e) has some sharp 
bends, while that for the T1 imaging model is smoother (Fig. 2a).
Evaluation of the radiomics models with additional MRI sequences
Most models with an additional MRI sequence had a similar performance to the T1 imaging 
model (Table S3, supporting information). However, the model combining the T1 and T2 
imaging features showed a clear improvement in performance, with an AUC of 0.89, sensitivity 
of 0.74 and specificity of 0.88. The distribution of patient characteristics and the distribution 
of WDLPS and lipoma were similar across patients who had a T2 scan, indicating that the 
added value is within the T2 imaging features and not a result of incidental correlation with 
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▲Fig. 2 Receiver operating characteristic (ROC) curves for the radiomics models based on the 
T1-weighted MRI sequence.
a Using imaging features only, b using patient features only, c using manually scored features only, d 
using T1 imaging features combined with manually scored features, and e using volume only. The shaded 
area indicates the 95 per cent confidence intervals of the 100 times random-split cross-validation; the 
curve is fit through their means. The performance of the three radiologists is shown.
Evaluation of models on volume-matched cohort
Model 5, based on volume alone, illustrated that volume is indeed a strong predictive factor. 
The 17 tumours with a volume above 70 cl were all WDLPS, whereas the 21 tumours with 
a volume below 7 cl were all lipoma. In the volume-matched cohort, consisting of the other 
78 tumours with a volume between 7 and 70 cl, the volume distributions for WDLPS and 
lipoma were more similar. As only the T2 scans provided additional value over the T1 imaging 
features, the T1+T2 imaging model was evaluated for the volume-matched cohort as well.
The performance of both imaging-based models (T1 and T1+T2) was worse on the 
volume-matched cohort (T1: AUC 0.69; T1+T2: AUC 0.81) (Table 2) than on the entire cohort 
(AUC 0.83 and 0.89 respectively) (Table S3, supporting information). The models based on the 
patient and manually scored features performed similarly to the models tested on the full 
cohort. The model based on volume alone still performed above chance (mean AUC 0.64), 
but considerably worse than on the entire data set. In this volume-matched data set, both the 
T1 imaging model (AUC 0.69, sensitivity 0.60, specificity 0.74) and the T1+T2 imaging model 
(AUC 0.81, sensitivity 0.66, specificity 0.84) performed considerably better than volume alone 
(Table 2). This showed that these models were not based solely on volume, and that other 
features provided additional predictive value over volume.
Radiomics in lipomas and well-differentiated liposarcomas
69 
5












AUC 0.69 [0.58, 0.80] 0.81 [0.72, 0.90] 0.74 [0.64, 0.84] 0.67 [0.56, 0.77] 0.64 [0.53, 0.74]
Accuracy 0.67 [0.57, 0.76] 0.75 [0.66, 0.83] 0. 66 [0.56, 0.75] 0.60 [0.51, 0.69] 0.66 [0.57, 0.74]
Sensitivity 0.60 [0.45, 0.75] 0.66 [0.52, 0.79] 0.69 [0.55, 0.83] 0.70 [0.53, 0.87] 0.50 [0.36, 0.64]
Specificity 0.74 [0.60, 0.87] 0.84 [0.71, 0.96] 0.62 [0.48, 0.76] 0.51 [0.36, 0.65] 0.82 [0.71, 0.92]
NPV 0.66 [0.54, 0.77] 0.72 [0.60, 0.83] 0.68 [0.56, 0.79] 0.65 [0.49, 0.80] 0.62 [0.53, 0.71]
PPV 0.72 [0.58, 0.85] 0.81 [0.69, 0.93] 0.65 [0.54, 0.76] 0.59 [0.49, 0.69] 0.74 [0.61, 0.87]
Values are mean [95 per cent c.i.] over the cross-validation iterations. AUC, area under the curve; NPV, 
negative predictive value; PPV, positive predictive value.
Model insights
Of the 116 lipomatous tumours, 69 (26 WDLPS, 43 lipoma) were always classified correctly 
by model 1 in all 100 cross-validation iterations. In contrast, 13 tumours (9 WDLPS, 4 lipoma) 
were always classified incorrectly. Fig. 3 shows four MRI slices of such typical and atypical 
examples of lipoma and WDLPS. The lesions that were always classified incorrectly were 
checked for possible sampling error of the biopsy. The MDM2 amplification status of eight 
of the 13 tumours always classified incorrectly was already determined on the resection 
specimen (6 WDLPS, 2 lipoma). For the other five patients, in whom it was tested on the 
biopsy (3 WDLPS, 2 lipoma), pathological examination of the resection specimen confirmed 
the diagnosis, except for one patient with a lipoma who did not undergo surgery. In the other 
patient with a lipoma, the resection specimen again tested negative for MDM2 amplification. 
The three WDLPS resection specimens were not retested.
Analysis of feature importance was done for the volume-matched cohort, as the results 
on the full data set were dominated by volume-related measures. In total, 16 individual 
features were found to be significant after Bonferroni correction on the volume-matched 
cohort (Fig. S2, supporting information). These included 11 shape features (including several 




(A) Typical Lipoma (B) Atypical Lipoma
(C) Atypical WDLPS (D) Typical WDLPS
▲Fig. 3 Examples of typical and atypical lipomas and well differentiated liposarcomas. 
a Typical lipoma, b atypical lipoma, c atypical well differentiated liposarcoma (WDLPS) and d typical 
WDLPS. The typical examples are from two patients always classified correctly by the T1 imaging model; 
the atypical examples are from two patients always classified incorrectly by the T1 imaging model.
Radiomics models compared with radiologists
On the entire cohort, the AUCs of all three radiologists (0.74, 0.72 and 0.61 for radiologist 1, 2 
and 3 respectively) (Table S4, supporting information) were below the lower limit of the 95 per 
cent c.i. of the T1 imaging model (0.75 to 0.90) (Fig. 2 and Table S2, supporting information), as 
well as of the 95 per cent c.i. of the T1+T2 imaging model (0.83 to 0.95) (Table S3, supporting 
information). The radiologists achieved sensitivity values similar to (0.64 and 0.74) or higher 
(0.91) than those of the radiomics models (T1: 0.68; T1+T2: 0.74), but their specificity was 
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much lower (radiomics: 0.84 and 0.88 respectively; radiologists 1–3: 0.55, 0.36 and 0.59 
respectively). The Cohen’s κ value was 0.24, 0.04 and 0.40 for all pairs of radiologists, with a 
mean of 0.23, indicating poor inter-observer agreement.
On the volume-matched cohort, the radiologists had a performance (AUC 0.68, 0.74 
and 0.55) (Table S4, supporting information) more similar to that of the T1 imaging model 
(AUC 0.69) (Table 2). On average, the T1 imaging model still performed better in terms of 
specificity (radiomics: 0.74; radiologists 1–3: 0.58, 0.37 and 0.50), whereas the radiologists 
again performed better on sensitivity (radiomics: 0.60; radiologists 1–3: 0.65, 0.88 and 0.60). 
However, the T1+T2 imaging model performed much better (AUC 0.81, sensitivity 0.66, 
specificity 0.84) than both the T1 imaging model and the radiologists. On this cohort, the 
Cohen’s κ values were 0.18, –0.04 and 0.34 for all pairs of radiologists, with a mean of 0.16, 
again indicating poor inter-observer agreement.
Distinction between dedifferentiated liposarcoma and well 
differentiated liposarcoma/lipoma
Besides classifying lipoma and WDLPS, the radiologists also classified the scans from 22 
patients with DDLPS to evaluate whether DDLPS can indeed be identified by imaging only, 
without the help of additional models. Radiologists 1–3 had an AUC of 0.97, 0.91 and 0.90 
respectively; a sensitivity of 0.95, 0.95 and 0.91; and a specificity of 0.95, 0.56 and 0.89 in 
distinguishing DDLPS from non-DDLPS (WDLPS/lipoma) (Table S4, supporting information).
Discussion
This study shows that there is a relationship between quantitative MRI features and the 
MDM2 amplification status, and that radiomics is a promising non-invasive method for 
differentiating lipoma from WDLPS. Although the radiologists were able to distinguish 
between DDLPS and non-DDLPS, they were outperformed by the T1 and T1+T2 imaging 
models in differentiating WDLPS from lipoma. Moreover, the agreement between radiologists 
was very poor, whereas the radiomics-based predictions were objective and reproducible 
(given a tumour segmentation).
Remarkably, the model trained on volume alone had a similar performance to the T1 
imaging model, which included many additional features. However, in the volume-matched 
data set, the T1 imaging model performed considerably better than the volume-only model, 
indicating that other features do provide additional predictive value. It is already known that 
WDLPS is on average larger than lipoma [3], and the relationship with volume (or size) in our 
data set was also strong; the database did not contain lipoma larger than 70 cl or WDLPS 




tumours and grow over time, so the measured tumour volume depends on the moment 
of presentation, and a small or intermediate tumour volume is therefore not a reliable 
biomarker. Future research should include expansion of the data set to make the volume 
distributions more representative (including lipoma larger than 70 cl and WDLPS smaller 
than 7 cl), thereby making the radiomics model less volume-dependent.
The models trained solely on either the patient or manually scored features performed 
slightly worse than the model trained on the T1 imaging features only. As the combined 
model did not outperform the T1 imaging model, the manually scored features did not add 
much in the search for the best radiomics model. Additionally, the manually scored features 
may be observer-dependent, and thus prone to subjectivity. Although patient features 
(age, sex and tumour location) are objective, the distribution in the present data set may 
not be representative of clinical practice. For example, none of the patients with WDLPS 
were younger than 35 years, there were no lipomas among patients older than 82 years, no 
lipomas in the head and neck region, and no WDLPS in the pelvis or shoulder/trunk; all these 
might occur in daily clinical practice. Therefore, the imaging-only models have more potential 
as an objective tool in clinical practice.
The results of present study are similar to those of Thornhill and colleagues [26], 
who used a comparable approach and showed that lipomas can be distinguished from 
liposarcomas by texture and shape analysis. Strong points of the present study include the 
larger sample size (116 versus 44 in Thornhill et al.). Thornhill and co-workers also included 
other liposarcoma subtypes in their model, such as DDLPS and myxoid liposarcoma (8 of 
20 included liposarcomas). These other liposarcoma subtypes have distinct radiological 
features [5, 10], which in general can be easily discriminated from lipomas by experienced 
radiologists. By solely including the two tumour types that are the most difficult to distinguish 
(WDLPS and lipoma) in the radiomics model, the present data set is more challenging and 
more clinically relevant. In contrast to the cases described by Thornhill et al., the diagnosis 
of all patients in the present data set was confirmed by verifying the MDM2 amplification 
status using FISH, the current standard for diagnosing and differentiating between lipoma 
and WDLPS [1, 12, 13]. The present radiomics model only requires routine MRI scans (T1, 
and optionally T2) without contrast injection; the other sequences did not add any predictive 
value to the model. As almost all standard MRI protocols include a T1 and T2 sequence, the 
present radiomics method is generalizable, feasible and applicable for use in daily practice. 
Finally, these radiomics models were developed and evaluated on a heterogeneous data 
set, thereby increasing the chance that the reported performance can be reproduced in a 
routine clinical setting when using other MRI scanners.
Advantages of using a radiomics approach over pathological assessment to differentiate 
between lipoma and WDLPS include sparing patients an invasive and painful biopsy, and 
saving the substantial costs of a radiologist performing the imaging-guided biopsy and of the 
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pathologist assessing it, including the costs of molecular testing by FISH. Radiomics makes 
use of MRI images obtained during routine diagnostic evaluation and patients do not need to 
undergo any additional procedure. When radiomics becomes a widely available tool, patients 
with WDLPS can be identified and referred to a soft tissue sarcoma expert centre at an earlier 
stage, with potential beneficial effects on further diagnostics, treatment and follow-up.
Several limitations of this study should be noted, besides the volume bias already 
mentioned. First, segmentation of ROIs of the tumours was done manually, which inherently 
leads to both inter-observer and intra-observer variability, as has been quantified for 
other cancer types [27-29]. Variability in segmenting the ROIs might lead to variability in 
the extracted imaging features and subsequently influence the classification of tumours. 
Additionally, manual segmentation is rather time-consuming. This could be addressed by 
use of automated segmentation tools that might be available in the future. Second, variation 
in imaging protocols might have influenced the imaging statistics. No restrictions were put 
on the T1 MRI sequences regarding field strength, slice thickness, or other MRI acquisition 
settings, as selecting a single protocol is an unrealistic reflection of daily clinical practice and 
would have made the results non-generalizable. Instead, this study shows that the present 
radiomics approach is robust to these variations by both training and testing the model 
on heterogeneous data. Third, the model is based on retrospectively collected data, which 
might have led to selection and information bias. This potential selection bias might have 
occurred particularly in the lipoma subgroup, as usually only large and atypical lipomas 
are referred to a sarcoma centre. However, this probably made the data set even more 
challenging and relevant, as these can be seen as the complex cases. Addition of the ‘small 
and typical’ lipomas would have made the classification easier, and radiomics is not needed 
to make the distinction for such lipomas.
The present radiomics model could serve as a non-invasive, quick and low-cost 
alternative to a biopsy. Although the model needs optimization to match the accuracy of a 
biopsy, there could be a certain patient group for whom the model may already be useful. 
For example, patients at high risk of complications of biopsy, or those in whom the radiomics 
model can predict the MDM2 amplification status with a high degree of certainty, could 
already be treated according to the prediction of the radiomics model. Although further 
research is required to identify which patients could benefit most from the present model, 
initial misclassification of a WDLPS as a lipoma would not harm the patient, considering that 
active surveillance seems a safe option in patients without (invalidating) symptoms and/or 
tumour growth, at least in the short term [30]. In addition, the performance of the radiomics 
model improved substantially when T2 images were added. However, only 65.5 per cent of 
the patients had a T2 scan available, so for a follow-up study it is proposed to use MRI with 
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Appendix S1: Radiomics feature extraction
In this study, radiomics features quantifying intensity, shape and texture were extracted. 
Intensity features were extracted using the histogram of all intensity values within the Regions 
of Interest (ROIs) and included several first order statistics such as the mean, standard 
deviation and kurtosis. Shape features were extracted by solely using the ROI and included 
shape descriptions such as the compactness, roundness and circular variance. Additionally, 
the volume and orientation of the ROI were used. Texture features were extracted using 
the Gray Level Co-occurrence Matrix, Gray Level Size Zone Matrix Gray Level Run Length 
Matrix and Neighborhood Grey Tone Difference Matrix. All features were extracted using the 
defaults for MR images from PyRadiomics.
The used dataset is highly heterogeneous in terms of acquisition protocols. Especially 
the variations in slice thickness and contrast may cause feature values to be highly dependent 
on the acquisition protocol. The slice thickness varies between 2.5mm and 10mm. Hence, 
extracting robust 3D features may be hampered by these variations, especially for the 
low resolutions. To overcome this issue, all features are extracted per 2D axial slice and 
aggregated over all slices. Due to the slice thickness and pixel spacing heterogeneity, the 
images were not resampled. Due to variations in especially the magnetic field strength, echo 
time, and repetition time, the image contrast highly varies, which will affect the feature values. 
To overcome this, each 3D MRI is normalized using z-scoring before feature extraction. 
The code to extract the features has been published open-source (https://github.com/
MStarmans91/LipoRadiomicsFeatures)
Appendix S2: Technical details on decision model creation
The Workflow for Optimal Radiomics Classification (WORC) toolbox1 makes us of adaptive 
algorithm optimization to create the optimal performing workflow from a variety of methods. 
We define a workflow as a sequential combination of algorithms and their respective 
parameters.
WORC includes algorithms to perform feature imputation, feature selection, feature 
scaling, oversampling, and machine learning. Feature selection was performed to eliminate 
features which are not useful to distinguish between WDLPS and lipoma. These included; 
1) a group-wise search, in which specific groups of features (i.e. intensity, shape, and the 
several subgroups of texture features as defined in Supplementary Materials 1) are selected 
or deleted; 2) a variance threshold, in which features with a low variance are removed; and 3) 
principal component analysis (PCA), in which only those linear combinations of features were 
kept which explained a large part of the variance in the features.




the machine learning methods may focus only on those features with large values. This was 
done through z-scoring, i.e. subtracting the mean value followed by division by the standard 
deviation. In this way, all features had a mean of zero and a variance of one.
Oversampling was used to make sure the classes (i.e. WDLPS and lipoma) were 
balanced in the training dataset. These include 1) random oversampling, which randomly 
repeats patients of the minority class; and 2) SMOTE2, which creates new synthetic patients 
using a combination of the patients in the minority class.
Lastly, machine learning methods were used to determine a decision rule to 
distinguish between WDLPS and lipoma. These included 1) logistic regression; 2) support 
vector machines; 3) random forests; 4) naive Bayes; and 5) linear and quadratic discriminant 
analysis.
Most of the included methods require specific settings or parameters to be set, which 
may have a large impact on the performance. As these parameters have to be determined 
before executing the workflow, these are so-called "hyperparameters". In WORC, we treat 
all parameters of all methods as hyperparameters, since they may all influence the decision 
model creation. Hence, we simultaneously determine which combination of algorithms and 
hyperparameters performs best.
In the training phase, a total of 100,000 pseudo-randomly generated workflows is 
created and executed. The workflows are ranked from best to worst based on the F1-score, 
which is the harmonic average of precision and recall. Due to the large number of workflows 
executed, there is a chance that the best performing workflow is overfitting, i.e. looking at too 
much detail or even noise in the training dataset. Hence, to create a more robust model and 
boost performance, WORC combines the 50 best performing methods into a single decision 
model, which is known as ensembling. The ensemble is created through averaging of the 
probabilities, i.e. the chance of a patient being WDLPS or lipoma, of these 50 workflows.
1. Workflow for Optimal Radiomics Classification (WORC). https://github.com/ 
MStarmans91/WORC. 
2. Han H, Wang W-Y, Mao B-H. Borderline-SMOTE: a new over-sampling method in   
imbalanced data sets learning. In; 2005; Berlin, Heidelberg: Springer Berlin Heidelberg; 
2005. p. 878-887.





Supplementary Figure S1. Visualization of the 100x stratified random-split cross-validation, including 
a second cross-validation within the training set to perform the automatic workflows optimization. 
Optimization was done solely on the training set in order to prevent overfitting on the test set. The 
ensemble averages the predictions of the best 50 performing workflows to create a more robust 
model. 
 
▲Figure S1. Visualization of the 100x stratified random-split cross-validation, including a second cross-
validation within the training set to perform the automatic workflows optimization. Optimization was 
done solely on the training set in order to prevent overfitting on the test set. The ensemble averages the 
predictions of the best 50 performing workflows to create a more robust model.
Supplementary Figure S2. P-values of Mann-Whitney U tests of feature values for WDLPS and lipomas. Only the features that 
had a corrected P-value <0.05 were included in the graph. The labels on the y-axis correspond to the feature names: see 
Supplementary Materials 1 for more details.
▲Figure S2. P-values of Mann-Whitney U tests of feature values for WDLPS and lipomas. Only the 
features that had a corrected P-value <0.05 were included in the graph. The labels on the y-axis 





Table S1. Several properties of the acquisition protocols of the 116 T1-weighted MRI sequences of 











Setting (Unit) Mean Std. Min. Max.
Slice Thickness (mm) 4.77 1.14 2.5 10.0
Repetition time (ms) 555 108 280 831
Echo time (ms) 13.2 4.3 5.7 37







Std.: standard deviation, min.: minimum value, max.: maximum value, mm: millimeters, ms: milliseconds, 
FS: Fat Saturation, GD: gadolinium contrast.
Table S2. Performance of the radiomics models based on T1 imaging features only; patient features 
only; manually scored features only; the combination of T1 imaging and manually scored features; and of 
volume only on the full dataset. Performance for the radiomics models is reported for each experiment 
















AUC 0.83 [0.75, 0.90] 0.75 [0.64, 0.85] 0.72 [0.62, 0.81] 0.69 [0.58, 0.79] 0.83 [0.75, 0.91]
Accuracy 0.68 [0.67, 0.84] 0.68 [0.59, 0.76] 0.67 [0.57, 0.76] 0.61 [0.51, 0.70] 0.76 [0.67, 0.84]
Sensitivity 0.68 [0.53, 0.82] 0.77 [0.63, 0.90] 0.76 [0.58, 0.94] 0.53 [0.37, 0.68] 0.67 [0.52, 0.81]
Specificity 0.84 [0.72, 0.95] 0.59 [0.45, 0.72] 0.57 [0.43, 0.71] 0.69 [0.54, 0.84] 0.84 [0.71, 0.97]
NPV 0.73 [0.63, 0.82] 0.73 [0.61, 0.85] 0.73 [0.59, 0.86] 0.60 [0.50, 0.69] 0.75 [0.66, 0.83]
PPV 0.82 [0.70, 0.93] 0.66 [0.58, 0.73] 0.64 [0.54, 0.74] 0.64 [0.51, 0.76] 0.81 [0.69, 0.93]
AUC: area under the curve, NPV: negative predictive value, PPV: positive predictive value
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Table S3. Performance of radiomics models trained on features extracted from various MRI sequences 
on the full dataset. Performance is reported as mean [95% confidence interval] over the cross-validation 
iterations.
T1 T1 + T1-FS T1 + T1-GD T1 + T1-FS-GD T1 + T2 T1 + T2-FS
AUC 0.83 [0.75, 0.90] 0.84 [0.75, 0.92] 0.81 [0.72, 0.90] 0.81 [0.73, 0.89] 0.89 [0.83, 0.95] 0.81 [0.73, 0.88]
Accuracy 0.68 [0.67, 0.84] 0.77 [0.69, 0.85] 0.76 [0.67, 0.84] 0.75 [0.66, 0.83] 0.81 [0.74, 0.87] 0.74 [0.66, 0.81]
Sensitivity 0.68 [0.53, 0.82] 0.69 [0.56, 0.82] 0.69 [0.56, 0.82] 0.66 [0.51, 0.81] 0.74 [0.61, 0.86] 0.66 [0.53, 0.79]
Specificity 0.84 [0.72, 0.95] 0.84 [0.73, 0.95] 0.77 [0.71, 0.83] 0.84 [0.72, 0.95] 0.88 [0.78, 0.98] 0.82 [0.70, 0.93]
NPV 0.73 [0.63, 0.82] 0.74 [0.65, 0.82] 0.73 [0.64, 0.82] 0.72 [0.63, 0.81] 0.78 [0.69, 0.86] 0.72 [0.63, 0.80]
PPV 0.82 [0.70, 0.93] 0.83 [0.72, 0.93] 0.80 [0.69, 0.91] 0.81 [0.69, 0.93] 0.88 [0.78, 0.97] 0.79 [0.68, 0.90]
AUC: area under the curve, NPV: negative predictive value, PPV: positive predictive value, FS: Fat Saturation, 
GD: gadolinium contrast  
Table S4. Performance of the three radiologists in differentiating between well-differentiated liposarcomas 
and lipomas on both the full and volume-matched cohort, and in differentiating dedifferentiated 
liposarcoma (DDLPS) and non-DDLPS (well-differentiated liposarcoma (WDLPS)/lipomas).
Full cohort Volume-matched cohort DDLPS vs. non-DDLPS
Rad. 1 Rad. 2 Rad.3 Rad. 1 Rad. 2 Rad. 3 Rad. 1 Rad. 2 Rad. 3
AUC 0.74 0.72 0.61 0.68 0.74 0.55 0.97 0.91 0.90
Accuracy 0.64 0.64 0.61 0.62 0.63 0.55 0.95 0.62 0.89
Sensitivity 0.74 0.91 0.64 0.65 0.88 0.60 0.95 0.95 0.91
Specificity 0.55 0.36 0.59 0.58 0.37 0.50 0.95 0.56 0.89
NPV 0.68 0.81 0.62 0.61 0.74 0.54 0.99 0.98 0.98
PPV 0.62 0.59 0.61 0.62 0.59 0.56 0.78 0.29 0.61
AUC: area under the curve, NPV: negative predictive value, PPV: positive predictive value, rad.: radiologist
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Background: Tumor location as a prognostic factor for patients with liposarcoma (LPS) has 
been studied modestly with varying outcomes. The aim was to establish the impact of tumor 
location on recurrence and survival of LPS patients.
Methods: A retrospective database of patients treated for LPS until December 2017 was used 
to assess 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) 
and disease-specific survival (DSS) per tumor location using the Kaplan-Meier method and 
log-rank test. A multivariable Cox regression analysis was performed to adjust for other 
prognostic factors.
Results: In total, 518 patients were identified with a median follow-up of 68 months 
(interquartile range 31–138). Patients with retroperitoneal/intrathoracic WDLPS or DDLPS 
(p = 0.014), or testicular WDLPS (p = 0.026) developed a local recurrence more often than 
patients with other tumor locations. No differences between LPS subtypes and tumor 
location in the development of metastases (p = 0.600) was observed. Five-year LRFS differed 
significantly between tumor locations (p < 0.001) as well as 5y-DSS (p < 0.001), but 5y-DMFS 
did not (p = 0.241), with retroperitoneal/intrathoracic LPS having a worse prognosis. Patients 
with WDLPS in the extremity, trunk or testicular region did not die of disease, except for the 
rare occasion of dedifferentiation upon recurrence. After adjustment for other prognostic 
factors, tumor location was only of prognostic value for DSS (retroperitoneal/intrathoracic 
vs. extremity: HR 5.08, 95% CI 2.41–10.71, p < 0.001).
Conclusion: For all tumor locations, DSS mimicked DMFS except for retroperitoneal/
intrathoracic LPS, where DSS mimicked LRFS and where DSS was worse than DMFS. This 
implies that these patients die of local disease instead of metastatic disease.
Keywords: Liposarcoma; Survival; Tumor location; Prognostic factor




Liposarcoma (LPS) is one of the most common subtypes of soft tissue sarcoma (STS), 
accounting for approximately 20% of all STS [1]. They arise from lipoblasts and adipocytes, 
and can therefore occur at any site of the body, but the most frequently observed locations 
are the extremity, the retroperitoneum and trunk [2]. Based on morphology and genetic 
aberrations, four subtypes can be distinguished: well-differentiated liposarcoma (WDLPS), 
dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS) and pleomorphic 
liposarcoma (PLPS) [2]. Some LPS cannot be further classified and form a residual group 
of LPS not otherwise specified (LPS NOS). For patients presenting with non-metastatic 
disease treatment usually consists of surgical removal of the tumor, optionally preceded or 
followed by radiotherapy, chemotherapy or an isolated limb perfusion (ILP). The choice for 
neoadjuvant/adjuvant treatment partially depends on the LPS subtype.
Unfortunately, a number of patients will develop a local recurrence and/or distant 
metastasis, or will die due to the disease. Previously identified prognostic factors for 
recurrence and survival include age, LPS subtype, tumor grade, tumor size and status of the 
resection margins [3-11], but the impact of primary tumor location as a prognostic factor has 
been studied modestly. Most of the studies compared multiple STS subtypes on one location 
[3-8], or just one of the LPS subtypes on multiple locations [12-15]. Until now, we identified 
only two articles studying primary LPS on multiple locations, but these two studies presented 
conflicting outcomes: one in which tumor location was of prognostic importance [16], and 
one in which location was not of significant importance [17]. The aim of this study was to 
establish the impact of tumor location in recurrence and survival in LPS patients.
Methods
Patient characteristics
Data of all patients diagnosed with and treated for LPS in the Erasmus MC Cancer Institute 
in Rotterdam, the Netherlands from June 1983 up to and including December 2017 were 
collected retrospectively. Patients with LPS NOS, distant metastases at time of diagnosis or 
with insufficient clinical data available were excluded.
Histological LPS subtypes were categorized according to the WHO classification and 
grading according to the FNCLCC [2]. Because of low numbers, tumors localized on the trunk 
and tumors localized in the head and neck region were combined, as well as retroperitoneal 
LPS with intrathoracic LPS. The resection margins were classified as R0 (microscopically 
negative margins), R1 (microscopically positive margins), R2 (macroscopically positive 




(alive, death of disease, death of other/unknown cause) and recurrence (local and/or distant) 
were obtained. In case of retroperitoneal LPS, a local recurrence was defined as recurrence 
of disease within the abdomen, including multifocal recurrences. Due to the retrospective 
nature of our data source, no distinction between a multifocal peritoneal recurrence (e.g. 
two peritoneal tumor depositions) and peritoneal sarcomatosis, which perhaps represents 
a more advanced stage of disease, could be made. Distant metastasis of retroperitoneal 
LPS was defined as disease outside of the abdomen. Follow-up was performed according to 
national and international guidelines [18].
Statistical analysis
Categorical data were presented as numbers with percentages, and continuous data were 
presented as medians with corresponding interquartile ranges (IQR). Chi-square and Fisher's 
Exact tests were used when appropriate. The median follow-up time was calculated using 
the reversed Kaplan-Meier method [19].
Local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and 
disease-specific survival (DSS) were defined as time (in months) between date of diagnosis 
and date of local recurrence, distant metastasis or death of disease, respectively. Time was 
censored at 5 years of follow-up for patients remaining free of local recurrences and distant 
metastasis or who were alive after 5 years of follow-up. The 5-year LRFS, DMFS and DSS were 
estimated using the Kaplan-Meier method and differences between subgroups were tested 
for their significance using the log-rank test.
To adjust for other prognostic factors, multivariable Cox regression analyses for LRFS, 
DMFS and DSS were performed. Firstly, the factors were tested univariably, and were added 
to the multivariable model in case the p-value was <0.05, together with the factor coding for 
tumor location. The results were reported as hazard ratios (HR) with their corresponding 
95% confidence intervals (95% CI). The main results of the Cox regression analyses are 
summarized in an overview, the complete results of both the univariable and multivariable 
analyses are presented in the supplemental tables. All statistical analyses were performed 
using SPSS (IBM SPSS Statistics, version 24).
Results
Patient characteristics
In total, 518 patients were identified who were diagnosed with and treated for LPS. There 
were slightly more males (56%) than females (44%), and the median age at time of diagnosis 
was 59 years (IQR 46–68). Most of the patients had a WDLPS (48%), followed by DDLPS (24%), 
MLPS (21%) and PLPS (8%). Most of the tumors were localized in one of the extremities 
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(49%), followed by the retroperitoneum/intrathoracic cavity (29%), trunk/head and neck 
region (15%) and testicular/inguinal region (7%). Most tumors were low-grade, due to the 
large proportion of WDLPS, and the median tumor size was 16 cm (IQR 10–23). A quarter 
of the patients received radiotherapy, mostly adjuvant, while a small fraction received 
chemotherapy (4%) or an ILP (6%) as part of their primary treatment. The median follow-up 
time was 68 months (IQR 31–138)(Table 1).
Tumor location versus liposarcoma subtype
More than half of the tumors localized in one of the extremities were WDLPS (51%), a third 
of the tumors MLPS (34%) and only a small proportion were DDLPS (7%) or PLPS (8%). 
Retroperitoneal/intrathoracic LPS were mostly of the DDLPS (55%) and WDLPS (38%) subtype, 
while tumors localized on the trunk/head and neck region were mostly WDLPS (58%) and 
less often MLPS (17%) or PLPS (17%). At last, testicular/inguinal tumors were mainly DDLPS 
(54%) and WDLPS (37%), and rarely PLPS (6%) or MLPS (3%)(Table 2).
Recurrence versus tumor location
In total, 36.7% of the patients developed a local recurrence (median time to local recurrence 
23 months, IQR 11–58) and 17.4% developed distant metastasis (median time to metastasis 
24 months, IQR 9–59)(Table 1). Since local recurrence and distant metastasis rates differ 
between LPS subtypes, the impact of tumor location was analyzed per subtype (Table 3). 
Patients with WDLPS developed significantly more often a local recurrence when the tumor 
was localized retroperitoneal/intrathoracic (53%) or in the testicular region (46%) than 
with tumors localized in the extremity (29%) or trunk/head and neck (30%, p = 0.014). Also 
patients with retroperitoneal/intrathoracic DDLPS experienced significantly more often a 
local recurrence (62%) than patients with other locations of DDLPS (extremity 33%, trunk/
head and neck 29%, testicular 37%, p = 0.026). In patients with MLPS (p = 0.274) and PLPS (p 
= 0.703) no differences in local recurrence rates between the different tumor locations were 
observed (Table 3).
Using Kaplan-Meier analysis, 5y-LRFS differed significantly between the different tumor 
locations (p < 0.001, Fig. 1A), with 5y-LRFS rates of 73.9% for patients with extremity LPS, 70.3% 
for patients with trunk/head and neck LPS, 64.5% for patients with testicular LPS and 35.8% 
for patients with retroperitoneal/intrathoracic LPS. After adjustment for other prognostic 
factors (LPS subtype, age, tumor size, status of the resection margins, neoadjuvant/adjuvant 
radiotherapy, chemotherapy and ILP) in a multivariable Cox regression analysis, tumor 




Table 1. Patient characteristics (N=518).
    N %
Gender Male 290 56.0
Female 228 44.0
Age (years), median (IQR) 59 (46-68)




Location Extremity 254 49.0
RPS + intrathoracic 150 29.0
Trunk + head&neck 79 15.3
Testis/inguinal 35 6.8








No resection 21 4.1
Tumor size (cm), median (IQR) 16 (10-23)
RTx No 387 74.7
Neoadjuvant 31 6.0
Adjuvant 100 19.3
CTx No 503 97.1
Neoadjuvant 8 1.5
Adjuvant 7 1.4
ILP No 491 94.6
Neoadjuvant 28 5.4
Local recurrence No 328 63.3
Yes 190 36.7
TLR (months), median (IQR) 23 (10.8-58)
Distant metastases No 428 82.6
Yes 90 17.4
TSD (months), median (IQR) 23.5 (8.8-58.5)
Survival Alive 352 68.0
Death of disease 122 23.6
Death of other/unknown cause 44 8.5
Follow-up (months), median (IQR) 68 (31-138)
WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; MLPS, myxoid 
liposarcoma; PLPS, pleomorphic liposarcoma; RPS, retroperitoneal sarcoma; IQR, interquartile range; 
RTx, radiotherapy; ILP, isolated limb perfusion; CTx, chemotherapy; TLR, time to local recurrence; TSD, 
time to systemic disease
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With regard to the distant metastasis rate, no significant differences between the 
different tumor locations in any of the LPS subtypes were observed (WDLPS: p = 0.773, DDLPS: 
p = 0.321, MLPS: p = 0.556, PLPS: p = 0.512, overall: p = 0.600)(Table 3). Additionally, there 
were no differences in the 5y-DMFS between the different tumor locations, with 5y-DMFS 
rates of 89.0% for patients with trunk/head and neck LPS, 84.8% for patients with extremity 
LPS, 80.1% for patients with testicular LPS and 77.3% for patients with retroperitoneal/
intrathoracic LPS (p = 0.241, Fig. 1B). Also in the multivariable analysis no significant impact 
for tumor location was observed (Table 4, Supplemental Table S2). 
Table 2. LPS subtype per primary tumor location
  Extremity RPS + intrathoracic Trunk + head&neck Testis Total
WDLPS 130 (51) 57 (38) 46 (58) 13 (37) 246 (48)
DDLPS 18 (7) 82 (55) 7 (9) 19 (54) 126 (24)
MLPS 86 (34) 7 (5) 13 (17) 1 (3) 107 (21)
PLPS 20 (8) 4 (3) 13 (17) 2 (6) 39 (8)
Total 254 (100) 150 (100) 79 (100) 35 (100) 518 (100)
WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; MLPS, myxoid 




▲Fig. 1. Five-year local recurrence-free survival (A), 5-year distant metastasis-free survival (B) and 5-year 
disease-specific survival (C) per tumor location of all patients diagnosed with and treated for liposarcoma. 
P-values were calculated using the log-rank test. RPS: retroperitoneal liposarcoma, H&N: head & neck.
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Table 3. Number of patients with a local recurrence (LR) and/or distant metastasis (DM).
LR, n (%) DM, n (%)
No Yes p No Yes p
WDLPS Extremity 92 (71) 38 (29) 0.014 127 (98) 3 (2) 0.773
RPS + intrathoracic 27 (47) 30 (53) 55 (96) 2 (4)
Trunk + head&neck 32 (70) 14 (30) 44 (96) 2 (4)
Testis 7 (54) 6 (46) 13 (100) 0 (0)
Total 158 (64) 88 (36) 239 (97) 7 (3)
DDLPS Extremity 12 (67) 6 (33) 0.026 16 (89) 2 (11) 0.321
RPS + intrathoracic 31 (38) 51 (62) 58 (71) 24 (29)
Trunk + head&neck 5 (71) 2 (29) 5 (71) 2 (29)
Testis 12 (63) 7 (37) 12 (63) 7 (37)
Total 60 (48) 66 (52) 91 (72) 35 (28)
MLPS Extremity 65 (76) 21 (24) 0.274 59 (69) 27 (31) 0.556
RPS + intrathoracic 4 (57) 3 (43) 5 (71) 2 (29)
Trunk + head&neck 10 (77) 3 (23) 10 (77) 3 (23)
Testis 0 (0) 1 (100) 0 (0) 1 (100)
Total 79 (74) 28 (26) 74 (69) 33 (31)
PLPS Extremity 17 (85) 3 (15) 0.703 10 (50) 10 (50) 0.512
RPS + intrathoracic 3 (75) 1 (25) 3 (75) 1 (25)
Trunk + head&neck 9 (69) 4 (31) 9 (69) 4 (31)
Testis 2 (100) 0 (0) 2 (100) 0 (0)
Total 31 (79) 8 (21) 24 (62) 15 (38)
Total   328 (63) 190 (37) <0.001‡ 428 (83) 90 (17) 0.600‡
‡χ2-test, all other tests were Fisher’s Exact tests. WDLPS, well-differentiated liposarcoma; DDLPS, 
dedifferentiated liposarcoma; MLPS, myxoid liposarcoma; PLPS, pleomorphic liposarcoma; RPS, 
retroperitoneal sarcoma; LR, local recurrence; DM, distant metastasis 
Remarkably, 7 of the patients with WDLPS developed metastatic disease, while 
this subtype is known for its lacking metastatic potential, unless the tumor undergoes 
dedifferentiation at recurrence. This was indeed the case for five out of the seven patients with 
metastatic 'WDLPS'. The sixth patient had multiple local recurrences which were all WDLPS, 
but at time of the last (multifocal) local recurrence also multiple lung lesions suspected for 
metastases were discovered. However, no biopsy or resection was performed on either 
the local recurrence or one of the lung lesions. A few months after the diagnosis of lung 
metastases the patient died. So, in our opinion it was likely that dedifferentiation also had 
occurred in this patient. The last patient developed a local recurrence and a paravertebral 
lesion simultaneously. The local recurrence was biopsied and showed WDLPS without any 
signs of dedifferentiation, but no biopsy of the paravertebral lesion was obtained. The patient 
is still alive, after ‘palliative’ radiotherapy of 24Gy, with a follow-up period of 60 months (42 
months after discovery of the paravertebral lesion), so we doubt if this atypical paravertebral 




Table 4. Impact of tumor location on local recurrence-free survival (LRFS), distant metastasis-free survival 
(DMFS) and disease-specific survival (DSS) after adjustment for other prognostic factors. Complete 
results of the Cox regression analyses are shown in supplemental tables S1, S2 and S3.
    N HR 95% CI p
LRFS Extremity 223 Ref
  RPS + intrathoracic 135 1.46 0.92-2.32 0.110
  Trunk + head&neck 68 1.16 0.66-2.05 0.604
  Testis/inguinal 30 1.29 0.62-2.70 0.503
DMFS Extremity 254 Ref
  RPS + intrathoracic 150 1.78 0.86-3.70 0.123
  Trunk + head&neck 79 1.08 0.53-2.21 0.838
  Testis/inguinal 35 1.64 0.66-4.03 0.285
DSS Extremity 223 Ref
  RPS + intrathoracic 135 5.08 2.41-10.71 <0.001
  Trunk + head&neck 68 1.87 0.81-4.30 0.142
  Testis/inguinal 30 1.15 0.32-4.14 0.826
LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; DSS, disease-specific survival; 
RPS, retroperitoneum; RTx, radiotherapy; CTx, chemotherapy; ILP, isolated limb perfusion; Tx, treatment; 
HR, hazard ration; 95% CI, 95% confidence interval.
Survival versus tumor location
The 5y-DSS differed significantly between the different tumor locations (p < 0.001, Fig. 
1C), with the best prognosis for patients with testicular LPS (5y-DSS 93.0%), patients with 
extremity LPS (86.4%) and trunk/head and neck LPS (86.1%). Patients with retroperitoneal/
intrathoracic LPS had a worse prognosis with a 5y-DSS rate of 62.2%. Also after adjustment 
for other prognostic factors, a retroperitoneal/intrathoracic tumor location had a worse 
prognosis compared to tumor location in the extremity (HR 5.08, 95% CI 2.41–10.71, p < 
0.001, Table 4, Supplemental Table S3).
Since the group of retroperitoneal/intrathoracic LPS mainly consisted of patients with 
WDLPS or DDLPS (total 93%, Table 2), an additional DSS analysis for these two LPS subtypes 
was performed to explore whether the worse prognosis was due to large proportion of 
DDLPS in this subgroup. As expected, DDLPS patients with a retroperitoneal/intrathoracic 
location had the worst prognosis (5y-DSS 50.3%), together with patients with a DDLPS on 
the trunk/head and neck (44.4%), followed by DDLPS patients with a location in the extremity 
(84.0%) and testis (88.2%, p = 0.023, Supplemental Fig. S1A). Also when analyzing patients 
with WDLPS, patients with retroperitoneal/intrathoracic WDLPS had a worse prognosis 
(5y-DSS 80.5%), while WDLPS patients with tumor locations in the extremity (99.2%), trunk/
head and neck (100%) or testis (100%) had an excellent prognosis (p < 0.001, Supplemental 
Fig. S1B). Only one patient with non-retroperitoneal WDLPS died of disease within 5 years of 
follow-up, which turned out to be treatment-related (5 days after ILP). In the total follow-up 
period, 4 patients with non-retroperitoneal WDLPS died of disease (after 75, 179, 210 and 
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226 months), all after dedifferentiation upon recurrence. Only of one patient with multiple 
local recurrences and lung metastases, dedifferentiation was not pathologically confirmed.
Neoadjuvant/adjuvant treatment in LPS
Neoadjuvant/adjuvant treatment of the primary tumor was also included in the Cox regression 
analyses for LFRS, DMFS and DSS. For LRFS, radiotherapy as well as chemotherapy and ILP 
tested significantly in univariable analysis, but only radiotherapy remained of significant 
influence in the multivariable analysis, reducing the risk of a local recurrence (HR 0.19, 95% 
CI 0.11–0.35, p < 0.001, Supplemental Table S1). Also for DMFS all three treatment modalities 
tested significantly in univariable analysis, but none of them remained significant in 
multivariable analysis (Supplemental Table S2). For DSS, only CTx and ILP tested significantly 
in univariable analysis, but again both lost their prognostic value in multivariable analysis 
(Supplemental Table S3).
Discussion
The results of this study show that primary tumor location has an impact on local recurrence-
free survival and disease-specific survival, while no differences in distant metastasis-free 
survival were observed.
Despite that there was no difference in DMFS, patients with retroperitoneal/
intrathoracic LPS have a worse prognosis than patients with a LPS localized elsewhere. 
Generally, patients with cancer die because of metastatic disease, but these data confirmed 
that retroperitoneal/intrathoracic LPS is one of the few entities where patients also can die 
because of local disease, as indicated by the worse LRFS. This is further underlined by Fig. 
1, showing that the DSS is worse than the DMFS and that the DSS curve of patients with 
retroperitoneal/intrathoracic LPS mimics the LRFS curve. For the other tumor locations, the 
DSS curves resemble the DMFS curves more. The worse prognosis of these patients might be 
explained by the large proportion of patients with DDLPS or a higher percentage of irradical 
resections (R1/R2) in this subgroup. However, after adjusting for the status of resection 
margins and for LPS subtype in a multivariable analysis, still a worse DSS for patients with 
retroperitoneal/intrathoracic tumors was observed. Additionally, we separately analyzed the 
patients with WDLPS, and patients with a retroperitoneal/intrathoracic tumor location again 
had a worse prognosis than patients with WDLPS on other locations (Supplemental Fig. S1). 
Multiple explanations for the worse prognosis of retroperitoneal/intrathoracic LPS can be 
thought of, including delayed detection because of a lack of symptoms, allowing the tumor 
to grow silently and resulting in more complex and extensive surgery, but it is still unclear if it 





Since patients with retroperitoneal/intrathoracic LPS die because of local disease and 
local control proved to be essential, we might need to reconsider the local treatment options, 
consisting of 1) surgery and 2) radiotherapy. Evidently, the goal of surgery is complete resection 
of the tumor, but especially for retroperitoneal sarcomas there is an ongoing discussion 
regarding the appropriate extent of resection. Usually, a ‘simple’ complete resection is 
performed, enucleating the tumor, sometimes in combination with en-bloc resection of an 
involved adjacent organ. However, there are clues that a compartmental resection, during 
which also uninvolved adjacent organs are resected to ensure wide margins, is associated 
with lower recurrences rates and improved overall survival [20-22]. However, these studies 
were based on retrospective data, which inherently leads to selection and information bias 
amongst others, and compartmental resections might lead to higher complications rates. 
Secondly, the use of neoadjuvant/adjuvant radiotherapy in this patient group might be 
reconsidered. Neoadjuvant/adjuvant radiotherapy as part of the primary treatment had no 
significant effect on DMFS or DSS, but did have a protective effect on LRFS in multivariable 
analysis in this study. Additionally, a previous study on extremity LPS also showed that an 
aggressive treatment approach (resection with wide margins and radiotherapy) resulted in 
excellent local control in extremity WDLPS, but also that this did not result in better disease-
specific survival [23]. Given its toxicity, varying effectivity and missing effect on survival, we are 
currently reluctant in giving radiotherapy in our center, despite the better local control. Only 
a quarter of the patients received radiotherapy in this cohort, whereas this percentage might 
be higher in other centers/cohorts [23]. However, since local control appears to be crucial 
in retroperitoneal/intrathoracic LPS, the use of radiotherapy for the sake of local control 
needs to be reevaluated, which is currently being done in the STRASS trial. Although the first 
results of the STRASS trial – randomizing between neoadjuvant radiotherapy plus surgery 
versus surgery alone for patients with retroperitoneal sarcoma – overall showed no benefit 
of neoadjuvant radiotherapy in terms of abdominal recurrence-free survival, a subgroup 
analysis demonstrated that neoadjuvant radiotherapy might benefit the LPS subgroup [24]. 
However, the final results, including data on overall survival, are pending and needed to 
see whether the improved abdominal recurrence-free survival will result in improved overall 
survival.
To the best of our knowledge, there were only two studies comparing the outcomes of 
the different LPS subtypes taking all tumor locations into account: one study in which tumor 
location was not of prognostic value [17] and one study in which it was of prognostic value 
[16]. In the latter study, patients with retroperitoneal disease also had a worse prognosis than 
patients with tumors in the lower extremity, upper extremity or trunk. This study confirms 
these results, but contradicts the results of the other study. Possible explanations for the 
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different outcomes could be the distribution of LPS subtypes, the distribution of the different 
tumor locations or the number of included patients. The distribution of LPS subtypes was 
comparable between the two studies and our study, but in the study of Knebel et al. [17] 
only 130 patients were included, of whom almost 85% had a tumor localized in the extremity, 
approximately 10% in the retroperitoneum/pelvis, and only 4.5% in the trunk/head and neck 
region and 1% in the spermatic cord. On the contrary, Dalal et al. [16] included 801 patients 
with a distribution of the tumor locations comparable to ours, with 56.5% of the tumors 
localized in the extremity, 28% in the retroperitoneum and 11% in the trunk.
The survival rates observed in this study are comparable to the survival rates reported 
in literature. For retroperitoneal LPS, 5-year overall survival (5y-OS) rates of 60% (all LPS) [11], 
57% (only 50% LPS included) [20] and 54% (58% LPS) [8] have been reported, compared to 
5y-DSS of 62% in this study. For extremity LPS, a 5y-DSS rate of 80% [9], 12y-DSS rate of 87% 
for the upper extremity and 82% [16] for lower extremity LPS have been reported, compared 
to 5y-DSS of 86% in our study.
Evidently, our study has some limitations. Because of the retrospective nature, which is 
inevitable when studying rare diseases, selection bias and information bias may have been 
introduced. We tried to minimize the selection bias by including all LPS patients without any 
exclusion criteria except for insufficient available data and metastatic disease at diagnosis. 
Strengths of this study are the large number of included patients and that the results are 
based on daily clinical practice.
Currently, treatment is more or less similar for the different LPS subtypes or tumor 
locations, but more and more evidence is becoming available showing STS and even LPS is 
not a single entity. For each STS/LPS subtype, and maybe even for each tumor location, a 
different treatment approach might be needed and preferable.
Conclusion
A retroperitoneal/intrathoracic tumor location had a negative effect on disease-specific 
survival of LPS patients. These patients also developed local recurrent disease more often 
than patients with other tumor locations, but no differences in distant metastases were 
observed. This implies that these patients die of local disease instead of metastatic disease 
and that the local treatment options, including the extent of surgery and radiotherapy, 
should be reevaluated. Radiotherapy improved local control, but had no effect on distant 
metastasis-free survival or disease-specific survival in this cohort. Therefore, pending the 
final results on overall survival of the STRASS trial, the use of radiotherapy in retroperitoneal/
intrathoracic LPS should be reconsidered, since in this patient group local control proved to 




region did not die of disease, except for rare cases in whom the tumor had dedifferentiated 
upon recurrence.
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Appendix A. Supplementary data 
Supplemental figure S1. Five-year disease-specific survival per tumor location 
specified for patients with (A) dedifferentiated liposarcoma (DDLPS) and (B) 
well-differentiated liposarcoma (WDLPS). RPS: retroperitoneal liposarcoma, 
H&N: head & neck.
▲Supplemental Figure S1. Five-year disease-specific survival per tumor location specified for patients 
with (A) dedifferentiat d liposarcoma (DDLPS) and (B) well-differentiated liposarcoma (WDLPS). RPS: 




Supplemental Table S1. Complete results of the univariable and multivariable Cox regression analyses 
for local recurrence-free survival.
    Univariable Multivariable
    N HR 95% CI p N HR 95% CI p
Age at time of diagnosis 518 1.02 1.00-1.03 0.006 456 1.02 1.00-1.03 0.009
Gender Male 290 Ref
  Female 228 1.14 0.86-1.52 0.363
Subtype WDLPS 246 Ref 218 Ref
DDLPS 126 2.07 1.50-2.85 <0.001 113 2.39 1.59-3.60 <0.001
MLPS 107 0.59 0.38-0.90 0.014 89 1.70 0.94-3.05 0.078
  PLPS 39 0.49 0.24-1.00 0.051 36 1.66 0.70-3.94 0.249
Grade I 297 Ref
II 36 1.14 0.66-1.95 0.646
III 76 1.42 0.95-2.13 0.091
  Unknown 109 1.24 0.86-1.79 0.243
Location Extremity 254 Ref 223 Ref
RPS + 
intrathoracic
150 3.40 2.46-4.70 <0.001 135 1.46 0.92-2.32 0.110
Trunk + 
head&neck
79 1.23 0.77-1.98 0.388 68 1.16 0.66-2.05 0.604
  Testis/inguinal 35 1.70 0.95-3.03 0.072 30 1.29 0.62-2.70 0.503
Tumor size   469 1.05 1.03-1.06 <0.001 456 1.02 1.01-1.04 0.012
Resection R0 149 Ref 136 Ref
margins R1 197 1.49 1.02-2.20 0.042 191 1.17 0.74-1.86 0.503
R2 45 4.07 2.39-6.91 <0.001 44 3.66 1.96-6.81 <0.001
  Rx 106 2.24 1.50-3.32 <0.001 85 1.39 0.84-2.32 0.204
RTx No 387 Ref 335 Ref
  Yes 131 0.21 0.13-0.35 <0.001 121 0.19 0.11-0.35 <0.001
CTx No 503 Ref 446 Ref
  Yes 15 2.48 1.15-5.32 0.020 10 1.69 0.75-3.81 0.210
ILP No 490 Ref 429 Ref
  Yes 28 0.36 0.15-0.88 0.026 27 0.71 0.28-1.84 0.479
WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; MLPS, myxoid liposarcoma; 
PLPS, pleomorphic liposarcoma; RPS, retroperitoneum; RTx, radiotherapy; CTx, chemotherapy; ILP, 
isolated limb perfusion; Tx, treatment; HR, hazard ration; 95% CI, 95% confidence interval.
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Supplemental Table S2. Complete results of the univariable and multivariable Cox regression analyses 
for distant metastasis-free survival.
    Univariable Multivariable
    N HR 95% CI p N HR 95% CI p
Age at time of diagnosis 518 0.99 0.98-1.01 0.180
Gender Male 290 Ref
  Female 228 0.71 0.46-1.08 0.108
Subtype WDLPS 246 Ref 246 Ref
DDLPS 126 13.08 5.80-29.52 <0.001 126 6.74 2.46-18.44 <0.001
MLPS 107 10.34 4.57-23.37 <0.001 107 8.43 3.26-21.84 <0.001
  PLPS 39 15.53 6.33-38.10 <0.001 39 9.02 2.96-27.46 <0.001
Grade I 297 Ref 297 Ref
II 36 4.42 2.13-9.16 <0.001 36 1.20 0.53-2.72 0.670
III 76 8.47 4.85-14.80 <0.001 76 2.18 1.07-4.41 0.031
  Unknown 109 4.60 2.59-8.15 <0.001 109 1.31 0.67-2.56 0.437
Location Extremity 254 Ref 254 Ref
RPS + 
intrathoracic
150 1.38 0.86-2.21 0.187 150 1.78 0.86-3.70 0.123
Trunk + 
head&neck
79 0.82 0.42-1.60 0.569 79 1.08 0.53-2.21 0.838
  Testis/inguinal 35 1.45 0.68-3.09 0.336 35 1.64 0.66-4.03 0.285
Tumor size   473 1.01 0.99-1.04 0.219
Resection R0 149 Ref
margins R1 197 0.73 0.45-1.19 0.204
R2 45 1.71 0.84-3.46 0.137
  Rx 106 0.46 0.24-0.86 0.016
RTx No 387 Ref 387 Ref
  Yes 131 2.11 1.39-3.21 0.001 131 1.11 0.65-1.88 0.702
CTx No 503 Ref 503 Ref
  Yes 15 2.95 1.19-7.28 0.019 15 1.87 0.71-4.96 0.208
ILP No 490 Ref 490 Ref
  Yes 28 2.97 1.65-5.35 <0.001 28 1.66 0.84-3.28 0.143
WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; MLPS, myxoid liposarcoma; 
PLPS, pleomorphic liposarcoma; RPS, retroperitoneum; RTx, radiotherapy; CTx, chemotherapy; ILP, 




Supplemental Table S3. Complete results of the univariable and multivariable Cox regression analyses 
for disease-specific survival.
    Univariable Multivariable
    N HR 95% CI p N HR 95% CI p
Age at time of diagnosis 518 1.02 1.00-1.03 0.029 456 1.01 1.00-1.03 0.126
Gender Male 290 Ref
  Female 228 0.90 0.63-1.29 0.569
Subtype WDLPS 246 Ref 218 Ref
DDLPS 126 7.28 4.44-11.94 <0.001 113 3.74 1.70-8.22 0.001
MLPS 107 2.53 1.44-4.42 0.001 89 3.99 1.56-10.18 0.004
  PLPS 39 4.39 2.24-8.59 <0.001 36 7.17 2.45-20.99 <0.001
Grade I 297 Ref 260 Ref
II 36 2.40 1.22-4.71 0.011 33 1.06 0.44-2.54 0.894
III 76 5.64 3.52-9.02 <0.001 71 2.01 0.99-4.07 0.053
  Unknown 109 4.14 2.62-6.52 <0.001 92 1.90 0.95-3.81 0.071
Location Extremity 254 Ref 223 Ref
RPS + 
intrathoracic
150 4.00 2.68-5.96 <0.001 135 5.08 2.41-10.71 <0.001
Trunk + 
head&neck
79 0.88 0.45-1.74 0.718 68 1.87 0.81-4.30 0.142
  Testis/inguinal 35 0.74 0.26-2.08 0.568 30 1.15 0.32-4.14 0.826
Tumor size   473 1.05 1.03-1.07 <0.001 456 1.04 1.02-1.07 <0.001
Resection R0 149 Ref 136 Ref
margins R1 197 1.11 0.70-1.76 0.671 191 0.63 0.34-1.14 0.127
R2 45 4.08 2.28-7.29 <0.001 44 2.17 1.07-4.41 0.032
  Rx 106 0.68 0.40-1.18 0.172 85 0.61 0.30-1.23 0.167
RTx No 387 Ref
  Yes 131 0.87 0.57-1.33 0.523
CTx No 503 Ref 446 Ref
  Yes 15 3.92 1.98-7.77 <0.001 10 1.10 0.44-2.71 0.845
ILP No 490 Ref 429 Ref
  Yes 28 1.93 1.08-3.43 0.026 27 1.69 0.76-3.75 0.198
WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; MLPS, myxoid liposarcoma; 
PLPS, pleomorphic liposarcoma; RPS, retroperitoneum; RTx, radiotherapy; CTx, chemotherapy; ILP, 
isolated limb perfusion; Tx, treatment; HR, hazard ration; 95% CI, 95% confidence interval.
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Background: Liposarcomas can be divided into four subtypes and are most frequently located 
in the extremities. There are currently no studies comparing the clinical outcomes, such as 
local recurrence and distant metastasis, between the distinct subtypes of primary LPS of the 
extremity specifically.
Methods: Retrospective databases of two expertise centres (Rotterdam-R, Warsaw-W) 
of patients with liposarcoma located in the extremities from 1985 to 2015 were used to 
analyse 5-year local recurrence-free survival (5y-LRFS), 5-year distant metastasis-free survival 
(5y-DMFS) and 5-year overall survival (5y-OS).
Results: We identified 456 patients: 192 well-differentiated liposarcomas (WDLPS), 172 myxoid 
liposarcomas (MLPS), 54 pleomorphic liposarcomas (PLPS), 23 dedifferentiated liposarcomas 
(DDLPS) and 15 other subtypes. The frequency of (neo)adjuvant radiotherapy (R: 34.5% vs. 
W: 78.4%) and R0-resections (R: 41.0% vs. W: 84.1%) differed between the datasets. Local 
recurrences (LR) were observed most frequently in DDLPS (5y-LRFS 62.4%), followed by PLPS 
(71.4%), WDLPS (77.0%) and MLPS (84.5%, p = 0.054). Distant metastases (DM) were most 
commonly observed in PLPS (5y-DMFS 46.9%), followed by MLPS (74.0%), DDLPS (86.3%) 
and WDLPS (97.3%, p < 0.001). 5y-OS was poorest in patients with PLPS (47.6%) and DDLPS 
(54.4%), followed by MLPS (79.7%) and WDLPS (92.4%, p < 0.001). Male gender significantly 
increased the risk of LR and DM. The subtypes MLPS and PLPS were significant prognostic 
factors for DM and OS. Additionally, DDLPS and age had significant impact on OS.
Conclusion: In the largest cohort of extremity LPS patients reported to date, LPS subtypes 
show distinct patterns of LR, DM and OS, stressing that 'extremity LPS' is not a single entity.
Keywords: Liposarcoma; Extremity; Survival; Recurrence; Treatment




Liposarcoma (LPS) is one of the most common subtypes of soft tissue sarcoma (STS), 
representing approximately 20% of all STS [1, 2]. They arise from lipoblasts and can be 
located throughout the body, but are most frequently localised in the extremities. Based 
on their morphological and genetic features, four major subtypes can be distinguished: 
well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid 
liposarcoma (MLPS) and pleomorphic liposarcoma (PLPS). Additionally, there is a small 
residual group with liposarcomas not otherwise specified (LPS NOS) [3]. These four major 
subtypes harbour distinct molecular aberrations. Where WDLPS (also known as atypical 
lipomatous tumours) and DDLPS – which are thought to arise from WDLPS – are characterized 
by amplification of the MDM2 gene, MLPS harbours in >90% of the patients a translocation of 
chromosome t(12;16)(q13;p11) resulting in the expression of the fusion protein FUS-CHOP. 
The last subtype, PLPS, has a complex karyotype with multiple defects.
Treatment of extremity LPS without distant metastases usually consists of surgical 
resection, optionally preceded by neoadjuvant radiotherapy, chemotherapy or isolated 
limb perfusion, and/or followed by adjuvant radiotherapy or chemotherapy. Indications for 
neoadjuvant/adjuvant treatment include large tumour size, involvement of the neurovascular 
bundle (neoadjuvant treatment) and positive resection margins (adjuvant therapy) amongst 
others. Despite optimal (multimodality) treatment, the different LPS subtypes often relapse 
locally and/or at distant sites, a situation in which patients generally only have very little 
chance of cure. Few studies have investigated the factors impacting recurrences of primary 
LPS of the extremities, but these studies were conducted mostly on small patient groups, 
using all primary tumour sites, focussing on all STS types or just one of the LPS subtypes [4-
14], rather than comparing the four major LPS subtypes in a larger cohort on one primary 
tumour site. This is in contrast with retroperitoneal STS or LPS, in which several studies 
already have been conducted and there is more clarity on different factors predicting 
recurrence and survival [15-17]. 
The Erasmus MC Cancer Institute in Rotterdam and Maria Skłodowska-Curie Institute-
Oncology Center in Warsaw are two tertiary referral centres and expertise centres for STS, 
treating a substantial part of STS patients in the Netherlands and Poland, respectively. The 
aim of this study is to investigate the differences in recurrence and survival of the different 
subtypes of primary LPS of the extremity, including the influence of diverse clinicopathological 






All patients treated for primary extremity LPS between 1986 and 2015 at the Erasmus MC 
Cancer Institute (Rotterdam-cohort), and between 1990 and 2015 at the Maria Skłodowska-
Curie Institute-Oncology Center (Warsaw-cohort) were identified based on pathology reports, 
and data was collected retrospectively. Patients with metastatic disease or local recurrence 
at presentation, or with insufficient clinical information available were excluded. This study 
was performed in accordance with local ethics committee guidelines and national legislation.
Histologic subtypes were classified following the WHO classification of soft tissue 
tumours, and round-cell LPS was considered high-grade MLPS [3]. Cases in which tumour 
characteristics (particularly subtype) were not clear based on the pathology reports were 
reviewed by a pathologist with expertise in soft tissue sarcomas. Resection margins were 
classified as R0 (microscopic negative margins), R1 (microscopic positive margins), R2 
(macroscopic positive margins) or Rx (unknown/not assessed). In the Rotterdam-cohort, 
patients who received radiotherapy were treated with standard schedules of 50 Gy 
(preoperatively) or 60-70 Gy (postoperatively). In the Warsaw-cohort, hypofractionated 
radiotherapy schedules of 5 x 4-5 Gy (preoperatively) and standard schedules of 60-70 Gy 
(post-operatively) were used. In patients who received both preoperative and postoperative 
radiotherapy, postoperative radiotherapy was used as a boost because of unsure resection 
margins. Follow-up schedules slightly differed between the two centres, but both included 
one-time imaging of the local site 3-6 months after surgery, more frequent follow-up visits 
in the first 3-5 year after treatment and regular imaging of the chest. Complete follow-
up schedules are shown in Appendix table A. During follow-up, information about status 
of disease (recurrence of disease, local and/or distant) and vital status (alive/death) was 
obtained. For the Rotterdam-cohort, also data on cause of death (death of disease, death of 
other/unknown cause) was available. Of patients who were classified as dying of unknown 
cause, there was no information on cause of death available, as well as no signs of recurrent 
or metastatic disease at last follow-up. These deaths were not attributed or unlikely related 
to LPS or LPS treatment.
Statistical methods
Patients' characteristics were described using descriptive statistics. Fisher's Exact tests, 
χ2-tests (for categorical data) and Mann-Whitney U tests (for continuous data) were used 
when appropriate. Median follow-up time with corresponding interquartile range (IQR) was 
calculated by using the reversed Kaplan-Meier method and statistics by the log-rank test [18]. 
Patients with LPS subtypes other than the four major subtypes (WDLPS, DDLPS, MLPS, and 
PLPS) were excluded from the survival and Cox regression analyses, because this subgroup 
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is too small. Local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and 
overall survival (OS) were defined as time (in months) between diagnosis and the occurrence 
of local recurrence (LR), distant metastasis (DM) and death from any cause respectively. 
Additionally, disease-specific survival (DSS) was analysed for the Rotterdam-cohort, defined 
as time (in months) to death of disease. Time was censored at 5 years follow-up for patients 
remaining LR-free, DM-free or alive. LRFS, DMFS, DSS and OS curves were estimated by using 
the Kaplan-Meier method and reported as 5-year survival rates with corresponding standard 
errors (SE). Differences between subgroups were tested for their significance by the log-
rank test. Because of the long time period during which patients were included, additional 
analyses were performed to determine whether there were differences in outcome over the 
years. To this end, incidence years were clustered into groups of five years and Kaplan-Meier 
estimates with log-rank test statistics were calculated.
Diverse clinicopathological variables (age at diagnosis, gender, LPS subtype, grade, 
site, size, resection margins, neoadjuvant and adjuvant treatment) were assessed for their 
impact on LR, DM and OS by Cox regression models. A variable coding for either one of 
the centres was added to the multivariable analyses to correct for differences in baseline 
characteristics. Due to the relatively small number of events, it was not possible to set up 
a reliable Cox regression analysis for DSS in the Rotterdam-cohort. Variables with a p-value 
<0.05 in univariable analysis were included in the multivariable Cox proportional hazard 
regression models. The definitive models were obtained with an enter method. Hazard ratios 
(HRs) with corresponding 95% confidence intervals (CIs) are described. P-values <0.05 were 
considered statistically significant. SPSS was used for statistical analyses (IBM SPSS Statistics 
for Windows, Version 21.0).
Results
Patient characteristics
In total, 456 patients were identified: 229 in the Rotterdam-cohort and 227 in the Warsaw-
cohort, with a median follow-up time of 61 months. In the Rotterdam-cohort, we observed 
113 patients with WDLPS (49.3%), 77 patients with MLPS (33.6%), 13 patients with DDLPS 
(5.7%), 20 patients with PLPS and 6 patients with other LPS subtypes (2.6%). In the Warsaw-
cohort, more aggressive subtypes were observed: MLPS was the most common subtype (95 
patients, 41.9%), followed by WDLPS with 79 patients (34.8%), PLPS (34 patients, 15.0%), DDLPS 
(10 patients, 4.4%) and other LPS subtypes (9 patients, 4.0%). Subsequently, significantly 
more high grade tumours were observed in the Warsaw-cohort. In the Rotterdam-cohort, 
in total 34.5% received neoadjuvant/adjuvant radiotherapy, where in the Warsaw-cohort in 
total 78.9% of the patients received neoadjuvant/adjuvant radiotherapy (p < 0.001, Table 




(84.1%) compared to the Rotterdam-cohort (41.0%, p < 0.001) and patients in the Rotterdam-
cohort experienced local recurrence more often (Rotterdam: 26.% vs. Warsaw: 11.9%, p < 
0.001). The patients with other LPS subtypes were excluded from further analyses.
Table 1. Patient characteristics.







    N % of 
total
N % of 
total
N % of 
total
Gender Female 224 49.1 115 50.2 109 48.0 0.638
Male 232 50.9 114 49.8 118 52.0
Age (yrs.), median (IQR) 55 (43-66) 56 (43-67) 54 (44-64) 0.138
Subtype WDLPS 192 42.1 113 49.3 79 34.8 0.014b
DDLPS 23 5.0 13 5.7 10 4.4
MLPS 172 37.7 77 33.6 95 41.9
PLPS 54 11.8 20 8.7 34 15.0
Other subtypes 15 3.3 6 2.6 9 4.0
Site Upper extremity 49 10.7 23 10.0 26 11.5 0.627
Lower extremity 407 89.3 206 90.0 201 88.5
Grade I 230 50.4 145 63.3 85 37.4 <0.001b
II 56 12.3 18 7.9 38 16.7
III 89 19.5 31 13.5 58 25.6
Unknown 81 17.8 35 15.3 46 20.3
Resection margins Radical (R0) 285 62.5 94 41.0 191 84.1 <0.001b
Non-radical (R1/R2) 129 28.3 93 40.6 36 15.9
Unknown 35 7.7 35 15.3 0 0
No resection 7 1.5 7 3.1 0 0
Tumor size (cm), median (IQR) 15 (10-21) 15 (10.5-21) 15 (10-20) 0.486
Neoadjuvant None 239 52.4 185 80.8 54 23.8 <0.001b,c
therapy RTx 168 36.8 14 6.1 154 67.8
ILP 28 6.1 28 12.2 0 0
CTx 5 1.1 0 0 5 2.2
CTx and RTx 14 3.1 0 0 14 6.2
Unknown 2 0.4 2 0.9 0 0
Adjuvant therapy None 370 81.1 160 69.9 210 92.5 <0.001b,c
RTx 82 18.0 65 28.4 17 7.5
CTx 1 0.2 1 0.4 0 0
Unknown 3 0.7 3 1.3 0 0
Local recurrence (LR) Yes 88 19.3 61 26.6 27 11.9 <0.001b
No 368 80.7 168 73.4 200 88.1
Time to LR (mo.), 
median (IQR)
22.5 (10.3-59.3) 43 (14-70.5) 13 (8-35) 0.006b
Distant metastasis (DM) Yes 92 20.2 40 17.5 52 22.9 0.148
No 364 79.8 189 82.5 175 77.1
Time to DM (mo.), 
median (IQR)
21 (9.3-34.3) 24.5 (9.3-58.8) 17 (9.3-27) 0.210
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    N % of 
total
N % of 
total
N % of 
total
Survival Alive 357 78.3 170 74.2 187 82.4 0.035b
Dead 99 21.7 59 25.8 40 17.6
- Death of disease - - 38 16.6 - -
- Death of other/
unknown causes
- - 21 9.2 - -
  Follow-up time 
(mo.), median (IQR)
61 (32-109) 68 (31-126) 57 (32-84) <0.001b,d
Abbreviations: WDLPS: well-differentiated liposarcoma, DDLPS: dedifferentiated liposarcoma, MLPS: 
myxoid liposarcoma, PLPS: pleomorphic liposarcoma, RTx: radiotherapy, ILP: isolated limb perfusion, 
CTx: chemotherapy 
a P-values calculated by χ2-tests (categorical data) and Mann-Whitney U tests (continuous data), unless 
otherwise stated       
b Significant at level of α<0.05  
c Calculated by Fisher’s Exact Test  
d Calculated by log-rank test (because median follow-up time was calculated by the reversed Kaplan-
Meier method)
Recurrence patterns
Of the remaining 441 patients, 57 patients (12.9%) developed a local recurrence (LR), 57 
patients (12.9%) developed distant metastasis (DM), 31 patients experienced both LR and 
DM (7.0%), while 296 patients (67.1%) had no evidence of recurrent disease at last follow-
up. LR was most commonly observed in DDLPS (5/23 patients) with a 5y-LRFS of 62.4% (SE 
14.7%), followed by PLPS (12/54, 71.4%, SE 7.5%), WDLPS (29/192, 77.0%, SE 4.0%) and MLPS 
(22/172, 84.5%, SE 3.2%, p = 0.054, Fig. 1A). Median time to LR was 22.5 months (IQR 10.3-
59.3).
DM was most frequently observed in patients with PLPS (25/54 patients) with a 5y-DMFS 
of 46.9% (SE 7.6%). MLPS was the second most common subtype experiencing DM (40/172, 
74.0%, SE 3.6%), followed by DDLPS (2/23, 86.3%, SE 9.2%). DM in patients with WDLPS was 
rare (4/192, 97.3%, SE 1.3%, p < 0.001, Fig. 1B). Of the four patients with metastatic WDLPS, 
at least two patients had dedifferentiated disease, one patient had non-dedifferentiated 
disease (i.e. WDLPS) and of one patient the dedifferentiation status is unknown. However, 
this patient died one month after diagnosis of extensive metastatic disease, suggesting 
















No. at risk      
WDLPS 192 168 144 116 96 76 
DDLPS 23 17 14 9 9 7 
MLPS 172 152 127 103 91 76 



















No. at risk      
WDLPS 192 168 145 119 99 79 
DDLPS 23 17 14 10 9 7 
MLPS 172 159 142 119 102 84 



















No. at risk      
WDLPS 192 162 132 110 86 63 
DDLPS 23 16 12 7 6 4 
MLPS 172 151 130 108 91 74 







▲Fig. 1. 5-year local recurrence-free survival per liposarcoma subtype (A), 5-year distant metastasis-free 
survival per liposarcoma subtype (B) and 5-year overall survival per liposarcoma subtype (C).
Lastly, 5y-OS also differed significantly between subtypes (p < 0.001, Fig. 1C). The 5y-
OS was poorest for patients with PLPS (23/54, 47.6%, SE 7.9%), followed by patients with 
DDLPS (7/23, 54.4%, SE 13.4%), patients with MLPS (29/172, 79.7%, SE 3.4%) and patients 
with WDLPS (11/192, 92.4%, SE 2.3%).
Because of the long time period during which patient data was collected, an additional 
analysis was performed to determine whether there was a difference in the outcome 
measures (5y-LRFS, 5y-DMFS or 5y-OS) over time. There were no significant differences in 
either of these outcomes over the years from 1986 to 2015 (5y-LRFS: p = 0.731, 5y-DMFS: p 
= 0.696, 5y-OS: p = 0.690, data not shown).
Differences between centres
Between centres, a significant difference in 5y-LRFS for all subtypes was observed (Rotterdam: 
73.1%, SE 3.7% vs. Warsaw: 85.5%, SE 2.8%, p = 0.030, Table 2). When analysing the 
subgroups, this difference was almost completely attributable to the difference in 5y-LRFS 
in patients with WDLPS (Rotterdam: 65.0%, SE 5.9% vs. Warsaw: 94.1%, SE 3.4%, p < 0.001), 
whereas in the other subtypes no significant difference in 5y-LRFS was found between the 
centres (DDLPS: p = 0.608, MLPS: p = 0.873, PLPS: p = 0.184, Table 2).
There was no significant difference in 5y-DMFS between the two centres (Rotterdam: 
84.6%, SE 2.7% vs. Warsaw: 77.2%, SE 3.1%, p = 0.056), nor in 5y-OS (Rotterdam: 78.5%, SE 
3.2% vs. Warsaw: 80.9%, SE 3.1%, p = 0.561, Table 2). However, when analysing differences 
in 5y-OS rates per subtype between the centres, we observed a significant difference in 5y-
OS between Rotterdam and Warsaw in patients with WDLPS (Rotterdam: 10/113, 88.2%, SE 
3.6% vs. Warsaw: 1/79, 98.5%, SE 1.5%, p = 0.027), but not in patients with one of the other 
subtypes (DDLPS: p = 0.570, MLPS: p = 0.243, PLPS: p = 0.360, Table 2).
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Table 2. 5-year local recurrence-free survival, 5-year distant metastasis-free survival and 5-year overall 
survival per centre and per subtype. 
5y-LRFS 5y-DMFS 5y-OS


































































Values in parentheses are the Standard Errors (SE) corresponding to the noted 5-year survival rates. 
Differences between the Rotterdam-cohort and Warsaw-cohort were tested for their significance by 
the log-rank test. 5y-LRFS: 5-year local recurrence free survival, 5y-OS: 5-year overall survival, WDLPS: 
well-differentiated liposarcoma, DDLPS: dedifferentiated liposarcoma, MLPS: myxoid liposarcoma, 
PLPS: pleomorphic liposarcoma       
a Significant at level of α<0.05
To explain this difference in 5y-OS in WDLPS patients between the two centres, the 
additional data on cause of death in the Rotterdam-cohort was assessed and 5y-DSS was 
calculated. For the Warsaw-cohort, we assumed that the one death occurring in the WDLPS 
subgroup was indeed death of disease, since the patient had metastatic disease. It turned 
out that two out of ten deaths in the Rotterdam-cohort were disease-related, and that the 
majority of deaths in patients with WDLPS (eight out of ten deaths) were due to other/
unknown causes that were not attributed or unlikely related to LPS or LPS treatment. This 
results in a 5y-DSS of 98.2% (SE 1.2%) for WDLPS in the Rotterdam-cohort, compared to 
98.5% (SE 1.5%) in Warsaw (p = 0.765, Appendix table B and Figure S1). The same pattern 
was observed for patients with DDLPS, where one out of four deaths was disease-related 
(in a total of 13 patients), resulting in a 5y-DSS of 90.9% (SE 8.7%). This is in contrast to the 
patients with MLPS and PLPS, where most deaths in the Rotterdam-cohort were disease-
related (MLPS: 14/16 deaths in 77 patients, PLPS: 7/8 deaths in 20 patients), with a 5y-DSS of 





In the Rotterdam-cohort, 34.5% of LPS patients received radiotherapy, mostly adjuvant. In 
contrast, 78.4% of LPS patients in Warsaw received radiotherapy, mostly neoadjuvant. The 
difference in use of radiotherapy was observed in all four subtypes, although this difference 
is not significant for the subtypes DDLPS and PLPS, probably because of the small subgroups 
(Table 3).
Table 3. Number of patients receiving (neo)adjuvant radiotherapy per centre and subtype.
  Rotterdam (N=223) Warsaw (N=218)  p-value
  N % of total N % of total
Well-differentiated liposarcoma 13/113 11.5% 44/79 55.7% <0.001a
 Neoadjuvant RTx 1 0.9% 42 53.2%
 Adjuvant RTx 12 10.6% 1 1.3%
 Both 0 0.0% 1 1.3%
Dedifferentiated liposarcoma 7/13 53.9% 9/10 90.0% 0.089b
 Neoadjuvant RTx 2 15.4% 9 90.0%
 Adjuvant RTx 5 38.5% 0 0%
 Both 0 0% 0 0%
Myxoid liposarcoma 43/77 55.8% 88/95 92.6% <0.001a
 Neoadjuvant RTx 10 13.0% 78 82.1%
 Adjuvant RTx 33 42.9% 6 6.3%
 Both 0 0.0% 4 4.2%
Pleomorphic liposarcoma 14/20 70.0% 30/34 88.2% 0.147b
 Neoadjuvant RTx 1 5.0% 25 73.5%
 Adjuvant RTx 13 65.0% 4 11.8%
 Both 0 0.0% 1 2.9%
Overall 77/223 34.5% 171/218 78.4% <0.001a
 Neoadjuvant RTx 14 6.3% 154 70.6%
 Adjuvant RTx 63 28.3% 11 5.0%
 Both 0 0.0% 6 2.8%  
RTx: radiotherapy. The numbers are in bold to indicate that these are the numbers belonging to the entire 
group, while the numbers that are not bold represent the subgroups (neoadjuvant/ adjuvant/both RTx). 
a χ2-test,  b Fisher’s Exact test
Except for the difference in neoadjuvant/adjuvant treatment with radiotherapy, also a 
difference in the number of radical (R0) versus non-radical resections (R1/R2) was observed. 
After excluding patients of whom the tumour was not resected (N = 6) and patients with 
unknown status of the resection margins (N = 34), 49.7% (N = 183) of the resections in the 
Rotterdam-cohort had negative resection margins and were radical, while in the Warsaw-
cohort this percentage was 83.5% (N = 218, p < 0.001). When analysing the different 
subtypes, only a significant difference in the WDLPS subgroup is observed (Rotterdam: 23.5% 
vs. Warsaw: 81.0%, p < 0.001), but not in the other subgroups (DDLPS: p = 0.198, MLPS: p = 
0.130, PLPS: p = 0.194, Table 4).
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Table 4. Radical/non-radical resections per subtype and centre.
Rotterdam Warsaw p-value
Well-differentiated liposarcoma R0 19 (23.5%) 64 (81.0%) <0.001a
R1/R2 62 (76.5%) 15 (19.0%)
Dedifferentiated liposarcoma R0 3 (27.3%) 6 (60.0%) 0.198b
R1/R2 8 (72.7%) 4 (40.0%)
Myxoid liposarcoma R0 56 (78.9%) 84 (88.4%) 0.094a
R1/R2 15 (21.1%) 11 (11.6%)
Pleomorphic liposarcoma R0 13 (65.0%) 28 (82.4%) 0.194b
R1/R2 7 (35.0%) 6 (17.6%)
Overall R0 91 (49.7%) 182 (83.5%) <0.001a
  R1/R2 92 (50.3%) 36 (16.5%)  
a χ2-test, b Fisher’s Exact test
Prognostic factors for recurrence and survival
In multivariable Cox regression analysis, male gender (HR 1.686, 95%CI 1.032-2.754, p = 
0.037) was the only factor of significant influence for the risk of LR (Table 5). The variable 
centre tested significant in univariable analyses (Appendix table C), but not in multivariable 
analysis (HR 0.696, 0.401-1.208, p = 0.198).
For DM, the subtypes MPLS and PLPS were significant negative prognostic factors 
(MLPS: HR 8.540, 2.895-25.194; PLPS: HR 25.792, 8.402-79.168; both p < 0.001), as well as 
male gender (HR 2.079, 1.245-3.470, p = 0.005, Table 5). Although not significant in univariable 
analysis (Appendix table C), the variable centre was added to correct for differences in 
baseline characteristics, but was not of significant influence (HR 1.125, 0.592-2.138, p = 
0.720).
Lastly, the factors age at time of diagnosis (HR 1.029, 1.012-1.047, p = 0.001) and all 
three subtypes compared to WDLPS (DDLPS: HR 4.755, 1.803-12.540, p = 0.002; MLPS: HR 
3.596, 1.745-7.398, p = 0.001; PLPS: HR 8.609, 4.177-17.747, p < 0.001) tested significant in 
multivariable analysis for OS (Table 5). Again, the variable centre was added, but was not of 
significant influence (HR 0.835, 0.517-1.347, p = 0.460).
Discussion
This study represents the largest cohort of extremity LPS patients published to date and 
demonstrates clear differences in recurrence and survival patterns between the different 
LPS subtypes. Patients with DDLPS, MLPS and PLPS show similar patterns of recurrence and 
survival in both cohorts, and in our multivariable analyses we could confirm some already 




resection margins [7, 9-12, 14]. The survival rates found in this study are comparable to the 
survival rates described in smaller series in literature [8, 12, 19].
Table 5. Results of the multivariable Cox regression analyses for local recurrence, distant metastasis 
and overall survival.
HR CI (95%) p-value
Local Recurrence
Gender Male vs. female 1.686 1.032-2.754 0.037*
Resection margins R1/R2 vs. R0 1.212 0.688-2.135 0.506
Unknown vs. R0 2.024 0.979-4.183 0.057
Centre Warsaw vs. Rotterdam 0.696 0.401-1.208 0.198
Distant Metastasis 
Gender Male vs. female 2.079 1.245-3.470 0.005*
Subtype DDLPS vs. WDLPS 4.950 0.884-27.708 0.069
MLPS vs. WDLPS 8.540 2.895-25.194 <0.001*
PLPS vs. WDLPS 25.792 8.402-79.168 <0.001*
Resection margins R1/R2 vs. R0 0.960 0.512-1.802 0.900
Unknown vs. R0 1.380 0.299-6.370 0.680
Neoadj. treatment RTx vs. none 1.665 0.801-3.458 0.172
Other vs. none 1.609 0.779-3.324 0.199
Centre Warsaw vs. Rotterdam 1.125 0.592-2.138 0.720
Overall Survival
Age (in years) 1.029 1.012-1.047 0.001*
Gender Male vs. female 1.573 0.966-2.562 0.069
Subtype DDLPS vs. WDLPS 4.755 1.803-12.540 0.002*
MLPS vs. WDLPS 3.596 1.745-7.398 0.001*
PLPS vs. WDLPS 8.609 4.177-17.747 <0.001*
Centre Warsaw vs. Rotterdam 0.835 0.517-1.347 0.460
WDLPS: well-differentiated liposarcoma, DDLPS: dedifferentiated liposarcoma, MLPS: myxoid 
liposarcoma, PLPS: pleomorphic liposarcoma, RTx: radiotherapy    
* Significant at level of α < 0.05.
A few valuable nomograms to predict overall/disease-specific survival and distant 
metastasis in soft tissue sarcoma patients have been developed, including for patients with 
liposarcoma, but focus either on one subtype and multiple primary tumour localisations [8], 
or on one localisation and multiple STS subtypes [6]. The added value of this study is that it 
specifically focuses on one type of STS (i.e. liposarcoma and its four distinct subtypes) and 
one localisation (i.e. the extremity), and describes not only survival and metastases, but also 
patterns of local recurrence for all the different subtypes in depth.
Despite having the most favourable prognosis of all subtypes, some remarkable 
differences were noticed in the subgroup of patients with WDLPS. Between the two centres, 
a large and significant difference in 5y-LRFS in patients with WDLPS was observed (Warsaw: 
94.1% vs. Rotterdam: 65.0%, Table 2). As mentioned, in the Warsaw-cohort, more than half 
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of the WDLPS patients received neoadjuvant/adjuvant radiotherapy, compared with 11.5% in 
the Rotterdam-cohort, possibly explaining this difference in 5y-LRFS. However, since WDLPS 
is generally not considered very radiosensitive, it is unlikely that this is the only explanation. 
Another contributing explanation can be the significantly more non-radical resections in the 
Rotterdam-cohort, which is most likely due to differences in surgical approach (enucleation 
vs. wide excision). Nevertheless, these differences in treatment do not lead to a significant 
difference in 5y-DMFS or 5y-DSS, although the 5y-OS was significantly higher in the Warsaw-
cohort. However, this difference was presumably not attributable to LPS or differences 
in LPS treatment, because there was no significant difference in 5y-DSS for the WDLPS 
subgroup. Furthermore, even with 20-40% more patients receiving radiotherapy in the 
Warsaw-cohort in the DDLPS, MLPS and PLPS subgroups than in the Rotterdam-cohort, no 
significant difference in LRFS, DMFS and survival between the centres is observed for these 
subgroups. So, in addition to the WDLPS subgroup, more radiotherapy does not seem to 
lead to significant less distant metastasis and better overall survival, but in these subgroups 
also not to significant less local recurrences, as one would expect.
Radiotherapy has proven to be effective in preventing LR in LPS patients, as shown 
in this study in WDLPS, as well as in literature in all LPS subtypes, and especially in MLPS 
[7, 20-25]. Nevertheless, radiotherapy has some well-known, serious side effects and 
disadvantages, such as wound complications, fibrosis, pathological fractures, functional 
impairment, oedema and secondary tumours [26-33]. The results of this study point out 
that radiotherapy as a local therapy should be applied very selectively, for example only in 
those patients in whom a possible local recurrence will lead to treatment issues and in whom 
re-resection is not feasible, so that the risk of having a LR should be minimized. In doing so, 
the toxicities of radiotherapy should be taken into consideration, especially in patients of 
young age, when joints are involved, and so on. The same arguments more or less apply 
for extent of resection in patients with extremity WDLPS, choosing between enucleating the 
tumour (R1 resection) and possibly a higher chance of LR, or resecting the tumour with wide 
margins (R0 resection) and lower risk of LR, but with higher chance of inducing morbidities, 
depending on local conditions during surgery. For the other and more aggressive subtypes, 
there is more consensus on resecting the primary tumour with wide resections margins, 
reflected in the non-significant difference in R0 and R1/R2 resections in these subgroups and 
the more frequent use of neoadjuvant/adjuvant radiotherapy. In summary, the presented 
data show that in WDLPS an aggressive approach of neoadjuvant/adjuvant radiotherapy and 
radical surgery leads to excellent local control rates. A more conservative approach carries 
a significantly higher risk of LR. As this is not influencing DMFS/survival, the local treatment 
strategy for WDLPS should be tailored to the need of the individual patient, balancing risks 




A limitation of our study is that a bias might have been introduced by the long time 
period during which patients were included. Due to changes and improvements in practice 
over the years, results of early years of inclusion and treatment might not be representative 
for outcomes and treatment in the more recent years. However, these changes in practice 
did not have a substantial effect on the outcomes, since we did not observe any significant 
differences in either 5y-LRFS, 5y-DMFS or 5y-OS over the years. Second, this study has a 
relatively short follow-up time of five years, particularly for the WDLPS subgroup. Censoring 
at five years of follow-up was chosen based on the median follow-up time (61 months) and 
because numbers at risk would be become too small to perform reliable tests, for example, 
at 10 years follow-up. Additionally, we observed that approximately 75% of all WDLPS 
patients with a local recurrence developed their recurrence within five years of follow-up. So, 
despite the relatively short follow-up, we believe this follow-up period is sufficient and useful 
in daily clinical practice. Third, in the Warsaw-cohort, more than 55% of the WDLPS patients 
received neoadjuvant/adjuvant radiotherapy. It should be mentioned that the high number 
of patients receiving radiotherapy is exceptional and that in most STS expertise centres as 
well as in most cohorts described in literature, this is not standard practice. Most cohorts 
that include patients with extremity WDLPS report percentages ranging from 18.7% to 47% 
of patients receiving radiotherapy [7, 34-36]. 
Importantly, this study is based on retrospective data, which therefore may bring 
some bias inherent to such analyses, such as selection bias, and depends on accurate 
record keeping. Patients receiving neoadjuvant/adjuvant therapy were probably fit patients 
with poor tumour characteristics, such as aggressive LPS subtype and a large tumour. This 
selection bias is probably present in both datasets, neutralizing each other in the comparisons 
between the centres. Additionally, we tried to minimize the selection bias by including all 
patients treated for primary LPS of the extremity, without any exclusion criteria except for 
metastatic disease at time of diagnosis and insufficient data available. In addition to using 
the largest cohort of extremity LPS patients reported to date, the strength of this study is 
that the data and results are based on daily clinical practice representative for all extremity 
LPS patients in the Netherlands, Poland and probably other European/western countries as 
well, and gives insight into the value and effectiveness of current treatment policies outside 
the context of a clinical trial. Furthermore, it can give guidance during treatment decision 
making, for example in determining the extent of surgery or in opting for neoadjuvant/
adjuvant radiotherapy.




Patients with the four liposarcoma subtypes in this large cohort show distinct patterns of 
local recurrence, distant metastasis and survival, with liposarcoma subtype also being one 
of the most important prognostic factors for these outcomes. This indicates that 'extremity 
liposarcoma' is not a single entity. Radiotherapy can reduce the risk of local recurrence in 
WDLPS, but its benefits should be carefully balanced against its disadvantages. Despite 
the differences in recurrence and treatment, five year (disease-specific) survival did not 
differ significantly between the two expertise centres. These prognostic patterns and 
characteristics may be used to further tailor treatment regarding surgery and neoadjuvant/
adjuvant radiotherapy.
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Appendix table A. Follow-up schedules of the Erasmus MC Cancer Institute, Rotterdam, the Netherlands 
and the Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland
Rotterdam Grade I Grade II-III
Physical examination
Year 1-2 Every 4 months Every 4 months
Year 3-5 Every 6 months Every 6 months
Year 6-10 Every 12 months Every 12 months
Imaging
Local evaluation 4 months after surgery, afterwards only 
on indication
4 months after surgery, afterwards 
only on indication
Chest X-ray every 12 monthsa X-ray at every follow-up visitb
Warsaw Grade I Grade II-III
Physical examination
Year 1-3 Every 3-6 months Every 3-4 months
Year 4-5 Every 12 months Every 6 months
Year 6-10 Every 12 months Every 12 months
Imaging
Local evaluation 6 months after surgery, afterwards only 
on indication
3-6 months after surgery, after-
wards only on indication
Chest X-ray every 6-12 months X-ray or CT every visit
a except for WDLPS. In case of WDLPS chest X-rays are not indicated.  
b in case of MLPS, also CT-abdomen
Appendix table B. 5-year overall survival and 5-year disease specific survival in the Rotterdam-cohort
5y-OSa SE 5y-DSSb SE
Well-differentiated liposarcoma 88.2% 3.6% 98.2% 1.2%
Dedifferentiated liposarcoma 59.9% 16.2% 90.9% 8.7%
Myxoid liposarcoma 75.6% 5.4% 77.7% 5.3%
Pleomorphic liposarcoma 57.5% 11.6% 60.6% 11.8%
Overall 78.5% 3.2% 85.9% 2.7%
a Difference between subtypes significant with p=0.005  
b Difference between subtypes significant with p<0.001  
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▲Figure S1. 5-year overall survival (A) and 5-year disease specific survival (B) compared between the 
two centres for the subgroup of patients with WDLPS.

PART III
EVALUATION OF THE 
SURGICAL TREATMENT OF 




NATURAL HISTORY OF 
WELL-DIFFERENTIATED 
LIPOSARCOMA OF THE 
EXTREMITY COMPARED 
TO PATIENTS TREATED 
WITH SURGERY
M. Vos, D.J. Grünhagen, H. Koseła-Paterczyk, 
 P. Rutkowski, S. Sleijfer, C. Verhoef





Background: Patients with well-differentiated liposarcoma (WDLPS) of the extremity are 
mostly treated surgically, thereby possibly inducing severe morbidities. Despite the excellent 
prognosis, the natural history is barely studied. The aim of this study was to evaluate the 
natural history of extremity WDLPS by evaluating the outcome of patients treated with active 
surveillance (AS), who thereby exhibited the natural history of extremity WDLPS, and of 
patients treated surgically.
Methods: A large retrospective database of patients with extremity WDLPS was assessed to 
evaluate treatment, dedifferentiation and disease-specific survival. Lastly, our experience 
with patients treated with AS was explored.
Results: Distant metastases (5/191 patients, 2.6%) were mainly seen after a dedifferentiated 
local recurrence. Death of disease occurred in 4/191 patients (2.1%); two patients died from 
metastatic disease (although not pathologically proven), two patients died of treatment-
related complications. In our center, 24 patients are treated with AS. Time of AS varied from 
0.1 to 8.9 years (median 1.8). Four patients eventually underwent surgery after a period 
of AS (range 14–52 months) because of symptoms and/or tumor growth. No areas of 
dedifferentiation were found in these resection specimens. The other patients are still under 
active surveillance.
Conclusion: Since surgical treatment might induce morbidity and even mortality, there might 
be overtreatment of these patients. Evaluation of the natural history of extremity WDLPS 
showed that AS could be a reasonable option for selected patients. Prospective studies in 
patients with extremity WDLPS are needed to assess the safety of AS as a treatment option.
Keywords: Well-differentiated liposarcoma; Extremity; Natural history; Active surveillance; 
Surgery




Well-differentiated liposarcoma (WDLPS) is the most common subtype of liposarcoma, 
accounting for approximately half of all liposarcoma patients. Most WDLPS patients present 
with a deep-seated, slowly growing and painless mass, most frequently located in one of the 
extremities. WDLPS are low-grade tumors and have very little to no metastatic potential. 
However, they can dedifferentiate into a more aggressive subtype, thereby gaining the 
ability to metastasize [1]. Patients with extremity WDLPS have a good prognosis with very 
low dedifferentiation rates and excellent survival rates of 90-100% after 10 years of follow-
up [1]. Because of this indolent disease course, extremity WDLPS is considered borderline 
malignant, and is therefore also called an atypical lipomatous tumor [1-3].
Despite of these disease characteristics, almost all patients undergo (extensive) 
surgery, optionally preceded or followed by radiotherapy. Although consensus has shifted 
from radical amputation to wide excision – and even marginal excision now is considered 
appropriate and adequate more often in case of localization in one of the extremities – 
patients still have to deal with the morbidities and complications induced by surgery, such as 
loss of limb function and wound infections [4-6].
To date, the natural history of extremity WDLPS has rarely been described in these 
patients. While this is much more studied in other borderline malignant tumors, such as 
desmoid-type fibromatosis [7-11], no study has ever been published yet in extremity WDLPS 
evaluating its natural history. Therefore, the aim of this study was to describe the natural 
history of patients with extremity WDLPS and to initiate and open a discussion on the 
treatment of patients with extremity WDLPS by discussing active surveillance as a treatment 
option for these patients. With this purpose we looked in detail into the disease course of 
both treated and untreated patients with extremity WDLPS.
Methods
Data collection
Data of surgically treated patients with primary WDLPS located in one of the extremities 
were extracted from the database previously described by Vos et al. [12]. This database 
was revolved around patients diagnosed with primary liposarcoma in the extremity in the 
Erasmus MC Cancer Institute in Rotterdam, the Netherlands, and the Maria Skłodowska-
Curie Institute-Oncology Center in Warsaw, Poland, between 1986 and 2015. Both centers 
are designated as tertiary referral and expertise centers for soft tissue sarcoma. One patient 
in this cohort eventually did not undergo surgery because of minimal complaints, although at 




was part of the standard diagnostic work-up in both expertise centers. In some patients the 
diagnosis was confirmed by fluorescent in situ hybridization (FISH) for MDM2 amplification, 
but in most of the patients the diagnosis was based on histological, morphological and/or 
immunohistochemical criteria. Patients who presented with a local recurrence or metastatic 
disease were excluded in this dataset. Although these patients underwent surgery, the 
results from this cohort gave rise to the current study and the discussion on treatment of 
these patients.
In the Erasmus MC Cancer Institute, Rotterdam, the Netherlands, already a few selected 
patients are being treated with active surveillance, thereby exhibiting the natural history of 
extremity WDLPS. These patients were identified during weekly multidisciplinary tumor board 
meetings, by the treating physicians and through the institutional database on liposarcomas. 
This group also includes patients who initially started with active surveillance but eventually 
underwent surgery after a period of active surveillance because of anxiety, occurrence of/
increase in symptoms and/or tumor growth. Frequency of follow-up and imaging during 
active surveillance was in accordance with the national soft tissue sarcoma guideline [13] 
and was similar to the follow-up schedule of low-grade sarcomas, or more often if indicated: 
first two years every 4 months, year three to five every 6 months and after five years once a 
year, with an X-ray of the thorax yearly and a MRI scan if indicated. Of these patients, data 
on characteristics such as primary or recurrent tumor, age at start of active surveillance, 
symptoms, time of active surveillance and vital status (death/alive) were obtained. If patients 
opted to undergo surgery after a period of active surveillance, the resection specimen was 
examined for (areas of) dedifferentiation. Time of active surveillance was defined as time 
between start of active surveillance and last follow-up or date of surgery.
This study was approved by the local ethics committee and performed in accordance 
with local ethics committee guidelines and national legislation.
Statistical analyses
All statistical analyses were performed by using SPSS (IBM SPSS Statistics for Windows, 
Version 24.0, IBM Corporation, Armonk, NY, USA). Categorical variables are shown as 
numbers with percentages in parentheses and continuous variables as medians with the 
interquartile ranges (IQRs) in parentheses. χ2-tests, Fisher's Exact tests and Mann-Whitney U 
tests were used to test for differences in clinicopathological variables between groups when 
appropriate. Two-sided p-values< 0.05 were considered statistically significant.




Course of disease of the surgically treated patients – distant 
metastasis
In total, 191 patients with primary WDLPS located in the extremity who were treated surgically 
were identified: 112 in the Rotterdam-cohort and 79 in the Warsaw-cohort. As described 
and discussed before [12], there was a difference in the number of radical resections, use 
of neoadjuvant and adjuvant radiotherapy and percentage of patients experiencing a local 
recurrence between the two centers (Table 1). In brief this study showed that an aggressive 
approach with radical surgery and neoadjuvant/adjuvant radiotherapy led to excellent 
local control, while a more conservative approach with enucleation of the tumor (i.e. R1-
resection) and without radiotherapy led to higher local recurrence rates, but also that these 
differences in treatment did not lead to a difference in disease-specific survival for patients 
with extremity WDLPS [12]. Distant metastases were scarcely observed, neither were 
dedifferentiation and death of disease, with a median follow-up time of 49 months (IQR 24–
75.5, Table 1). In total, five patients out of 191 patients developed metastatic disease (Table 
2). Three of these five patients first developed a dedifferentiated local recurrence before 
developing metastatic disease, the fourth patient developed a local recurrence and a distant 
metastasis simultaneously. The local recurrent tumor was confirmed by biopsy, showing 
WDLPS without any signs of dedifferentiation, but no material from the metastatic site was 
obtained for pathological examination. The patient is still alive, after 'palliative' radiotherapy 
with a total of 24Gy, with a follow-up period of 60 months (42 months after diagnosis of 
metastatic disease). The last patient developed massive distant metastases in lungs and liver 
as a first manifestation of recurrent disease, within four months since the prior follow-up 
visit with a 'clean' chest X-ray, and died one month later. No data on confirmation of the LPS 
diagnosis and dedifferentiation in the metastases were available, although the aggressive 
course of disease suggests either dedifferentiation or that these lesions were metastases 
from another unknown primary tumor. So, it is questionable whether the last two patients 
with 'metastases', without a dedifferentiated local recurrence, really had metastatic WDLPS.
Course of disease of the surgically treated patients - survival
Death of disease was also rarely observed in this group of patients (4 out of 191 patients),with 
a 5-year disease-specific survival of 98.3% [12]. Two of the deceased patients were with 
metastatic disease described above; the other two deaths were both one month after 
diagnosis of the primary tumor and turned out to be treatment-related, instead of disease-
related. One patient died a few days after neoadjuvant treatment with isolated limb perfusion, 













    N % N % N %
Sex Female 103 53.9 61 54.5 42 53.2 0.859
Male 88 46.1 51 45.5 37 46.8
Age at diagnosis (years)a 59 (49-67) 60 (50-68.5) 58 (48-64.5) 0.104
Site Lower extremity 163 85.3 97 86.6 66 83.5 0.556
Upper extremity 28 14.7 15 13.4 13 16.5
Size (cm)a 17 (12-23) 18.5 (13-23) 16 (10.5-20.3) 0.106
Resection margins R0 83 43.7 19 17.1 64 81.0 <0.001
R1/R2 78 41.1 63 56.8 15 19.0
Unknown 29 15.3 29 26.1 0 0.0
Neoadjuvant None 143 74.9 107 95.5 36 45.6 <0.001‡
treatment Radiotherapy 44 23.0 1 0.9 43 54.4
ILP 2 1.0 2 1.8 0 0.0
Unknown 2 1.0 2 1.8 0 0.0
Adjuvant None 175 91.6 98 87.5 77 97.5 0.042‡
treatment Radiotherapy 14 7.3 12 10.7 2 2.5
Unknown 2 1.0 2 1.8 0 0.0
Local recurrence None 154 80.6 79 70.5 75 94.9 <0.001
Yes 37 19.4 33 29.5 4 5.1
Time to local 
recurrence (months)a
41 (15-57) 41 (15-57) 43 (21.5-64) 0.869
Dedifferentiation None 186 97.4 109 97.3 77 97.5 0.448‡
Yes 4 2.1 3 2.7 1 1.3
Unknown 1 0.5 0 0.0 1 1.3
Distant metastasis None 186 97.4 109 97.3 77 97.5 1.000‡
Yes 5 2.6 3 2.7 2 2.5
Time to metastasis 
(months)a
24 (18-26) 24 (21-25) 68.5 (17-120) 1.000
Survival Alive 174 91.1 98 87.5 76 96.2 0.110‡
Death of disease 4 2.1 3 2.7 1 1.3
Death of other/un-
known cause
13 6.8 11 9.8 2 2.5
Follow-up (months)a 49 (24-75.5) 49.5 (19-82.5) 48 (27-74) 0.949
a Presented as median (interquartile range). $Calculated by χ2-tests (categorical data) or Mann-Whitney U 
tests (continuous data). ‡Fisher’s Exact test
Natural history of extremity well-differentiated liposarcoma
135 
8
Natural history of extremity WDLPS in untreated patients
These observations raised questions on the treatment of patients with extremity WDLPS. 
Since patients only die of the disease after dedifferentiation, dedifferentiation rates are low, 
dedifferentiation only occurred in local recurrences after surgical removal of the primary 
tumor, and surgery might induce morbidity and even mortality, we could be overtreating these 
patients. This might especially apply for patients with inconveniently localized or deep seated 
and large tumors (i.e. surgeries where chances of inducing morbidity are substantial) without 
any debilitating symptoms, elderly patients and/or patients with significant comorbidities.
Therefore, in the Erasmus MC Cancer Institute Rotterdam, the Netherlands, already a 
few patients with extremity WDLPS have been treated with active surveillance, in whom the 
natural history of extremity WDLPS can be studied. In all these patients, a conscious decision 
for active surveillance was taken. Most of these patients have local recurrent WDLPS without 
any (debilitating) symptoms (19 out of 24 patients treated with AS), in a smaller number of 
patients the primary tumor is treated with AS (5 out of 24 patients). Reasons for choosing 
active surveillance included one, or a combination, of the following motives: the absence 
of any debilitating symptoms, no/minimal tumor growth, an inconvenient localization (i.e. 
minimal chance of radical resection), and/or a high risk of inducing severe morbidity during 
surgery. Follow-up of the patients treated with active surveillance ranges from a few months 
to almost 9 years (median 22 months, IQR 10–51 months, total range 1–107 months) and 
the median age at time of start of active surveillance was 70 years (IQR 62–74.5) (Table 
4). Of these 24 patients, four patients opted to undergo surgery after a period of active 
surveillance, because of symptoms and/or tumor growth. Time of active surveillance in these 
four patients was 14, 16, 24 and 52 months. After surgery, no areas of dedifferentiation were 
found in any of the tumor specimens. The tumors of the remaining 20 patients are still in 
situ (with a median follow up of 26 months, IQR 5–51 months). These patients are monitored 
according to the follow-up schedule of low-grade sarcomas as stated in the national soft 
tissue sarcoma guidelines, including imaging on indication, except for two patients (one 
patient died to a cause unrelated to WDLPS, one patient is lost to follow-up). Although some 
of the patients only have been treated with active surveillance for a few months so far, there 
is no/minimal growth of these tumors and they do not have any signs of dedifferentiation up 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The cases described above in a large dataset of 191 surgically treated patients with extremity 
WDLPS outline that patients do not or seldom die because of extremity WDLPS, unless the 
recurrent tumor has dedifferentiated, while two deaths were induced by its treatment. These 
observations raised questions about the possible overtreatment of this patient group, and 
led to a discussion on whether a more conservative treatment or even no treatment at all 
(active surveillance) is more appropriate and justified in selected cases.
In line with the results of our study, other studies of extremity WDLPS have reported 
low rates of dedifferentiation [1, 6, 14, 15], metastatic disease [4, 16] and mortality [17-19]. 
Despite these excellent outcomes, treatment of these patients remains almost similar to that 
of patients with more aggressive subtypes, such as dedifferentiated, myxoid or pleomorphic 
liposarcoma. The extent of treatment of extremity WDLPS is already under debate, with 
ongoing discussions regarding the harms and benefits of wide excision versus marginal 
excision [4, 6, 20], and the use of neoadjuvant/adjuvant radiotherapy [21, 22]. To this debate, 
we can now add the question whether excision – or treatment in general – is indicated at all. 
The morbidity and risks of marginal resections (i.e. R1 resections) are generally quite low, but 
they are still present and should be taken into account. The results of this study, together 
with those of other studies reporting excellent survival rates, indicate that not all cases 
of extremity WDLPS may require surgical removal. In selected cases, especially in elderly 
patients, patients with comorbidities and/or patients with inconveniently localized, large and 
deep-seated tumors without any symptoms in whom surgical resection most probably will 
lead to substantial morbidity, it may be appropriate and adequate to pursue conservative 
treatment in the form of active surveillance. The appropriateness of active surveillance was 
further underscored by the observation that it has been safe so far to apply this approach in 
selected patients with extremity WDLPS who do not experience any debilitating symptoms 
and who have inconveniently localized tumors at the Erasmus MC Cancer Institute, although 
follow-up is still short. In these patients, the natural history of extremity WDLPS showed 
no/minimal growth of the tumors. In the few patients (4/24) who did experience growth/
symptoms after a period of active surveillance and therefore opted to undergo surgery, no 
dedifferentiation was found in the specimens. However, it remains unknown whether it is 
preferable to remove these large and inconveniently localized WDLPS quickly after diagnosis, 
or to observe them for a period of time for possible tumor growth and/or dedifferentiation.
During treatment decision making numerous factors have to be taken into 
consideration, balancing the risks and benefits of the treatment for each patient. Radical 
local treatment leads to better local control, but comes at the costs of morbidity, impaired 
functional outcome and even mortality, but does not affect disease-specific survival [12]. 
Factors that influence this balance include patient-related factors, such as age, performance 
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status, comorbidities and the patient's own wish, and tumor-related factors, such as 
symptoms, localization, tumor size and signs of dedifferentiation. A tumor localized in the 
extremity is particularly suitable for an active surveillance approach, since tumor growth 
can be monitored by physical examination – even by the patient him/herself – and does not 
completely rely on imaging alone [23, 24]. For example, for the 91-year old patient in our 
study who died due to the treatment (Table 3), the risk of dying of an age-related disease (e.g. 
cardiovascular disease, stroke, dementia) was probably higher than the risk of developing 
dedifferentiated metastatic disease and dying as a result of extremity WDLPS. In retrospect, 
we feel that active surveillance with a natural course of disease might have been both feasible 
and adequate in this case. In patients who are younger and fitter or who have smaller and 
more favorable localized tumors (i.e. less complex surgery), this consideration is likely to be 
different and surgery might be the preferred option.
Active surveillance in WDLPS has been discussed and suggested before, but such 
discussions have mainly focused on specific situations, such as after resection of recurrent 
tumors, after surgical treatment of the primary tumor, or for large inoperable primary tumors 
[22, 25-27]. There is a distinct lack of studies and data regarding patients with extremity WDLPS 
who actually have been treated with active surveillance. A further problem with previous 
studies is that overall or disease-specific survival alone might not be the most appropriate 
outcome measurements for this subgroup of patients, since survival rates approach 100% 
[1, 17-19]. Other outcome measurements, such as quality of life, are becoming more and 
more relevant. To date, no studies on quality of life have been conducted in patients with 
extremity WDLPS. On the one hand, quality of life of patients with active surveillance might 
be better than those undergoing surgery, because they would avoid the necessity of surgery 
and its related complications and morbidities. On the other hand, their quality of life might 
be poorer than those undergoing surgery, because living with a tumor in situ might lead to 
tumor-related symptoms and cause anxiety.
A limitation of our study is that it was based on retrospective data – inherent when 
studying rare diseases – which relies on accurate recordkeeping and which has induced bias. 
We acknowledge that there is most probably a selection bias in the patients currently treated 
with active surveillance, although we believe that this type of treatment will always be subject 
to some extent of selection bias, since patients with symptoms most likely will refuse active 
surveillance and prefer surgical treatment. Notwithstanding these assumptions and bias, 
this study was set up to initiate a discussion regarding the (over)treatment of these patients 
and to generate hypotheses for further research to test the safety and feasibility of active 
surveillance in a larger prospective trial. A second limitation was that not all diagnoses were 
confirmed by FISH for MDM2 amplification. Furthermore, data regarding imaging was missing, 




Since the life expectancy is high and unaffected by local treatment [12], we believe 
that active surveillance is feasible for selected cases, in particular for elderly patients with 
comorbidities and minimal symptoms and/or for patients with a large, deep-seated or 
otherwise inconveniently localized tumor without symptoms in whom surgical resection 
most probably will lead to substantial morbidity. However, further research is needed before 
active surveillance can be safely applied in daily clinical practice. Therefore, we propose a 
prospective observational study to investigate the differences between surgical treatment 
and active surveillance in patients with extremity WDLPS regarding disease-specific 
survival, dedifferentiation rates, tumor growth (using the RECIST criteria [28]) and quality 
of life, comparable to the prospective studies in patients with desmoid-type fibromatosis 
treated with active surveillance [10, 29, 30]. This future prospective trial should include 
regular MRI imaging, allowing for timely intervention in case of tumor growth and/or signs of 
dedifferentiation.
Conclusion
Although the numbers are small and the follow-up relatively short, the evaluation of the natural 
history of extremity WDLPS illustrated that active surveillance could be a reasonable option 
for selected patients. This highlights the observation that there might be an overtreatment 
of these patients, since surgical treatment might lead to morbidity and even mortality in 
patients with this borderline malignant tumor. The harms and benefits of surgical treatment 
and active surveillance should be carefully balanced, taking the extension and localization 
of the tumor (i.e. complexity of the surgery), comorbidities and the indolent disease course 
into account. This especially applies for elderly patients with comorbidities and/or patients 
with large, deep-seated or otherwise inconveniently localized tumors without symptoms. We 
propose to conduct a prospective observational study to assess the safety and outcomes of 
active surveillance in this patient group.
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Background: Diagnosing and treating soft tissue sarcomas (STSs) remains challenging, 
stressing the urgency for centralisation. This nationwide survey aimed to evaluate the 
centralisation of STS surgery and its effect on survival.
Methods: Patients operated for primary STS from 2006 to 2015 were queried from 
the Netherlands Cancer Registry. Hospitals in which STS surgery was performed were 
allocated into three categories: low-volume (1-9 resections per year), medium-volume (10-
19 resections) or high-volume (≥20 resections). Differences in tumour characteristics and 
outcome were calculated. A multivariable regression analysis was performed to adjust for 
case-mix.
Results: Of the 5282 identified patients, 42% was treated in low-volume hospitals, 7.7% in 
medium-volume hospitals and 51% in high-volume hospitals, with a significant trend over 
time towards treatment in a high-volume hospital (p < 0.01). In high-volume hospitals, more 
often patients with non low-grade, large and deep-seated tumours were treated than in 
low-volume hospitals. For the whole group, there was no survival benefit for patients treated 
in high-volume hospitals, with 10-year net survival rates of 76% (low-volume), 68% (medium-
volume) and 68% (high-volume). However, subgroup analysis for patients with non low-grade 
and deep-seated tumours did reveal a benefit from treatment in a high-volume hospitals 
with 10-year survival rates of 54% (high-volume), 49% (low-volume) and 42% (medium-
volume) and a relative risk of 1.3 (high-volume versus low-volume, p = 0.03).
Conclusion: Centralisation of STS surgery has increased in the past decade. Surgery in a high-
volume hospital improved survival of patients with non low-grade and deep-seated tumours, 
and therefore these patients should be referred to such a hospital.
Keywords: Soft tissue sarcoma; Centralisation; Survival; Surgery




Soft tissue sarcomas (STSs) are a group of rare mesenchymal tumours and comprise 
approximately 1% of all adult malignancies. Within the group of STS, over 50 different 
malignant histological subtypes have been described, with a broad variety in biological 
behaviour, presentation, treatment approach and prognosis. Owing to the rarity of these 
tumours, it is estimated that a general practitioner in the Netherlands only sees one patient 
with STS every 20 years and a surgeon in a general hospital only once every 4 years, which 
makes it difficult to gain sufficient clinical experience in diagnosing and treating these 
patients [1, 2].
These observations highlight the urgency for centralisation of sarcoma care, in both 
diagnosis and treatment. Within the Netherlands, we strive to centralise sarcoma care into 
dedicated STS expertise centres, but centralisation until 2011 was limited and in need of 
improvement [3].
The aim of this nationwide study was to determine whether centralisation of STS care 
has increased over time and whether this has affected survival and other surgical outcomes, 




All patients diagnosed with primary STS and who underwent surgery during the time interval 
2006-2015 were identified and queried from the NCR. Gastrointestinal stromal tumours 
(GISTs), visceral sarcomas, Kaposi sarcomas and children (age at diagnosis <18 years) were 
excluded. Data on patient characteristics, tumour characteristics and primary treatment 
were obtained directly from patients’ medical records by data managers of the Netherlands 
Comprehensive Cancer Organisation, which hosts the NCR.
The STS were categorised according to the World Health Organisation-classification 
and graded according to the Fédération Nationale des Centres de Lutte Contre Le Cancer 
(FNCLCC) [1]. Grade I tumours were labelled as low-grade tumours. Grade II tumours, grade 
III tumours and tumours in which grading is not applicable were pooled and labelled as non 
low-grade tumours. Tumour subtypes and localisations were recorded in the NCR following 
the International Classification of Diseases for Oncology (third version) (ICD-O-3) morphology 
and ICD-O-3 topography codes. There was no central pathology review. Tumours were 
classified as superficial when located entirely above the fascia or as deep-seated when 




For assessing patients’ survival, information on their vital status during follow-up was 
obtained through linkage with the Municipal Personal Records Database. The most recent 
linkage for the current study was performed in February 2018.
Potential ’whoops’ resections were identified by coinciding dates of first pathological 
confirmation and surgical resection. They were named ’potential’ because not all these 
resections may have been unplanned but instead deliberately be performed without prior 
biopsy (i.e. diagnostic excision). Resection margins were classified as R0 (microscopically 
negative margins), R1 (microscopically positive margins), R2 (macroscopically positive 
margins) or Rx (unknown/margins not assessed). The proportion of patients requiring 
multiple procedures (i.e. re-resections) included patients who underwent more than one 
operation as part of their primary treatment.
Owing to the nature of our data source, no data were available regarding comorbidities/
medical history, local recurrence rate, distant metastasis rate or causes of death/disease-
specific survival (DSS).
Hospitals performing STS surgery
The hospitals in which the patients were treated were allocated into three categories based 
on the number of STS resections performed annually: 1-9 resections (low-volume), 10-19 
resections (medium-volume) or ≥20 resections per year (high-volume).
Statistical analyses
Trends in STS treatment and in centralisation of STS surgery over the study period were 
tested for significance using the np-trend test [4]. Age of the different subgroups was 
presented as medians with corresponding interquartile ranges (IQRs). To estimate the 
impact of surgical volume on survival, net survival rates were calculated as an approximation 
of – and perhaps more robust alternative to [5] – DSS. Accordingly, crude survival rates were 
adjusted for the expected survival in the general population according to persons’ age, sex 
and birth year by applying the lifetable approach. In other words, the crude survival rates 
were adjusted for mortality in a comparable ’healthy’ population of equal age and gender 
as a proxy for DSS, since the NCR does not register information on recurrence and DSS. For 
high-volume and low-volume hospitals, the Pohar Perme method [6] was used to estimate 
the net survival rates, while for medium-volume hospitals the Ederer-II method [7] was 
chosen to prevent overcorrection because of the low number of patients in this subgroup. 
The univariable impact of surgical volume was displayed graphically, and a multivariable 
Poisson regression model was developed to assess the effect of surgical volume adjusted for 
established prognostic factors (age, STS subtype, grade, depth and size). Subsequently, the 
same analyses were performed for the subgroup of patients with non low-grade and deep-
Centralization of soft tissue sarcoma surgery
149 
9
seated tumours. All tests were two-sided, and p-values <0.05 were considered statistically 




In total 5282 patients who were diagnosed with primary STS and who underwent STS surgery 
between 2006 and 2015 were identified, with a median age of 61 year (IQR 47-73). The 
most common subtypes were liposarcoma, leiomyosarcoma and fibrosarcoma, and the 
extremity and trunk were the most frequently observed localisations. Most tumours were 
non low-grade, superficially located and larger than 5 cm (Supplementary table S1). Most 
patients underwent surgery only (61%), and approximately a third of the patients received 
radiotherapy. A small subgroup received systemic therapy as part of their primary treatment 
(5.9%) (Table 1).
Hospitals performing STS surgery
On annual average, in 76 hospitals STS surgery was performed. This number decreased from 
82 hospitals in 2006-2007 to 66 in 2014-2015 (p = 0.05), mainly because of a decrease in the 
number of low-volume hospitals (72 to 56) (Table 1). Of the hospitals in which STS surgery 
was performed, 88% of the hospitals were low-volume hospitals in which 42% of all STS 
patients were treated, 3.9% were medium-volume hospitals in which 7.7% of all STS patients 
were treated, and 7.9% were high-volume hospitals in which 51% of all STS patients were 
treated (Table 1, Fig. 1A, Fig. 1B). Patients treated in low-volume hospitals had a median age 
of 64 years (IQR 49-77), patients treated in medium-volume hospitals had a median age of 
62 years (IQR 46-72), and patients treated in high-volume hospitals had a median age of 59 
years (IQR 46-70). During the study period, there was a significant trend over time towards 
treatment in a high-volume hospital, from 43% of the patients in 2006-2007 to 62% of the 
patients in 2014-2015 being treated in a high-volume hospital (p < 0.01) (Table 1, Fig. 1B).
We observed a skewed distribution of patients across the hospitals in which STS 
surgery was performed, although a significant change over time was observed (p < 0.01) 
(Fig. 2). While in 2006-2007 10.3% of all hospitals accounted for half of all STS resections, this 
proportion decreased to 6.0% in 2014-2015. In 2014-2015, 75% of the STS resections were 
performed in 21% of the hospitals (35% in 2006-2007), and 90% of the resections in 46% 
of the hospitals (59% in 2006-2007). The last 10% of resections are widely spread over the 




Table 1. Trends in the treatment and centralisation of patients diagnosed with soft tissue sarcoma and 















No. of STS patients with 
primary surgery
1052 969 1050 1064 1147 5282
Primary treatment regimen, n (%) p < 0.01
    Surgery only 611 (58%) 596 (62%) 643 (61%) 660 (62%) 735 (64%) 3245 (61%)
    Surgery + RTx 364 (35%) 305 (32%) 352 (34%) 337 (32%) 367 (32%) 1725 (33%)
    Surgery + RTx + CTx 37 (3.5%) 24 (2.5%) 31 (3.0%) 37 (3.5%) 22 (1.9%) 151 (2.9%)
    Surgery + CTx 40 (3.8%) 44 (4.5%) 24 (2.3%) 30 (2.8%) 23 (2.0%) 161 (3.0%)
No. of patients treated per surgical volume, n (%) p < 0.01
1–9 resections/year 
(low-volume)
502 (48%) 472 (49%) 453 (43%) 406 (38%) 363 (32%) 2196 (42%)
10–19 resections/year 
(medium-volume)
101 (9.6%) 54 (5.6%) 92 (8.8%) 85 (8.0%) 75 (6.5%) 407 (7.7%)
≥20 resections/year 
(high-volume)
449 (43%) 443 (46%) 505 (48%) 573 (54%) 709 (62%) 2679 (51%)
Mean no. of hospitals per-
forming STS surgerya
82 80 77 77 66 76 p =0.05d
Total no. of hospitals 
performing STS surgeryb
87 89 86 88 83 105 p = 0.09
Mean no. of hospitals performing STS surgery per surgical volume, n (%) p = 0.29
1–9 resections/year 
(low-volume)
72 (88%) 72 (90%) 67 (87%) 67 (87%) 56 (86%) 67 (88%)
10–19 resections/year 
(medium-volume)
4 (4.9%) 2 (2.5%) 4 (5.2%) 3 (3.9%) 3 (4.6%) 3 (3.9%)
≥20 resections/year 
(high-volume)
6 (7.3%) 6 (7.5%) 6 (7.8%) 7 (9.1%) 7 (11%) 6 (7.9%)
Proportion of 
operations in top 
quartile of hospitals
69% 71% 74% 80% 77% 76% p < 0.01
STS, soft tissue sarcoma; RTx, radiotherapy; CTx, chemotherapy 
a Mean over period 
b Including mergers 
c Tested for trend over total study period using the np-trend test 
d Tested for trend over total study period using a linear regression analysis
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▲Fig. 1. Trends in centralisation of STS surgery of patients diagnosed in the Netherlands from 2006 
to 2015 stratified by surgical volume (low-volume: 1-9 resections, medium-volume: 10-19 resections, 
high-volume: ≥20 resections). (A) Number of hospitals performing STS surgery. (B) Number of patients 






Case-mix in hospitals performing STS surgery
In high-volume and medium-volume hospitals, mainly patients with non low-grade STS (73% 
and 75%) were treated, while the proportion of patients with non low-grade tumours treated 
in low-volume hospitals was 56%. In high-volume centres also mainly patients with large 
tumours (70%) were treated, whereas this number was lower in medium-volume hospitals 
(61%) and low-volume hospitals (46%). At last, in low-volume hospitals, mainly patients 
Table 2. Tumour characteristics and surgical characteristics of patients undergoing surgery for soft 













Surgery in low-volume 
hospitals 
(1–9 resections/year)
502 472 453 406 363 2196
Tumour gradea, n (%) p = 0.93
     Low grade 184 (44%) 154 (40%) 177 (49%) 143 (46%) 104 (40%) 762 (44%)
     Non low-grade 236 (56%) 228 (60%) 184 (51%) 165 (54%) 156 (60%) 969 (56%)
Tumour sizeb, n (%) p < 0.01
     ≤5 cm 148 (50%) 140 (47%) 161 (53%) 164 (56%) 181 (64%) 794 (54%)
     >5 cm 149 (50%) 159 (53%) 140 (47%) 130 (44%) 102 (36%) 680 (46%)
Tumour depthc, n (%) p < 0.01
     Superficial 333 (75%) 289 (70%) 333 (77%) 290 (76%) 271 (79%) 1516 (75%)
     Deep 110 (25%) 122 (30%) 98 (23%) 93 (24%) 70 (21%) 493 (25%)
Potential 'whoops' 
resections, n (%)
293 (58%) 282 (60%) 298 (66%) 256 (63%) 239 (66%) 1368 (62%) p = 0.02
Potential 'whoops' resections 
for large, deep-seated and 
non-low grade tumours, n(%)
20 (40%) 28 (48%) 25 (48%) 17 (36%) 16 (55%) 106 (45%) p = 0.83
Patients with R1/R2 
resection, n (%)
72 (14%) 65 (14%) 66 (15%) 53 (13%) 57 (16%) 313 (14%) p = 0.76
Patients requiring 
multiple procedures, n (%)




101 54 92 85 75 407
Tumour gradea, n (%) p = 0.74
     Low grade 20 (22%) 10 (24%) 20 (26%) 24 (32%) 11 (18%) 85 (25%)
     Non low-grade 72 (78%) 32 (76%) 56 (74%) 50 (68%) 49 (82%) 259 (75%)
Tumour sizeb, n (%) p < 0.01
     ≤5 cm 17 (22%) 14 (33%) 28 (40%) 32 (54%) 32 (50%) 123 (39%)
     >5 cm 62 (78%) 29 (67%) 42 (60%) 27 (46%) 32 (50%) 192 (61%)















Tumour depthc, n (%) p = 0.01
     Superficial 37 (40%) 26 (52%) 60 (69%) 58 (77%) 33 (47%) 214 (57%)
     Deep 55 (60%) 24 (48%) 27 (31%) 17 (23%) 37 (53%) 160 (43%)
Potential 'whoops' 
resections, n (%)
37 (37%) 23 (43%) 42 (46%) 43 (51%) 33 (44%) 178 (44%) p = 0.17
Potential 'whoops' resections 
for large, deep-seated and 
non-low grade tumours, n(%)
7 (20%) 2 (13%) 4 (27%) 3 (30%) 5 (31%) 21 (23%) p = 0.74
Patients with R1/R2 
resection, n (%)
26 (26%) 10 (19%) 8 (8.7%) 8 (9.4%) 12 (16%) 64 (16%) p = 0.01
Patients requiring multiple 
procedures, n (%)
25 (25%) 17 (32%) 27 (29%) 30 (35%) 18 (24%) 117 (29%) p = 0.70
Surgery in high-volume 
hospitals (≥20 resections/
year)
449 443 505 573 709 2679
Tumour gradea, n (%) p = 0.48
     Low grade 107 (26%) 101 (26%) 112 (25%) 144 (29%) 164 (27%) 628 (27%)
     Non low-grade 301 (74%) 292 (74%) 336 (75%) 357 (71%) 444 (73%) 1730 (73%)
Tumour sizeb, n (%) p = 0.35
     ≤5 cm 109 (30%) 106 (30%) 114 (28%) 139 (30%) 197 (32%) 665 (30%)
     >5 cm 257 (70%) 247 (70%) 299 (72%) 330 (70%) 410 (68%) 1543 (70%)
Tumour depthc, n (%) p < 0.01
     Superficial 218 (56%) 193 (51%) 260 (56%) 303 (57%) 352 (52%) 1326 (54%)
     Deep 171 (44%) 184 (49%) 204 (44%) 232 (43%) 330 (48%) 1121 (46%)
Potential 'whoops' 
resections, n (%)
128 (29%) 132 (30%) 147 (29%) 170 (30%) 198 (28%) 775 (29%) p = 0.76 
Potential 'whoops' resections 
for large, deep-seated and 
non-low grade tumours, n(%)
19 (18%) 16 (14%) 9 (8%) 18 (14%) 24 (12%) 86 (13%) p = 0.51
Patients with R1/R2 
resection, n (%)
98 (22%) 86 (19%) 103 (20%) 118 (21%) 105 (15%) 510 (19%) p = 0.01
Patients requiring 
multiple procedures, n (%)
132 (29%) 133 (30%) 141 (28%) 164 (29%) 204 (29%) 774 (29%) p = 0.70
 a Excluding unknown grade. b Excluding unknown size c Excluding unknown depth. d Tested for trend 
over total study period using the np-trend test.
with superficial tumours (76%) were treated, whereas in medium-volume and high-volume 
hospitals, the distribution between superficial and deep-seated tumours was more equal 
(medium-volume: 57% superficial versus 43% deep; high-volume: 54% superficial versus 





























▲Fig. 2. Allocation of patients undergoing STS surgery in the Netherlands from 2006 to 2015 across the 
hospitals performing STS surgery. Trend over time was tested by a test for equality of the regression 
coefficients of the fitted values. STS, soft tissue sarcoma.
Over the years, in low-volume and medium-volume hospitals, significantly less patients 
with deep-seated tumours were operated (low-volume: 25% in 2006-2007 to 21% in 2014-
2015, p < 0.01; medium-volume: 60% to 53%, p = 0.01), and significantly less patients with 
large tumours were operated (low-volume: 50% to 36%, p < 0.01; medium-volume: 79% to 
50%, p < 0.01). On the contrary, in high-volume hospitals, the proportion of patients with 
deep-seated tumours increased (44% to 48%, p < 0.01), while the proportion of patients with 
large tumours remained stable (70% to 68%, p = 0.35). There were no significant changes 
over time in the proportions of patients with non low-grade and low-grade tumours (low-
volume: p = 0.93, medium-volume: p = 0.74, high-volume: p = 0.48) (Table 2).
Shift in use of treatment modalities
Most probably related to this case-mix, the use of neoadjuvant/adjuvant radiotherapy and 
chemotherapy raised as the annual surgical volume increased (p < 0.001). Whereas in low-
volume hospitals, 75% of the patients were treated with surgery alone, this proportion was 
61% in medium-volume hospitals and 50% in high-volume hospitals. Subsequently, the 
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proportion of patients receiving neoadjuvant/adjuvant radiotherapy increased from 23% in 
low-volume hospitals to 35% in medium-volume hospitals and 46% in high-volume hospitals. 
The proportion of patients receiving chemotherapy also increased from 2.1% in low-volume 
hospitals to 6.1% in medium-volume hospitals and 9.0% in high-volume hospitals (Table 3).
Table 3. Use of the different treatment modalities of patients undergoing surgery for soft tissue sarcoma 
in the Netherlands from 2006 to2015, stratified by surgical volume.
Treatment Low-volume, n (%) Medium-volume, n (%) High-volume, n (%) Total, n (%)
Surgery alone 1656 (75%) 250 (61%) 1339 (50%) 3245 (61%)
Surgery + RTx 493 (22%) 132 (32%) 1100 (41%) 1725 (33%)
Surgery + RTx + CTx 14 (0.6%) 11 (2.7%) 126 (4.7%) 151 (2.9%)
Surgery + CTx 33 (1.5%) 14 (3.4%) 114 (4.3%) 161 (3.0%)
χ2-test: p < 0.001  
RTx: radiotherapy, CTx: chemotherapy
STS surgery – Potential ’whoops’ resections, resection margins and 
multiple procedures
The proportion of patients undergoing a potential ’whoops’ resection was lower as the annual 
surgical volume increased: 62% in low-volume hospitals, 44% in medium-volume hospitals 
and 29% in high-volume hospitals (p < 0.01). For medium-volume and high-volume hospitals, 
there were no significant changes in this proportion over time (p = 0.17 and p = 0.76), but 
for low-volume hospitals, this proportion increased from 58% in 2006-2007 to 66% in 2014-
2015 (p = 0.02) (Table 2).
Considering R1/R2 resections, the number of non-radical resections was higher when 
patients were treated in high-volume hospitals (19%) than in medium-volume (16%) and 
low-volume (14%) hospitals (p < 0.01). Over time, the amount of non-radical resections was 
stable for low-volume hospitals (p = 0.76) but decreased for medium-volume (26% to 16%, p 
= 0.01) and high-volume hospitals (22% to 15%, p = 0.01) (Table 2).
The number of patients requiring multiple procedures varied from 29% in high-volume 
hospitals and in medium-volume hospitals to 36% in low-volume hospitals (p < 0.01). These 
proportions remained stable over time (low-volume: p = 0.99, medium-volume: p = 0.70, 
high-volume: p = 0.70) (Table 2).
Effects on survival
Univariable net survival rates were significantly higher for patients treated in low-volume 
hospitals than for those treated in medium-volume and high-volume hospitals, with 10-year 
net survival rates of 76% versus 68% and 68% respectively and relative rates of 1.5 (medium-




volume versus low-volume, 95% CI 1.3-1.7, p < 0.001) (Fig. 3A). However, after adjustment 
for other prognostic factors, a multivariable Poisson regression analysis did not show any 
impact of surgical volume on net survival (medium-volume versus high-volume: relative rate 
[RR] 1.2, 95% CI 0.93-1.4, p = 0.20; low-volume versus high-volume: RR 1.01, 95% CI 0.87-1.2, 
p = 0.91) (Table 4A).
Table 4. Effect of surgical volume on survival after adjustment for case-mix (age, STS subtype, size, grade 
and depth) in a multivariable Poisson regression analysis. Results of the total study cohort (A) and of the 
subgroup analysis including only patients with non low-grade and deep-seated tumours (B). Full results 
with all covariates are shown in Supplementary Table S2.
Hospital volume RR 95% CI p-value
(A)
≥20 (high) ref
10-19 (medium) 1.2 0.93-1.4 0.20
1-9 (low) 1.01 0.87-1.2 0.91
(B)
≥20 (high) ref
10-19 (medium) 1.3 0.98-1.8 0.07
1-9 (low) 1.3 1.02-1.6 0.03*
STS, soft tissue sarcoma; RR, relative risk; 95% CI, 95% confidence interval  
* means statistically significant/p<0.05.
Since in high-volume hospitals more often patients with non low-grade, large and 
deep-seated tumours were treated (Table 2), which is associated with more complex surgery, 
a subgroup analysis was performed including only patients with non low-grade and deep-
seated STS (median age 61 years, IQR 48-71). The univariable analysis on patients with 
non low-grade and deep-seated tumours (n = 1222) did not show a difference in survival 
anymore, with net survival rates of 49%, 42% and 54%, respectively and relative rates of 
1.03 (medium-volume versus low-volume, 95% CI 0.76-1.4, p = 0.84) and 0.83 (high-volume 
versus low-volume, 95% CI 0.69-1.01, p = 0.06) (Fig. 3B). However, in multivariable analysis, 
surgery in a high-volume hospital did show a significant and beneficial effect on net survival 
compared with surgery in a low-volume hospital (RR 1.3, 95% CI 1.02-1.6, p = 0.03). The same 
impact was observed in comparison with medium-volume hospitals, although this failed to 
reach statistical significance (RR 1.3, 95% CI 0.98-1.8, p = 0.07) (Table 4B). The full results of 
the multivariable Poisson regression analysis are shown in Supplementary Table S2.
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1–9 2,196 1,966 1,799 1,581 1,356 1,141 968 767 597 439 291
10–19 407 365 324 252 224 193 151 125 84 57 45




















1–9 operations 10–19 operations ≥20 operations
1–9 2,196 1,966 1,799 1,581 1,356 1,141 968 767 597 439 291
10–19 407 365 324 252 224 193 151 125 84 57 45



















1–9 operations 10–19 operations ≥20 operations
1–9 310 245 209 168 135 110 95 76 59 41 22
10–19 116 99 82 56 45 35 29 28 18 15 12
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1–9 310 245 209 168 135 110 95 76 59 41 22
10–19 116 99 82 56 45 35 29 28 18 15 12
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▲Fig. 3. Net survival curves of patients undergoing STS surgery in the Netherlands from 2006 to 
2015 stratified by surgical volume (low-volume: 1-9 resections, medium-volume: 10-19 resections, high-
volume: ≥20 resections). (A) Net survival rate of all patients undergoing STS surgery (medium-volume 
versus low-volume: RR 1.5, 95%CI 1.2-2.0, p = 0.001; high-volume versus low-volume: RR 1.5, 95%CI 
1.3-1.7, p ≤ 0.001). (B) Net survival rate of patients undergoing STS surgery for non low-grade and deep-
seated tumours (n = 1222) (medium-volume versus low-volume: RR 1.03, 95%CI 0.76-1.4, p = 0.84; high-
volume versus low-volume: RR 0.83, 95%CI 0.69-1.01, p = 0.06). STS, soft tissue sarcoma; RR, relative 
rate; 95% CI, 95% confidence interval.
Discussion
We observed a significant effect of surgery in a high-volume hospital on net survival rate for 
patients with non low-grade and deep-seated tumours (i.e. tumours for which more complex 
surgery and more multidisciplinary treatment is required) and an increase in referring 
and treating STS patients to/in high-volume hospitals, although STS surgery is still highly 






more frequent referral of patients with deep-seated and large tumours from low-volume and 
medium-volume hospitals to high-volume hospitals, whereas there was no increase in the 
referral of non low-grade STS.
Previous studies regarding centralisation of STS care mainly reported not only on 
improvements in surgical outcomes [3, 8-10] and disease-free, relapse-free or progression-
free survival [11-15], but also on improvements in overall survival after treatment at expert 
sites/high-volume hospitals [10, 14-16]. The added value of this study to these studies on 
centralisation of STS care is the nationwide set-up, and the use of net survival rates as an 
alternative to and proxy for DSS [5], especially since many patients with low-grade STS 
are included who most probably will not die from their STS. In the current study, we could 
confirm an effect on net survival, but only in the subgroup of patients with poor prognostic 
characteristics, such as non low-grade and deep-seated tumours.
Notably, we observed a large proportion of and an increase in the number of potential 
’whoops’ resections in low-volume hospitals, although the absolute number of ’whoops’ 
resections decreased over time. It should be remarked that this proportion includes 
resections of large and deep-seated tumours as well as resections of small and superficial 
tumours. Especially the latter category, ’whoops’ resections of a small and superficial STS, 
cannot be prevented at all times and are ’all-in-the-game’, considering that benign soft tissue 
lesions are 100 times more prevalent [1]. Furthermore, some of these resections might 
deliberately have been performed without prior histological confirmation by biopsy (i.e. 
diagnostic excision). The increase in the proportion of ’whoops’ resections in low-volume 
hospitals even might be the result of centralisation itself. The proportion of tumours that are 
unrecognised as an STS probably will be stable over time. When low-volume hospitals perform 
less surgeries, the proportion of these ’whoops’ resections will increase. Nonetheless, in a 
considerable part of these patients suboptimal surgical approaches are chosen [17, 18], 
with unclear/inadequate resection margins [17-19], and these patients will need to undergo 
a re-resection to remove residual tumour and obtain adequate margins [19, 20]. This is also 
reflected in the current study, where patients treated in low-volume hospitals significantly 
more often needed to undergo re-resection than patients treated in high-volume hospitals.
The higher number of irradical resections in high-volume hospitals, although 
decreasing over time, is most probably because these hospitals more often operate on large 
and deep-seated tumours. They might perform planned R1-resections more often, after 
neoadjuvant radiotherapy, to spare surrounding vital structures, such as the neurovascular 
bundle, or even to prevent amputation. This hypothesis is also supported by the observation 
that patients treated in high-volume hospitals more often receive neoadjuvant/adjuvant 
radiotherapy, instead of surgery alone.
It has been shown that simple referral guidelines (referral of all deep-seated tumours 
and all superficial tumours ≥5cm) can result in nearly complete referral of STS patients to 
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expertise centres, with an acceptable surplus referral of benign tumours [21]. Currently, the 
guidelines in the Netherlands list a set of requirements that hospitals have to meet in order 
to treat STS patients, rather than indicate when to refer patients to an STS expertise centre 
regarding size, localisation or depth of the tumour [22]. Three of these requirements state 
that hospitals have to perform at least 10 primary STS resections annually, that all patients 
have to be discussed in an STS multidisciplinary team regarding diagnostic and treatment 
procedures and that the formulated advice during these multidisciplinary meetings is 
mandatory to follow. These referral guidelines allow general surgeons to consult an STS 
expertise centre for diagnostic and treatment advice without necessarily referring the 
patient in person. Remarkably, over 85% of the hospitals in which STS surgery is performed 
do not meet the specific requirement of at least 10 STS resections per year. Unfortunately, 
the rationales behind deviating from the guidelines are not registered in the NCR. For various 
reasons, such as travel distance, the patient’s own wish, unawareness of the existence of STS 
expertise centres or based on the (binding) advice of the multidisciplinary tumour board, 
patients are treated in low-volume hospitals.
On top of the beneficial effect on survival of patients with non low-grade and deep-
seated STS and the lower number of ’whoops’ resections and re-resections, treatment 
in a high-volume and expertise centre also might improve STS care on other levels. For 
example, patients will be treated by more experienced clinicians with more insight into the 
heterogeneity of the disease, its diagnosis and the rapidly evolving treatment options. Other 
examples include patient counselling regarding treatment decision-making and inclusion in 
clinical trials, which might be more optimal in high-volume multidisciplinary hospitals than in 
low-volume hospitals. However, in order to establish the best possible care for these patients, 
centralisation of STS care into high-volume hospitals should be paired with improving the 
diagnostic work-up for soft tissue tumours of unknown origin and creating more awareness, 
since centralisation is not only a result of high-volume hospitals recruiting these patients 
but mostly relies on the alertness and willingness of physicians in low-volume and medium-
volume hospitals to refer their patients.
Conclusion
Centralisation of STS surgery has increased in the past 10 years, although it is still highly 
fragmented across the country. Treatment in a high-volume hospital had a beneficial effect 
on net survival rates for patients with non low-grade and deep-seated STS on a population-
level, and it most probably also does reduce surgery-related morbidities reflected by the 
lower number of potential ’whoops’ resections and re-resections. Therefore, we plea for 
centralisation of STS care into dedicated multidisciplinary expertise centres and for more 




be at least discussed in an expertise centre. Patients with suspected non low-grade and 
deep-seated STS based on imaging – and subsequently more complex surgeries and more 
multidisciplinary treatment required – have to be referred to a high-volume hospital for a 
imaging-guided biopsy prior to start of treatment.
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Supplementary table S2. Results of the multivariable Poisson regression analysis of the total study 
cohort of patients undergoing surgery for soft tissue sarcoma in the Netherlands from 2006-2015 (A) 
and of the subgroup analysis including only patients with non-low grade and deep-seated tumors (B).
(A) RR 95% CI p-value (B) RR 95% CI p-value
Hospital 
volume
≥20 (high) ref ref
10-19 (medium) 1.22 0.93-1.4 0.20 1.3 0.98-1.8 0.07
1-9 (low) 1.01 0.87-1.2 0.91 1.3 1.02-1.6 0.03 *
Age 1.01 1.01-1.02 <0.01 * 1.01 1.00-1.02 <0.01 *
STS subtype Liposarcoma ref ref
Fibrosarcoma 0.82 0.62-1.1 0.16 0.75 0.50-1.1 0.15
Leiomyosarcoma 1.5 1.2-1.8 <0.01 * 1.3 0.97-1.7 0.08
PUS (MFH) 1.7 1.3-2.2 <0.01 * 1.5 1.1-2.1 0.02 *
Angiosarcoma 3.4 2.4-4.8 <0.01 * 1.9 0.62-6.0 0.26
Rhabdomyosar-
coma
2.1 1.4-3.1 <0.01 * 1.6 1.00-2.7 0.05
Synovial sarcoma 1.9 1.4-2.5 <0.01 * 1.3 0.86-2.0 0.22
MPNST 2.0 1.6-2.6 <0.01 * 1.9 1.3-2.6 <0.01 *
DFSP 0.09 0.01-0.97 0.05 * - - -
Other 1.9 1.5-2.3 <0.01 * 1.1 0.81-1.5 0.59
Size ≤5cm Ref Ref
>5cm 3.1 2.5-3.8 <0.01 * 2.3 1.7-3.2 <0.01 *
Unknown 1.8 1.3-2.5 <0.01 * 2.6 1.5-4.4 <0.01 *
Grade Low grade Ref
Non-low grade 4.1 2.9-5.8 <0.01 *
Unknown 3.1 2.1-4.6 <0.01 *
Depth Superficial Ref
Deep 1.6 1.4-1.8 <0.01 *
Unknown 1.5 1.2-1.8 <0.01 *
RR, relative rate; 95% CI, 95% confidence interval; PUS (MFH), pleomorphic undifferentiated sarcoma 
(malignant fibrous histiocytoma)
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In the last decade the limited treatment options for patients with metastatic soft tissue 
sarcoma have expanded considerably. With the addition of olaratumab to first-line treatment 
with doxorubicin, the introduction of several new agents in second-line treatment and 
beyond and other promising agents in the pipeline, perspectives of patients with metastatic 
soft tissue sarcoma are improving. Due to increasing insight into the biology of the different 
soft tissue sarcoma subtypes, choice of treatment has become much more histology-
driven, although more prognostic and predictive factors are needed to further personalise 
therapy. This report summarises the current state of the art and discusses the promising 
developments in the treatment of patients with metastatic soft tissue sarcoma.
Keywords: Soft tissue sarcoma; Metastatic soft tissue sarcoma; Chemotherapy; Systemic 
treatment; Immunotherapy




Soft tissue sarcomas (STSs) form a heterogeneous group of rare, mesenchymal tumours, 
accounting for approximately 1% of all adult malignancies and comprising over 50 different 
histological subtypes. Roughly they can be divided into three groups; small blue round cell 
tumours (SBRCTs), gastrointestinal stromal tumours (GISTs) and adult-STSs. The latter group, 
adult-STSs, forms the topic of the current overview.
Most adult-STS patients are diagnosed at an early stage and can be treated with 
curative intent by local treatment options such as surgery and radiotherapy. Unfortunately, a 
substantial proportion of patients presents with metastatic disease at time of initial diagnosis 
(10-15%) or will develop metastases over time (up to 40%). Here, we summarise the different 
aspects of the treatment of metastatic STSs while putting the recent developments into 
perspective.
First-line treatment of widespread metastatic disease
Despite the large heterogeneity in terms of pathogenesis, clinical course and sensitivity 
to systemic agents across the different STS entities, almost all STS subtypes are treated in 
the first-line treatment with doxorubicin-based regimens (Table 1). The majority of patients 
receive doxorubicin monotherapy, yielding a response rate of approximately 10-14%, a 
median progression-free survival (PFS) of 4.5 months and median overall survival (OS) of 12-
18 months in most recent trials [1-5]. Aiming to improve outcome, multiple different regimens 
have been assessed during the last decades. These efforts were all in vain, apart from the 
combination of doxorubicin and ifosfamide. This combination resulted in a higher response 
rate and PFS, but failed to prolong OS and is therefore mainly considered for fit patients in 
need of a response [1]. Other randomized studies assessing the combinations of doxorubicin 
plus evofosfamide or palifosfamide, both ifosfamide derivatives, failed to demonstrate 
clinically relevant superior outcomes over doxorubicin alone [4,5]. Recently, another phase 
III trial compared the combination of gemcitabine and docetaxel to doxorubicin as first-line 
treatment. No benefit for the combination was seen over doxorubicin in this case either, also 
not in specific subtypes in which this combination was thought to be active. Additionally, the 
combination induced more toxicity and was at the expense of a lower quality-of-life, which 
only reconfirmed the role of doxorubicin monotherapy in advanced STS [3].
A doxorubicin-based combination that might have a huge impact on the outcome 
of advanced/metastatic STS patients is the combination with olaratumab, a monoclonal 
antibody directed towards the platelet-derived growth factor receptor-alpha (PDGFR-α). 
Based on a phase II trial, randomising patients to either receive doxorubicin plus olaratumab 




Agency (EMA) as first-line treatment in combination with doxorubicin. The primary goal of the 
study, a 50% improvement in median PFS, was met (6.6 versus 4.1 months in the combination 
group versus the doxorubicin alone group; hazard ratio (HR) 0.67; 95% confidence interval 
(CI) 0.44-1.02). Remarkably, a much larger difference in median OS was seen favouring the 
combination therapy (26.5 versus 14.7 months in the doxorubicin alone group; HR 0.46; 
95% CI 0.30-0.71). This gain was at the expense of an increase in adverse events, such as 
neutropenia and mucositis, although the rate of treatment discontinuation due to adverse 
events was lower in the combination group [2]. Recently, accrual of the phase III trial with a 
similar design has been completed and results are expected in 2020. Obviously, confirmation 
of these results would mean a substantial improvement for these patients.
Table 1.. Overview of the different agents commonly given in first-line treatment, second-line treatment 
and beyond in advanced STS patients.
Agent STS subtype Ref. Level of evidence and additional remarks
First-line treatment
Doxorubicin monotherapy All [1, 2] IA
Doxorubicin + olaratumab All [2] IB, conditionally approved pending results of 
the phase III trial
Doxorubicin + ifosfamide All [1] IA, mainly given to fit patients in need of a 
response
Second-line treatment and beyond
Trabectedin All [6, 7, 22] IIB, only level IA available in LPS and LMS
Pazopanib All but LPS [8, 9] IB
Eribulin LPS [12] IA
Taxanes AS [15] IIIB
VEGF-TKIs (cediranib, sunitinib) ASPS [16, 17] IIA
Gemcitabine-based regimens LMS [13, 14] IIC
STS, soft tissue sarcoma;  LPS, liposarcoma; AS, angiosarcoma; LMS, leiomyosarcoma; ASPS, alveolar soft 
part sarcoma
Second-line treatment and beyond of widespread 
metastatic disease
Given the great heterogeneity among the STS subtypes, over 50 of them, it is likely that 
different systemic treatment approaches will have to be used in diverse STS entities. Whereas 
this is rarely the case in first-line therapy yet, in second-line therapy, a histology-driven 
choice is already much more common (Table 1). In the last decade, trabectedin (a synthetic 
compound derived from a Caribbean sea squirt) was EMA approved for all adults with 
advanced STS failing first-line treatment. Based on phase II studies, it is mostly used in patients 
with leiomyosarcomas or liposarcomas (‘L-sarcomas’). A recent phase III study in advanced 
L-sarcoma patients showed superior disease control and clinical benefit, but no significant 
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survival benefit, over dacarbazine [6,7]. Pazopanib, a multikinase angiogenesis inhibitor, is 
another second-line treatment option for patients with advanced STS failing to doxorubicin-
based regimens, and also here histology matters. Following the results of the preceding 
phase II trial showing no efficacy of pazopanib in liposarcoma patients, these patients were 
not included in the phase III trial that formed the basis for registration of pazopanib [8,9]. 
This was confirmed by a large retrospective cohort study [10], but contradicted by another 
phase II trial in advanced intermediate/high-grade liposarcomas showing potential activity 
of pazopanib in this cohort [11]. These apparently conflicting results on the efficacy in 
liposarcomas are probably associated with the heterogeneity within the liposarcoma entity, 
consisting of five different subtypes, and the variation in distribution of these subtypes 
across the various studies. Another agent active in second-line is eribulin, which significantly 
increased OS compared to dacarbazine in patients with advanced L-sarcomas, although 
the effect seems to be restricted to the liposarcoma subgroup [12]. Therefore, eribulin was 
recently approved in 2016, but for advanced liposarcoma only. In addition to these agents 
for which data from phase III studies are available, several other agents are being used in the 
second-line treatment for specific STS entities, including vascular endothelial growth factor 
receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in alveolar soft part sarcoma, gemcitabine-
based regimens in leiomyosarcoma and taxanes in angiosarcoma [13-17]. However, evidence 
from randomised studies (in second line treatment) showing that these options truly result in 
better outcomes compared to the above mentioned treatment strategies is currently lacking.
Future perspectives
Although treatment of metastatic STS has improved over the years and options have 
expanded, there is much to be gained. A considerable proportion of patients are not eligible 
to receive any of the relatively toxic drugs due to poor performance status or comorbidities. 
As for now, best supportive care is the only option for these patients, underlining the urgent 
need for novel treatment strategies.
Despite multiple clinical trials in search for a more effective and/or less toxic drug, 
doxorubicin has remained the mainstay of first-line treatment. Its treatment can be 
accompanied by severe side-effects, such as myelosuppression and mucositis, but its use 
is mostly limited due to cumulative cardiotoxicity. At present, there is ongoing research on 
aldoxorubicin, a prodrug of doxorubicin [18]. Based on preliminary data of a phase III trial, 
aldoxorubicin, compared to investigator’s choice of treatment, seems to have a slightly longer 
PFS, but only in patients with L-sarcomas. There was no significant improvement in response 
rate or OS, nor a significant difference in any of these outcomes in other STS subtypes. 
Remarkably, minimal cardiotoxicity was observed, suggesting it might be worthwhile to 




Moreover, several studies have been conducted to assess the feasibility of numerous 
agents and regimens in elderly patients. For example, metronomic cyclophosphamide 
and trabectedin showed efficacy as well as favourable toxicity profiles and safety in elderly 
patients, indicating that there are certainly treatment options available for this fragile patient 
population [20-22].
Furthermore, there are some promising agents in the pipeline. Regorafenib is one of 
those agents, demonstrating antitumour activity in multiple non-adipocytic STS subtypes 
with a significant improvement in PFS. There was no significant difference in OS, although 
the study design (allowing cross-over from placebo to regorafenib after progression) made 
it impossible to adequately assess OS, but the results are promising enough to consider a 
phase III trial with this drug [23].
Additionally, numerous clinical trials investigating different immunotherapies and 
in different combinations are currently ongoing. Especially the combination of nivolumab 
and ipilimumab with a response rate of 16% compared to 5% for nivolumab alone, showed 
favourable and promising results in multiple STS subtypes in phase II, though its toxicity 
profile is substantial [24]. Also pembrolizumab, albeit evaluated in small patient groups, 
demonstrated clinical activity in undifferentiated pleomorphic sarcoma (response rate 40%) 
and dedifferentiated liposarcoma (20%).The expansion cohorts are enrolling to confirm the 
antitumour activity in these subtypes [25]. Another discovery is the expression of the NY-
ESO-1-antigen in approximately 20% of all STS subtypes, with higher expression levels in 
specific subtypes (88.0% in myxoid liposarcoma, 49.3% in synovial sarcoma) [26]. The cancer-
testes antigen NY-ESO-1 represents an attractive target in STS establishment. CMB305 is 
an immune modulating agent, aiming to generate and expand anti-NY-ESO-1 T-cells and 
antibodies. The sequential and alternating administration of the two components leads to 
priming of the immune system followed by a boost, resulting in a robust and prolonged 
immune response against NY-ESO-1. Trials with CMB305, but also genetically engineered 
anti-NY-ESO-1 T-cells are ongoing and show promising effects in early phase trials in synovial 
sarcoma and myxoid liposarcoma [27-29].
Although the treatment decision making in STS is increasingly histology driven, more 
specific and sensitive predictive factors to tailor therapy are warranted. Increasing insight 
into the biology of the different STS subtypes will hopefully lead to the identification of 
predictive markers beyond conventional histology. For example, in the context of a phase 
II trial, a subset of miRNAs, regardless of underlying histology, was revealed that might 
identify patients benefiting from eribulin [30]. Likewise, studies are investigating whether 
programmed cell death ligand-1 (PD-L1) expression, mutational load or composition of 
immune infiltrates can be used to predict outcome to anti-PD(L)1-antibodies [24,31].




The treatment of metastatic STS has changed considerably over the last few years, with 
addition of olaratumab to the first-line treatment probably being the biggest development, 
provided that its preliminary efficacy can be confirmed. Moreover, the limited treatment 
options in second-line treatment and beyond have expanded, introducing trabectedin, 
pazopanib and eribulin amongst others. Despite these innovations, overall survival of 
metastatic STS patients remains poor, underlining the great need for novel agents and 
strategies to further personalise treatment. 
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MINIMAL INCREASE IN 
SURVIVAL THROUGHOUT 
THE YEARS IN PATIENTS 
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WITH SYNCHRONOUS 
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Background: Treatment options for patients with metastatic soft tissue sarcoma (STS) have 
increased in the last decade. We aimed to examine whether this is associated with improved 
overall survival (OS) in patients with STS with synchronous metastases.
Patients and Methods: Patients diagnosed with STS and synchronous metastases from 1989 
to 2014 were queried from The Netherlands Cancer Registry. Trends in OS were assessed by 
the Kaplan-Meier method and log-rank test in time intervals of 5 years, for the whole study 
population and in subgroups for liposarcomas, leiomyosarcoma, and other STS subtypes. A 
multivariable Cox regression analysis was performed to identify characteristics prognostic 
for OS.
Results: Median OS of the 1,393 identified patients did not improve significantly over the 
years from 5.8 months in 1989–1994 to 8.1 months in 2010–2014, but there was an evident 
trend. Median OS was prolonged in the subgroups of liposarcomas (3.6 to 9.3 months), 
leiomyosarcomas (11.3 to 14.6 months), and other STS subtypes (5.7 to 6.3 months), 
although there were no significant improvements in OS over the years. Primary tumor site 
in one of the extremities and surgery in an academic center had a favorable effect on OS, 
whereas significant negative predictors were no treatment, elderly age, STS subtype other 
than liposarcoma or leiomyosarcoma, high or unknown grade, and nodal involvement.
Conclusion: Although overall survival of patients with STS with synchronous metastases in this 
nationwide and “real-life” population has improved over the years, the improvement was not 
statistically significant, despite new treatment options.
Keywords: Soft tissue sarcoma; Synchronous metastases; Overall survival; Population-based 
study
Implications for Practice: Treatment of patients with metastatic soft tissue sarcoma (STS) has 
changed in the past years, with new drugs such as trabectedin (2007) and pazopanib (2012) 
becoming available. By using data from the nationwide Netherlands Cancer Registry, the 
impact of these changes in treatment policies on survival is analyzed in a “real-life” population 
of patients with STS with synchronous metastases, rather than in a strictly selected trial 
population. Unfortunately, overall survival improved only minimally and not significantly 
for these patients diagnosed from 1989 to 2014. Hopefully, the advent of novel treatment 
options, such as eribulin and olaratumab, will further improve the outcome of this patient 
group.




Soft tissue sarcomas (STSs) are a group of rare and heterogeneous tumors of mesenchymal 
origin, comprising over 50 different histological subtypes and accounting for approximately 
1% of all adult malignancies [1, 2]. Roughly 650 to 700 new patients are diagnosed 
annually with STS in the Netherlands, with a slightly increasing incidence over the years 
[3]. Leiomyosarcomas and liposarcomas form the two most prevalent subtypes, each 
representing approximately 20% of patients with STS [1]. When STS is diagnosed at an early 
stage and complete resection of the tumor can be carried out, cure may be achieved in up 
to 90% of patients [4-6]. Unfortunately, cure is generally not attainable in case of metastatic 
disease, a situation for which only palliative treatment remains. Most of these cases occur as 
a relapse after primary treatment, which may take several years of follow-up. Approximately 
10% to 15% of patients present with synchronous metastases, that is, metastases that are 
diagnosed before or simultaneously with the primary tumor [7]
In the majority of patients with advanced STS, the disease cannot be cured, and only 
treatment with palliative intent remains. However, in selected cases with oligometastatic 
disease, mostly isolated and solitary lung metastases, long-term survival and in rare cases 
even cure can be achieved by surgical resection of the metastasis, also called metastasectomy 
[8-11]. Besides surgical resection, other local treatment options can be applied. Examples 
include radiofrequency ablation, isolated limb perfusion and (stereotactic) radiotherapy [12]. 
In contrast to metastasectomy of solitary (lung) metastases, these treatment options are 
used rarely with therapeutic intent but rather with a palliative intent. Although they might 
prolong remission or prevent or slow down progression [13], these treatment modalities are 
usually used to reduce symptoms and thereby improve quality of life.
In recent years, the number of systemic palliative treatment options for patients with 
metastatic STS has increased. Whereas doxorubicin-based chemotherapy is the mainstay 
of first-line treatment, mostly as a single agent and sometimes in combination with 
ifosfamide [14, 15], two new agents have been approved in the last decade for patients 
in whom doxorubicin-based chemotherapy fails or is unsuitable. In the Netherlands, the 
alkylating agent trabectedin became available in 2007 for adults who have advanced STS 
and who fail on treatment with anthracyclines and/or ifosfamide or who are unsuited to 
receive these agents. Although registered for all STS subtypes, it is mostly applied in patients 
with liposarcomas or leiomyosarcomas, as efficacy was proved most pronounced in these 
entities [16, 17]. Secondly, the tyrosine kinase inhibitor pazopanib was introduced in 2012. 
In the Netherlands, it is registered for advanced STS after prior chemotherapy for metastatic 
disease or advanced STS with progressive disease within 12 months after neoadjuvant/




Besides these two new agents, other chemotherapeutic drugs are increasingly used in daily 
clinical practice, although these have not been formally registered for STS. Examples include 
gemcitabine in leiomyosarcoma and taxanes in angiosarcoma, which are also mentioned in 
international guidelines [13, 20]. These drugs can be used in multiple lines of therapy or in 
combination with other locoregional treatment options [13].
For this study, a population-based analysis was performed to determine the impact 
of the changes in treatment policies on overall survival in patients with STS presenting with 
metastatic disease at time of diagnosis (also known as synchronous metastases) and to 
establish whether the survival has improved over the years. Because our data source, the 
nationwide database of The Netherlands Cancer Registry (NCR), does not include information 
on patients who relapsed after initial treatment for non-metastatic disease, the focus in this 
study is on the 10% to 15% of patients with soft tissue sarcoma with synchronous metastases.
Materials and methods
Data Collection
From the NCR, data on all patients with STS diagnosed with synchronous metastases 
between 1989 and 2014 were identified and extracted. Synchronous metastases were 
defined as metastases detected prior to or during screening in the diagnostic workup 
before start of (neoadjuvant) treatment of the primary tumor. Children (age at diagnosis 
<18 years), gastrointestinal stromal tumors (GIST) and small blue round cell tumors (SBRCTs: 
Ewing’s sarcomas, mesenchymal chondrosarcomas, peripheral neuroectodermal tumors, 
and rhabdomyosarcomas) were excluded because of the different tumor biologies, different 
treatment regimens, and outcomes.
Information in the NCR on patient characteristics, disease characteristics, and primary 
treatment was retrieved from patients’ medical records by trained registration employees of 
The Netherlands Comprehensive Cancer Organisation (IKNL). Follow-up information on vital 
status was obtained through yearly linkage with the Municipal Personal Records Database 
(MPRD). For our study, the last linkage was performed in February 2016.
Primary tumors were staged according to the TNM classification and STS subtypes were 
classified following the World Health Organization classification [2, 21]. No central pathology 
review was performed. Primary tumor site as well as metastatic site(s) and STS subtype 
were coded under the International Classification of Diseases of Oncology topography 
and morphology codes, respectively. STS subtypes that are acknowledged for exhibiting 
aggressive behavior but usually not graded (malignant peripheral nerve sheath tumors, 
angiosarcoma, extraskeletal chondrosarcoma, epithelioid sarcoma, clear cell sarcoma not 
otherwise specified, alveolar soft part sarcoma) were pooled with grade III tumors and 
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classified as high-grade tumors. Grade I and II tumors were pooled and classified as low-
grade tumors. For the study period, the NCR database lacked information on the type of 
systemic therapy (cytostatic drugs, kinase inhibitors, etc.) or intent of surgery (resection of 
primary tumor, palliative debulking, etc.). In addition, no data were available on patients’ 
performance score or comorbidities.
The study was performed in accordance with local ethics committee guidelines and 
national legislation.
Statistical Analysis
Median follow-up time with corresponding interquartile range (IQR) was calculated by the 
reversed Kaplan–Meier method [22]. Overall survival (OS) was defined as time in months 
between diagnosis (first pathological confirmation) and death or last follow-up. Patients alive 
at date of last linkage to the MPRD were censored. To assess trends in overall survival over 
the study period, the data were analyzed in intervals of 5 years, using the Kaplan–Meier 
method. Overall survival was assessed for the total study population, as well as in subgroups 
for patients with liposarcomas, leiomyosarcomas, and other STS subtypes. Survival times are 
noted as median survival times in months, together with the corresponding IQRs. Differences 
between subgroups were tested by the log-rank test. An additional survival analysis focusing 
on patients who received systemic therapy was performed to explore the effect of the new 
agents. Because of small subgroups, liposarcomas and leiomyosarcomas were combined 
(“L-sarcomas”) for this analysis.
A multivariable Cox proportional hazards regression analysis for OS was performed 
to identify relevant patient, tumor or treatment related characteristics. Also, we explored 
possible influences on survival of the type of hospital (academic vs. nonacademic) where 
patients were diagnosed and treated. Factors that tested significantly at an α-level of 0.05 in 
univariable analyses were included in the multivariable Cox regression analysis. The definitive 
model was obtained with a backward stepwise elimination method. Results are described as 
hazard ratios (HRs) with corresponding 95% confidence intervals (95% CI). P values ≤.05 were 
considered statistically significant. SPSS was used for the statistical analyses (SPSS Statistics 
for Windows; IBM, Armonk, NY).
Results
Between 1989 and 2014, 1,689 patients were diagnosed with STS and synchronous 
metastases, including children and those diagnosed with GIST and SBRCTs, representing 
roughly 12% of all patients diagnosed with STS. Over the years, an increase in incidence was 




and patients with GISTs and SBRCTs, 1,393 patients with STS and synchronous metastases 
were included in the analyses. There was a slight male predominance, and the trunk was 
the primary tumor site in approximately half of the patients (Table 1). The most common 
localizations of metastases were the lungs (42.9% of patients), liver (13.3%), bones (11.6%), 





















































































▲Figure 1. Incidence of STS and metastatic STS at time of initial diagnosis in the Netherlands. The blue 
fractions of the bars represent patients with non-metastatic/localized STS. The red fractions and the 
numbers above the bars represent the proportion of patients with metastatic STS at initial diagnosis. 
STS: soft tissue sarcoma. 
Trends in Survival
Median OS over the whole period and for all subtypes was 6.3 months (IQR 2.4–15.5). 
Throughout the years, median OS did not improve significantly; it increased from 5.8 months 
(IQR 2.3–14.8) in 1989–1994 to 8.1 months (IQR 2.7–17.1) in 2010–2014 (p = .095), although 
there was an evident trend (log-rank trend test, p = .015; Fig. 2A).
When analyzing the different STS subtypes, median OS for patients with liposarcoma 
did not change significantly from 3.6 months (IQR 1.7–18.5) in 1989–1994 to 9.3 months 
(IQR 3.8–28.8) in 2010–2014 (p = .180; Fig. 2B). Neither did the median OS for patients with 
leiomyosarcomas improve significantly (11.3 months, IQR 3.5–19.5, to 14.6 months, IQR 
5.5–21.0, p = .449; Fig. 2C). Also, for patients with one of the other STS subtypes, median OS 
remained stable from 5.7 months (IQR 2.1–12.7) in 1989–1994 to 6.3 months (IQR 2.2–13.5) 
in 2010–2014 (p = .559; Fig. 2D).
In our study population, almost one third of patients did not receive any treatment. 
This subgroup had a poor median OS of 2.1 months (IQR 0.9–5.8) compared with 9.5 months 
(IQR 4.2–20.0) for patients who received any type of treatment (p < .001; Table 2). Among the 
latter group, those who underwent multimodality treatment had a better OS, and patients 
treated with both radiotherapy and surgery had the most favorable median OS (19.9 months, 
IQR 8.0–45.2).
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   Male 742 53.3
   Female 651 46.7
Age (years), median (range) 64 (18-96)
Subtype
   Liposarcoma 129 9.3
      Well differentiated liposarcoma 9 7.0
      Dedifferentiated liposarcoma 34 26.4
      Myxoid liposarcoma (including round cell liposarcomas) 42 32.6
      Pleomorphic liposarcoma 24 18.6
      Liposarcoma NOS 19 14.7
      Mixed type liposarcoma 1 0.8
   Leiomyosarcoma 348 25.0
   Other 916 65.8
Site
   Retroperitoneum & peritoneum 132 9.5
   Trunk 712 51.1
   Head & neck 73 5.2
   Upper extremity 83 6.0
   Lower extremity 393 28.2
Grade
   Low (G I/II) 181 13.0
   High (G III/NA) 680 48.8
   Unknown (Gx) 532 38.2
Depth
   Superficial 136 9.8
   Deep 571 41.0
   Unknown 686 49.2
Size (T-stadium)
   ≤ 5 cm (T1) 121 8.7
   > 5 cm (T2) 913 65.5
   Unknown (Tx) 359 25.8
Lymph Node Involvement
   N0 475 34.1
   N1 189 13.6
   Nx (lymph nodes not assessed) 729 52.3
Pulmonary metastases
   No 796 57.1





Treatment (in any order)
   Chemotherapy (CTx) 316 22.7
   Radiotherapy (RTx) 159 11.4
   Surgery 206 14.8
   CTx and RTx 52 3.7
   CTx and surgery 107 7.7
   RTx and surgery 79 5.7
   CTx, RTx and surgery 28 2.0
   No therapy 446 32.0
FU time (months), median (IQR)    136.2 (53.1-198.0)
Abbreviations: CTx, chemotherapy; FU, follow-up; IQR, interquartile range; NA, not applicable; NOS, not 
otherwise specified; RTx, radiotherapy.
Table 2. Median overall survival in months of patients with metastatic STS at initial diagnosis per 
(combination of) treatment modality
Treatment modalities n (%) median OS (IQR), months
No therapy 446 (32.0%) 2.1 (0.9-5.8)
Therapy 947 (68.0%) 9.5 (4.2-20.0)
   RTx 159 (11.4%) 5.8 (2.8-12.2)
   Surgery 206 (14.8%) 6.9 (3.3-18.3)
   CTx 316 (22.7%) 9.4 (4.4-16.1)
   CTx-RTx 52 (3.7%) 10.8 (5.6-23.0)
   CTx-Surgery 107 (7.7%) 15.6 (7.1-29.8)
   CTx-RTx-Surgery 28 (2.0%) 16.1 (9.5-37.5)
   RTx-Surgery 79 (5.7%) 19.9 (8.0-45.2)
Overall 1,393 (100%) 6.3 (2.4-15.5)
Combinations of treatment modalities can be in any order, i.e., RTx-CTx is pooled with CTx-RTx, surgery-
RTx is pooled with RTx-surgery, etc. P-values were calculated by using the log-rank test (p < .0001). 
Abbreviations: CTx, chemotherapy; IQR, interquartile range; OS, overall survival; RTx, radiotherapy.
A subanalysis of the subgroup of patients who received chemotherapy (n = 503) 
was performed to explore the effect of the new systemic therapies. Median OS over the 
total period in the chemotherapy subgroup was 10.8 months (IQR 5.5–20.4) and improved 
minimally from 10.5 months (IQR 4.9–17.1) in 1989–1994 to 13.0 months (IQR 5.8–24.3) 
in 2010–2014 (p = .446; Fig. 3A). In the different STS subgroups, median OS also did not 
improve for the L-sarcomas (13.0 months, IQR 4.9–34.5, in 1989–1994 to 18.1 months, IQR 
8.4–29.7, in 2010–2014, p = .485, Fig. 3B) or for the other STS subtypes (10.1 months, IQR 
4.9–14.1, in 1989–1994 to 10.6 months, IQR 4.5–20.8, in 2010–2014, p = .789; Fig. 3C).
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259 84 30 22 13 10 10 9 8
230 63 27 15 9 8 8 8 6
269 75 35 22 19 15 14 13 11
273 85 45 22 14 10 7 4 3
362 132 47 23 13 4 0 0 0−−−
−−
Number at risk
22 6 3 3 2 2 2 1 0
20 5 1 1 1 1 1 1 1
23 7 4 1 1 1 1 1 1
17 11 6 4 3 1 1 1 0















































64 30 9 5 2 1 1 1 1
72 21 10 6 3 3 3 3 2
59 22 10 6 3 2 2 2 2
79 34 19 5 3 3 2 1 1
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173 48 18 14 9 7 7 7 7
138 37 16 8 5 4 4 4 3
187 46 21 15 15 12 11 10 8
177 40 20 13 8 6 4 2 2
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▲Figure 2. Overall survival of all patients with STS with synchronous metastases per 5-year time 
intervals (A), specified for liposarcomas (B), leiomyosarcomas (C), and other STS subtypes (D). P values 
were calculated by the log-rank test. For (A), an additional log-rank trend test was performed, showing a 
significant trend over the years (p = .015).
Prognostic Factors for Overall Survival in Metastatic STS at Initial 
Diagnosis
In the univariable Cox regression analyses almost all factors tested significantly, except 
for the variables gender, socioeconomic status, pulmonary metastases, and the annual 
volume of the hospital where patients received their (first-line) chemotherapy (Table 3). In 
multivariable analysis seven factors remained independently prognostic (Table 4). Whereas 
an elderly age, STS subtype other than liposarcoma or leiomyosarcoma, high or unknown 




in the upper or lower extremity, any type of treatment (chemotherapy, radiotherapy, and/
or surgery), and undergoing surgery in an academic center (compared with a nonacademic 
center) had a favorable effect on survival.
Discussion
Several new therapeutic agents and/or regimens for the treatment of patients with advanced 
STS have been introduced in the last decade, including trabectedin in 2007 and pazopanib in 
2012. Despite these new options, the overall survival of patients with STS with synchronous 
metastases has improved only minimally and not statistically significantly over the years.
As probably only a small proportion of patients received one of the new agents, the 
survival benefit of trabectedin reported in several trials apparently has not translated to 
patients with advanced disease at initial diagnosis on a population level [16, 17, 23-25]. A 
possible contributing factor could be the different composition of STS subtypes included 
in our study population compared with the study populations of clinical trials. For instance, 
the efficacy of trabectedin was most pronounced in the L-sarcomas and especially myxoid 
liposarcomas, and whereas in most trabectedin trials 50% to 100% of the included patients 
had liposarcoma or leiomyosarcoma, only approximately 35% of the patients in our study 
population were diagnosed with an L-sarcoma, of whom only 3.0% had myxoid liposarcoma.
In line with the results from the PALETTE trial, in which a significant difference in progression-
free survival but not in overall survival was observed between the pazopanib and placebo 
arm [19], we did not observe a significant difference in overall survival. It must be noted that 
a possible beneficial effect might be masked because of short follow-up, with 2012 being the 
year of introduction of pazopanib [26].
Throughout the years, we observed a median overall survival across all STS subtypes of 
6.3 months, which is poorer than reported in clinical trials for patients with metastatic STS, 
in which median OS times of 12 to 24 months have been described [9, 27-35]. However, 
these studies have included only patients who received any kind of treatment, whereas this 
study also included a substantial number of patients who did not receive any treatment. As 
expected, patients who did not receive therapy, probably because of a poor performance 
status or multiple comorbidities, have a poorer prognosis than patients receiving (any kind of) 
treatment. Unfortunately, no data on comorbidities or performance status were available to 
confirm this hypothesis or to correct for possible interactions in our analyses. When focusing 
only on the group receiving any kind of treatment, we observed a median OS of 9.5 months, 
which is still poorer than described in literature. It is likely that the patients who received 
treatment in our cohort did not meet the strict eligibility criteria that patients included into 
clinical studies have to fulfil. Remarkably, patients who made it to a combination of local 
treatment only (i.e., surgery and radiotherapy) had the most favorable median OS of 19.9







































































































































































































































































































































































































































































































































































































































































































































































Table 3. Results of univariable Cox proportional hazards regression analysis for overall survival of 
patient-, tumor-, and treatment-related characteristics
Characteristics N HR 95% CI pa
Patient-related characteristics
Age 1393 1.016 1.012-1.019 <.001
Gender Male 742 1
Female 651 0.977 0.877-1.089 .673
Socioeconomic status High 400 1
Medium 544 1.137 0.995-1.299 .059
Low 449 1.091 0.950-1.253 .219
Tumor-related characteristics 
Year of diagnosis 1393 0.991 0.984-0.998 .010
Site Trunk 712 1
(Retro)peritoneum 132 0.826 0.682-0.999 .049
Head and neck 73 0.766 0.598-0.982 .036
Upper extremity 83 0.619 0.487-0.788 <.001
Lower extremity 393 0.684 0.602-0.777 <.001
Subtype Leiomyosarcoma 348 1
Liposarcoma 129 0.937 0.758-1.159 .548
Other 916 1.282 1.129-1.455 <.001
Grade Low (I/II) 181 1
High (III/NA) 680 1.422 1.196-1.690 <.001
Unknown (X) 532 1.556 1.303-1.857 <.001
Depth Deep 571 1
Superficial 136 0.698 0.571-0.853 <.001
Unknown 568 1.124 0.998-1.267 .054
Size (T-stadium) ≤5cm (T1) 121 1
>5cm (T2) 913 1.195 0.983-1.454 .074
Unknown (Tx/T0) 359 1.501 1.215-1.859 <.001
Nodal involvement N0 475 1
N1 189 1.463 1.229-1.742 <.001
Nx (unknown) 729 1.511 1.340-1.704 <.001
No. of metastases 1 650 1
2 231 1.171 1.004-1.367 .045
≥3 83 1.481 1.172-1.872 .001
Unknown 429 1.100 0.970-1.247 .137
Pulmonary metastases No 796 1
Yes 597 0.914 0.819-1.020 .108
Treatment-related characteristics
Treatment modalitiesb No treatment 446 1
CTx 316 0.406 0.350-0.471 <.001
RTx 159 0.526 0.438-0.632 <.001
Surgery 206 0.387 0.326-0.460 <.001
CTx and RTx 52 0.293 0.217-0.397 <.001
CTx and surgery 107 0.258 0.206-0.322 <.001
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Characteristics N HR 95% CI pa
RTx and surgery 79 0.189 0.143-0.249 <.001
CTx, RTx and surgery 28 0.248 0.166-0.372 <.001
Hospital type of diagnosis General/non-academic 1047 1 <.001
Academic 346 0.786 0.692-0.892 <.001
Diagnosis at sarcoma center No 1163 1
Yes 230 0.794 0.684-0.921 .002
Resection margins R0 68 1
R1 22 0.763 0.432-1.348 .352
R2 96 1.443 1.030-2.020 .033
Rx 234 1.625 1.211-2.179 .001
Annual surgery volume 1-10 151 1
10-19 44 0.736 0.512-1.058 .097
≥20 124 0.613 0.473-0.795 <.001
Hospital type of surgery General/non-academic 175 1
Academic 172 0.599 0.477-0.752 <.001
Unknown 73 1.047 0.793-1.381 .747
Surgery in sarcoma center No 284 1
Yes 136 0.617 0.492-0.773 <.001
Annual volume (first-line) CTx 1-10 254 1
10-19 96 0.867 0.676-1.112 .260
≥20 50 0.951 0.693-1.306 .758
Hospital type of (first-line) CTx General 190 1
Academic 238 0.782 0.641-0.954 .015
Unknown 75 1.065 0.811-1.398 .650
CTx in sarcoma center No 273 1
Yes 224 0.707 0.588-0.850 <.001
aVariables with p value <.05 are included in multivariable analysis. bTreatment modalities used, in any 
order (i.e., CTx and RTx can be first CTx followed by RTx, but also RTx first followed by CTx). Abbreviations: 
CI, confidence interval; CTx, chemotherapy; HR, hazard ratio; NA, not applicable; Nx, lymph nodes not 




Table 4. Results of multivariable Cox proportional hazards regression analysis for overall survival of 
patient-, tumor-, and treatment-related characteristics
Characteristics N HR 95% CI pa
Patient-related characteristics
Age 1393 1.011 1.007-1.015 <.001
Tumor-related characteristics 
Site Trunk 712 1
(Retro)peritoneum 132 0.911 0.748-1.110 .356
Head and neck 73 0.805 0.625-1.038 .095
Upper extremity 83 0.723 0.565-0.926 .010
Lower extremity 393 0.782 0.685-0.894 <.001
Subtype Leiomyosarcoma 348 1
Liposarcoma 129 1.159 0.926-1.450 .197
Other 916 1.418 1.233-1.631 <.001
Grade Low (I/II) 181 1
High (III/NA) 680 1.561 1.291-1.887 <.001
Unknown (X) 532 1.347 1.115-1.628 .002
Nodal involvement N0 475 1
N1 189 1.315 1.101-1.572 .003
Nx (unknown) 729 1.150 1.015-1.304 .029
Treatment-related characteristics
Treatment modalitiesb No treatment 446 1
CTx 316 0.462 0.393-0.543 <.001
RTx 159 0.498 0.412-0.603 <.001
Surgery 206 0.431 0.353-0.526 <.001
CTx and RTx 52 0.299 0.218-0.410 <.001
CTx and surgery 107 0.364 0.277-0.478 <.001
RTx and surgery 79 0.257 0.189-0.350 <.001
CTx, RTx and surgery 28 0.373 0.241-0.576 <.001
Hospital type of surgery General/non-academic 175 1
Academic 172 0.688 0.542-0.874 .002
Unknown 73 1.169 0.882-1.551 .277
aVariables significant at an α-level of .05. bTreatment modalities used, in any order (i.e., CTx and RTx can 
be first CTx followed by RTx, but also first RTx followed by CTx). Abbreviations: CI, confidence interval; CTx, 
chemotherapy; HR, hazard ratio; NA, not applicable; Nx, lymph nodes not assessed; RTx, radiotherapy.
months. Probably, this group of patients represents the subgroup of patients fit enough to 
undergo both these treatment modalities, but also a subgroup with minimal or oligometastatic 
disease, although the exact intents of surgery and radiotherapy are unknown. Furthermore, 
because we only focused on patients with STS with metastatic disease at initial diagnosis, and 
clinical trials generally do not limit their inclusion to patients with synchronous metastases, 
these cases may represent a different, perhaps more aggressive, subgroup of STS compared 
with patients who initially present with non-metastatic localized STS and experience a relapse 
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at a later point in time. Dossett et al. showed that after pulmonary metastasectomy patients 
with synchronous metastases had poorer median OS than patients with metachronous 
metastases, with synchronous metastases also being a negative significant prognostic 
factor in multivariate analyses [36]. These findings may give support to the abovementioned 
hypothesis of patients with synchronous metastases representing a more aggressive 
subgroup of patients with STS, resulting in a poorer survival.
Although the current study only focuses on patients with STS with synchronous 
metastases, one of its strengths is that it shows survival in a “real-life” population rather than 
in a strictly selected trial population. Many patients are excluded from clinical trials by strict 
eligibility criteria but nonetheless receive these drugs when available in routine care. This, in 
combination with the large number of patients included in the cohort, makes it likely that this 
study gives a reliable reflection and accurate estimation of the “real” survival in daily clinical 
practice of patients with STS with synchronous metastases.
A limitation of this study is that for the patients who received chemotherapy, it is not 
specified which types of drugs were administered, how many lines of treatment patients 
received, and whether these patients received (one of) the new agents. Second, health care 
in general has improved over the years, and sarcoma care in The Netherlands has been 
largely centralized in five designated sarcoma centers [1]. Additionally, the “Will Rogers 
phenomenon” might have an effect [37, 38]. As mentioned, the incidence of metastatic 
disease at initial diagnosis increased slightly over the years, which is likely to be explained by 
better imaging techniques and thereby the ability to detect smaller metastases. Subsequently, 
it might be possible that patients with minimal metastatic disease in former years have been 
categorized as having localized/non-metastatic STS, and they theoretically perform worse 
than “true” localized STS, but in later periods, because of advancements in imaging, they are 
categorized as having metastatic STS, and they theoretically do better compared with other 
patients with (more extensive) metastatic STS. In this way, survival improves in both groups. 
Therefore, the trend in improvement of survival cannot completely be attributed to the new 
drugs alone.
Finally, the NCR started to register all patients with cancer in 1989. In this period, GIST 
was not yet recognized as a distinct entity, and most of these non-epithelial gastrointestinal 
tract tumors were classified as leiomyosarcomas. It was not until the late 1990s, after 
discovery of the cell of origin [39], the presence of c-KIT proto-oncogene mutations [40], and 
effectiveness of imatinib in these tumors [41, 42], that GIST was distinguished and treated 
as a separate entity. Therefore, it cannot be ruled out that in the earlier years of registration 
some of the registered leiomyosarcomas in fact were GISTs.
Recently, in 2016 another two new agents were registered for advanced or metastatic 




of these agents is eribulin, which in comparison with dacarbazine significantly improves OS in 
patients with advanced liposarcoma who received at least two systemic treatment regimens 
(including an anthracycline) [43]. The second new drug is olaratumab, a PDGFRα-inhibitor. 
It has been conditionally approved, pending the results of the phase III trial, and temporary 
access for the treatment of adults with advanced STS not amenable to curative treatment 
(with surgery and/or radiotherapy) has been established. It is used in combination with 
doxorubicin as first-line treatment, improving median OS by almost a year compared with 
doxorubicin alone in a randomized phase II study [44]. Although only a few trials have been 
conducted with these new drugs, they seem promising and hopefully they will increase the 
survival of patients with metastatic STS further.
Conclusion
Despite new treatment options and improved health care, overall survival of patients with 
STS and synchronous metastases treated in ‘real’ life has improved only minimally and not 
statically significantly over the years. Nonetheless, the relatively small increase of a few 
months in survival might entail a valuable difference for individual patients. Hopefully, the 
advent of novel treatment options, such as eribulin and olaratumab, will further improve the 
outcome of this patient group.
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Background: There is an unmet need for markers predicting the outcome of patients with 
advanced soft tissue sarcoma (STS) treated with pazopanib. Since toxicity might be related to 
the anti-tumor activity of the drug, the aim of this study was to determine whether pazopanib-
induced proteinuria, hypothyroidism and cardiotoxicity grade 3-4 were associated with 
outcome.
Methods: The combined results of the EORTC 62043 and 62072 trials were retrospectively 
assessed and used in a landmark analysis to evaluate the effect of the toxicities on 
progression-free survival (PFS) and overall survival (OS), using the Kaplan-Meier method and 
Cox regression models.
Results: Of the 333 eligible patients, 259 patients were included in the analyses, for which a 
landmark time point of 60 days after randomization/registration was selected. Proteinuria 
occurred in 25.1%, hypothyroidism in 22.0% and cardiotoxicity grade 3–4 in 5.8% of the 
patients (any grade in 41.7%). There was no effect of the occurrence of proteinuria 
(6-months PFS 35.4% for patients with vs. 38.3% for patients without proteinuria, HR 1.01, 
p=0.953), hypothyroidism (41.2% vs. 36.5%, HR 0.82, p=0.210) or cardiotoxicity grade 3–4 
(26.7% vs. 38.2%, HR 0.97, p=0.897) on PFS. Nor was there an effect of proteinuria (6-months 
OS 63.2% for patients with vs. 74.4% for patients without proteinuria, HR 1.22, p=0.196), 
hypothyroidism (76.2% vs. 70.5%, HR 0.75, p=0.093) or cardiotoxicity grade 3–4 (80.0% vs. 
77.2%, HR 0.93, p=0.801) on OS.
Conclusion: There was no association between the occurrence of pazopanib-induced 
proteinuria, hypothyroidism and cardiotoxicity and outcome. Therefore, these toxicities 
cannot be used as predictors for pazopanib activity in patients with advanced STS.




Soft tissue sarcomas (STS) are a heterogeneous group of tumors originating from 
mesenchymal tissue. These rare tumors account for approximately 1% of all adult 
malignancies and consist of over 50 different histological subtypes [1]. Cornerstone of 
the treatment of localized STS is surgery, optionally preceded or followed by neoadjuvant/
adjuvant therapy, such as radiotherapy, systemic therapy and/or isolated limb perfusion. 
Unfortunately, a considerable proportion of patients present with locally advanced and/
or metastatic STS or will develop these stages over time. For these patients only palliative 
treatment remains with median overall survival times of 12–18 months [2-7]. First-line 
treatment usually consists of doxorubicin, sometimes in combination with ifosfamide for 
fit patients in need of a response [7]. Recently, the addition of olaratumab to doxorubicin 
as first-line treatment was conditionally approved, based on a randomized phase II study 
showing a significant improvement in overall survival compared to doxorubicin alone [8].
Up to the last decade, there were not many systemic treatment options for patients 
failing to doxorubicin-based first-line treatment, but in the past few years several other agents 
have become available for patients with advanced STS. One of these agents is pazopanib, 
an oral angiogenesis tyrosine kinase inhibitor (TKI), targeting the vascular endothelial growth 
factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR). Based on an 
improvement in progression-free survival (PFS) and an acceptable toxicity profile, pazopanib 
was registered as second-line treatment for patients with advanced non-adipocytic STS after 
failure to prior chemotherapy [9, 10].
Although pazopanib yielded an almost three-fold prolongation of PFS over placebo, the 
observed response rates were low (6–9%) and came at the expense of toxicities [9, 10]. On 
the other hand, there is also a subgroup of STS patients treated with pazopanib with a long-
term response (PFS≥6 months, 36%) and long-term survival (OS≥18 months, 34%), including 
patients remaining progression-free for more than 2 years (3.5%) [11]. These results illustrate 
the need for markers predicting response and outcome at an early stage.
This unmet need for markers predicting response is underlined by the observation that 
many patients in daily clinical practice are worried about the effectivity of their treatment, 
especially in the absence of any side-effects or toxicity. The hypothesis that the occurrence of 
toxicity is related to the anti-tumor activity of the drug, and that toxicity therefore can be used 
as a biomarker of efficacy has been tested in multiple combinations of various types of drugs 
and different types of cancer and for different toxicities. Examples include the occurrence 
of sunitinib-induced hypertension in renal cell carcinoma (RCC) [12, 13] or gastrointestinal 
stromal tumors (GIST) [14, 15], sorafenib-induced diarrhea or hand-foot syndrome in 




VEGF TKI-induced hypothyroidism in RCC [19]. In these studies, the occurrence of VEGF TKI-
induced toxicity was associated with an improved response rate and/or survival. Recently, 
also the occurrence of hematological toxicity in patients with advanced STS treated with the 
classic chemotherapeutic agent doxorubicin was studied, but no association between the 
severity of hematological toxicity and response, progression-free survival or overall survival 
could be demonstrated [20].
For the combination of pazopanib and advanced STS, one of the most common 
toxicities of pazopanib, hypertension, and its association with outcome has already been 
studied [21]. In this study, pazopanib-induced hypertension was not associated with outcome 
in STS patients treated with this agent. However, what does not hold true for hypertension, 
might be true for other pazopanib-specific toxicities. Therefore, the aim of this study was to 
investigate whether the occurrence of three other common pazopanib-induced toxicities, 
namely proteinuria, hypothyroidism and cardiotoxicity, following treatment with pazopanib 
in patients with advanced STS, was associated with outcome. Additionally, this study provides 
more insight into the exact incidences of these pazopanib-specific toxicities in patients with 
advanced STS. These three toxicities were chosen, because they are pazopanib-specific, 
most likely not to affected/caused by the underlying disease, and well registered during the 
study period.
Methods
Primary and secondary objectives
The primary objective of this study was to assess the potential association between three 
pazopanib-induced toxicities and progression-free survival (PFS) of STS patients treated with 
pazopanib: proteinuria, hypothyroidism and cardiotoxicity related adverse events of grade 
3–4. Secondary objectives of this study were to assess the association between these three 
pazopanib-induced toxicities and overall survival (OS) of STS patients treated with pazopanib, 
and to describe tumor and patient characteristics of the patients having these toxicities. 
Additionally, the potential association between cardiotoxicity of any grade and PFS and OS 
was assessed.
Patient population
The potential association between these pazopanib-induced toxicities and outcome were 
assessed retrospectively in the combined results of two prospectively performed studies 
of the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone 
Sarcoma Group (EORTC-STBSG): the phase II EORTC 62043 trial [9] and the subsequent 
phase III EORTC 62072 trial [10]. Details of these studies are listed in supporting information 
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Table S1. All patients eligible for the 62043 trial and 62072 trial who received pazopanib 
were included, except for patients with liposarcoma. These patients were excluded based 
on results of the phase II 62043 trial, where pazopanib failed to demonstrate a sufficient 
beneficial effect in this STS subtype. To investigate the potential impact of treatment with 
pazopanib, all analyses for the three types of pazopanib-induced toxicities were also 
performed on the patients in the phase III 62072 trial receiving placebo.
Measurements of toxicity
Proteinuria was measured using the Urine Protein/Creatinine (UPC) ratio and was defined as 
an UPC ratio greater than 45 mg/mmol, which is equivalent to an albumin/creatinine ratio of 
greater than 30 mg/mmol. In both studies, urine creatinine and protein levels were reported 
at baseline, at day 8 of the first treatment period, at day 1 of each following treatment period 
(28 days) and 28 days after the last treatment administration. A patient was considered to 
have persistent proteinuria when two of the UPC ratio measurements with an interval of 
1–2 weeks minimum exceeded the cutoff point of 45 mg/mmol. Because the time period 
between two sequential urinary samples was at least 2 weeks in both studies, patients with 
two consecutive positive tests were categorized as having persistent proteinuria.
To determine the presence of hypothyroidism, thyroid stimulating hormone (TSH) 
levels were measured and used as a biomarker. Although there is no clear cutoff point, 
generally an upper normal limit between 2.5 mU/L and 4.0 mU/L is used [22]. For the current 
study, a patient was considered as having developed hypothyroidism if at least one TSH 
value surpassed the threshold value of 4.0 mU/L. According to the study protocols, the TSH 
levels were reported at baseline and at 12 weeks in both studies. Thereafter, levels were 
reported every 12 weeks (62043 trial) or 16 weeks (62072 trial). Additionally, TSH levels were 
often measured in between, with peaks around day 8, day 28 and day 56 (coinciding with the 
times of UPC assessment and start of new treatment periods).
Cardiotoxicity related adverse events were defined as events which occurred after date 
of randomization/registration and were part of the following list: cardiac ischemia/infarction, 
edema, hypertension, hypotension, supraventricular arrhythmia or extrasystole, or prolonged 
QTc interval. Grading of the cardiotoxicity related adverse events was determined according 
to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 
3.0 (NCI-CTCAE v3.0) [23].
Statistical analyses
PFS was defined as time from date of registration/randomization to the first documentation 
of progression or death, whichever occurred first. If no progression or death was observed, 




of registration/randomization and date of death. Patients alive at time of clinical cutoff were 
censored at the date of last follow-up.
To determine the appropriate landmark for further analyses, the cumulative incidence 
of proteinuria, hypothyroidism and cardiotoxicity related adverse events was assessed. These 
landmark time points were used to assess the effect of the pazopanib-induced toxicities 
on PFS and OS compared to patients without toxicity, using the Kaplan Meier method for 
univariate analyses and Cox regression models for multivariable analyses. The 6-months 
survival rates are calculated taking the selected landmark as starting point (t = 0) and are 
reported as percentages with their associated 95% confidence intervals (95% CI). The 
multivariable models were adjusted for other prognostic factors and included: performance 
status (0 or 1), gender (male or female), tumor grade (low, intermediate or high), age at 
time of randomization (≤50 years or >50 years) and histological subtype (leiomyosarcoma, 
synovial sarcoma or other). In the multivariable model for cardiotoxicity, cardiac history 
(yes or no) was also included. For the multivariable analyses, an overview summarizing the 
hazard ratios (HRs) with corresponding 95% CIs for the three pazopanib-induced toxicities is 
presented. Complete results including all covariates are shown in the supplemental materials 
(supporting information Table S3–S10). Two-sided tested p-values <.05 were considered 
statistically significant. All statistical analyses were performed using SAS version 9.4.
Results
Patient population
In total, 333 patients receiving pazopanib (118 out of the 62043 trial and 215 out of the 
62072 trial) and 110 patients receiving placebo met the eligibility criteria and were included 
in the study (Figure 1). Of the 333 eligible patients receiving pazopanib, 248 patients (74%) 
developed at least one toxicity, of whom approximately one-third had just one toxicity, 40% a 
combination of two toxicities and a quarter of the patients all three toxicities. The remaining 
85 patients (26%) did not experience any of the three toxicities (supporting information Table 
S2). Assessment of the incidence of the three toxicities showed that the majority of patients 
who developed proteinuria, hypothyroidism or cardiotoxicity (both of any grade and of grade 
3–4) did so within 60 days after registration/randomization (supporting information Figure 
S1). Considering this time point as the landmark for further analyses leaves a reasonable 
number of patients at risk (N = 259).
Association between proteinuria and outcome
Overall, 65 of the 259 patients (25.1%) who received pazopanib and who were included in 
the landmark analyses had proteinuria at a certain point in time within the landmark period 
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▲Figure 1. Flow chart illustrating the inclusion of patients out of the EORTC 62043 and 62072 trials in 
the current study. 
of 60 days, of whom 22 patients had persistent proteinuria (33.8% of the patients with 
proteinuria, 8.5% of the total study population). These patients more often had a performance 
score of 1 and a high grade tumor, were more often female and >50 years of age than 
patients without proteinuria (Table 1).
Univariate analysis showed no difference in PFS between patients with proteinuria 
and patients without proteinuria (Figure 2A), nor for patients with persistent proteinuria 
(supporting information Figure S2A). After adjustment for other prognostic factors, 
multivariable analysis also showed no significant prognostic effect of proteinuria or persistent 
proteinuria on PFS (Table 2). The presence of proteinuria or persistent proteinuria also had 
no significant influence on OS (Figure 2B and Table 2; supporting information Figure S2B).
Association between hypothyroidism and outcome
Approximately one-quarter of the patients developed hypothyroidism within the landmark 
time point of 60 days (N = 57, 22.0%). These patients were slightly more often female and 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































There was no effect of the presence of hypothyroidism on PFS (Figure 3A), also not 
after adjustment for other prognostic factors (Table 2). Similarly, there was no significant 
prognostic effect of the presence of hypothyroidism on OS (Figure 3B), although an trend in 
favor of patients with hypothyroidism was observed (Table 2).
Association between cardiotoxicity related adverse events and 
outcome
In total, 108 patients (41.7%) experienced a cardiotoxicity related adverse event of any 
grade within the landmark period of 60 days, of whom 15 patients experienced grade 3–4 
cardiotoxicity (13.9% of the patients with any grade cardiotoxicity and 5.8% of the total study 
population). Three patients experienced arrhythmia, one patient ischemia, but the majority 
of patients had hypertension (N = 107). Notably, the number of patients experiencing 
cardiotoxicity other than hypertension was too low to perform separate reliable analyses on. 
Most of the patients experiencing cardiotoxicity had a performance score of 0, were female, 
over 50 years old and had intermediate or high-grade tumors. Patients with cardiotoxicity 
grade 3–4 more often had a cardiac history (46.7%) compared to patients without toxicity 
(23.0%) and patients with cardiotoxicity of any grade (25.9%) (Table 1).
▲Figure 2. Kaplan-Meier curves showing the progression-free survival (A) and overall survival (B) of 
patients with and without pazopanib-induced proteinuria.
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Table 2. Overview of the effect of the three pazopanib-induced toxicities on PFS and OS in patients 
receiving pazopanib at landmark time point of 60 days, univariate (6-months PFS/OS rates) and 
multivariable after adjustment for other prognostic factors in multivariable Cox regression analysis. 
The reported p-values belong to the multivariable Cox regression model. Results of the complete Cox 
regression analyses are shown in supplemental tables S3–S10.
Progression-free survival Overall survival
6m PFS (95%CI) HR (95% CI) p-value 6m OS (95% CI) HR (95% CI) p-value
Proteinuria
No 38.3% (31.4-45.1) 1 .953 74.4% (68.3-79.5) 1 .196
Yes 35.4% (24.0-46.9) 1.01 (0.75, 1.36) 63.2% (51.3-72.9) 1.22 (0.90, 1.64)
Persistent proteinuria
Noz 37.7% (31.5-43.8) 1 .937 73.3% (67.7-78.0) 1 .169
Yes 36.4% (17.4-55.7) 0.98 (0.62, 1.55) 53.9% (33.3-70.6) 1.38 (0.87, 2.19)
Hypothyroidism
No 36.5% (29.9-43.2) 1 .210 70.5% (64.3-75.7) 1 .093
Yes 41.2% (28.3-53.6) 0.82 (0.61, 1.12) 76.2% (63.7-84.9) 0.75 (0.54, 1.05)
Cardiotoxicity grade 3-4
No 38.2% (32.1-44.3) 1 .897 77.2% (71.4-82.0) 1 .801
Yes 26.7% (8.3-49.6) 0.97 (0.57, 1.64) 80.0% (50.0-93.1) 0.93 (0.52, 1.65)
Cardiotoxicity any grade
No 40.6% (32.7-48.3) 1 .380 75.9% (68.1-82.0) 1 .120
Yes 33.3% (24.7-42.2) 1.12 (0.87, 1.46) 79.5% (70.5-86.0) 0.81 (0.63-1.06)
6m PFS: 6-months progression-free survival, 6m OS: 6-months overall survival, 95% CI: 95% confidence 
interval, HR: hazard ratio.
▲Figure 3. Kaplan-Meier curves showing the progression-free survival (A) and overall survival (B) of 




▲Figure 4. Kaplan-Meier curves showing the progression-free survival (A) and overall survival (B) of 
patients receiving pazopanib with and without pazopanib-induced cardiotoxicity of grade 3–4.
Univariate analysis showed no difference in PFS between patients with and without 
cardiotoxicity related adverse events grade 3–4 (Figure 4A). Also in multivariable analysis, 
after adjustment for other prognostic factors, no significant effect of the occurrence of 
cardiotoxicity related adverse events grade 3–4 on PFS was observed (Table 2). Likewise, 
cardiotoxicity of any grade was not of significant influence (Table 2, supporting information 
Figure S3A). Additionally, there was no association between the occurrence of cardiotoxicity 
grade 3–4 and OS (Figure 4B), nor in multivariable analysis (Table 2). There was also no 
association between the occurrence of cardiotoxicity of any grade and OS (Table 2, supporting 
information Figure S3B).
Association between toxicity and outcome in patients receiving 
placebo
For all three pazopanib-induced toxicities, the analyses were also performed on the patients 
receiving placebo in the 62072 trial. However, no effect on PFS or OS was observed for any 
of the toxicities in patients receiving placebo (supporting information Tables S5, S7 and S10).
Discussion
The association between three pazopanib-induced toxicities and outcome of patients with 
advanced STS has been investigated in this study. We observed that pazopanib-induced 
proteinuria occurred in 25.1% of the patients treated with pazopanib within 60 days after 
start of treatment, of whom 8.5% had persistent proteinuria. Hypothyroidism was observed 
in 22.0% of the patients while on treatment with pazopanib. At last, cardiotoxicity (any grade) 
occurred in 41.7% of patients on treatment, of whom 5.8% had grade 3–4 cardiotoxicity. 
Additionally, we observed that cardiotoxicity other than hypertension only occurred 
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occasionally in 1.5% of the patients and was only of grade 1 or 2. Overall, no significant 
prognostic effects were observed for one of these three pazopanib-induced toxicities on 
PFS or OS. However, although not significant, a trend towards a better prognosis for patients 
developing hypothyroidism (i.e. high TSH levels) within 60 days after start of pazopanib was 
observed.
The incidences of the three pazopanib-induced toxicities observed in this study differ 
slightly from incidences observed in patients with RCC treated with pazopanib. The incidences 
of proteinuria (25.1%) and hypothyroidism (22.0%) observed in this study were higher than 
observed for RCC patients. For proteinuria, incidences of 14–18% for patients with RCC 
have been reported [18, 24, 25]. Importantly, the majority of these patients underwent a 
prior nephrectomy, which might have affected the onset of proteinuria. Hypothyroidism 
was observed in <10%–18% of RCC patients treated with pazopanib [24-26], but to the best 
of our knowledge, no clear explanation for the differences in incidence of hypothyroidism 
between patients with RCC and patients with STS exists. On the contrary, the incidence of 
any grade cardiotoxicity (including hypertension) was slightly lower than observed in RCC 
patients, varying from 42 to 69%, although definitions of cardiotoxicity differed among RCC 
studies [24, 25, 27, 28]. Comparable to STS patients treated with pazopanib, the majority 
of the RCC patients with cardiotoxicity had hypertension, and only a small proportion had 
myocardial ischemia/infarction or QTc prolongation. Inhibiting the VEGF signaling pathway 
itself can already induce cardiotoxicity because of its working mechanism [29], but other 
aspects, such as preceding cancer therapy (anthracyclines), preexisting hypertension or 
other cardiac history, may also play a role in inducing/worsening cardiotoxicity [30]. Even 
though most STS patients had received doxorubicin as first-line treatment, which is known 
for its cumulative cardiotoxicity, the incidence of pazopanib-induced cardiotoxicity was not 
higher than was described in patients with RCC.
Depending on the severity of toxicity, actions were taken according to protocols. In case 
of proteinuria, pazopanib was interrupted until the UPC ratio had recovered and pazopanib 
was restarted at a lower dose. For patients developing hypothyroidism, thyroid replacement 
therapy was started. At last, in case of cardiotoxicity grade 3–4, pazopanib was discontinued 
and the cardiotoxicity was treated, whereas for grade 1–2 cardiotoxicity, pazopanib could be 
continued at the current dose or restarted at a lower dose while treating the cardiotoxicity.
In line with the study on the association between pazopanib-induced hypertension 
and outcome [21], we did not observe a significant prognostic effect of pazopanib-induced 
proteinuria, hypothyroidism or cardiotoxicity in patients with advanced STS. This is in 
contrast to studies examining toxicities induced by anti-VEGF treatment in other types of 
cancer, such as RCC, hepatocellular cancer, colorectal cancer and GIST. In these studies, 




observed in RCC patients [18], and bevacizumab-induced proteinuria was associated with 
response rate in patients with metastatic colorectal cancer [31]. Additionally, RCC patients 
with sunitinib-induced or sorafenib-induced hypothyroidism showed increased response 
rates [32], improved PFS [19, 33] and improved OS [19, 32]. Furthermore, the occurrence 
of other sunitinib-induced or sorafenib-induced toxicities, such as hypertension, skin 
toxicity and diarrhea, was significantly associated with an increase in response rate [12-14], 
improved PFS [12, 14, 15] and improved OS [12, 14-17, 34, 35]. To the best of our knowledge, 
no studies have been published regarding anti-VEGF therapy-induced cardiotoxicity and its 
association with outcome, except for hypertension.
The thresholds used to determine toxicity, especially for hypothyroidism, and the 
choice of the landmark time points might be considered as an arbitrary choice to some 
extent. Whereas the NCI-CTCAE and UPC ratio are well known and established methods to 
determine and document cardiotoxicity and proteinuria, no clear TSH cutoff point for the 
diagnosis of hypothyroidism has been agreed upon. Normal ranges of TSH levels may vary 
by individual, over the day, and even among laboratories, but generally an upper normal limit 
between 2.5 mU/L and 4.0 mU/L is used [22]. Hence, the TSH threshold value of 4.0 mU/L 
used in this study is relatively high and conservative, but allowed us to identify each case of 
hypothyroidism with more certainty, while still a reasonable number of patients were at risk 
in both groups.
Although the data included in this study were collected prospectively in the two EORTC 
trials, there are still some potential sources of bias and limitations related to the retrospective 
design of this study. There were some small differences in, for example, patient and disease 
characteristics between the two study populations, as well as small differences in the follow-
up schedules and in the definition of PFS in the two studies, which might have influenced 
the outcome. Furthermore, time-to-event bias might have an impact, a type of bias where 
patients with a favorable response to pazopanib are more likely to continue treatment for 
a longer period of time, and the longer the exposure to the agent, the higher the chance of 
developing toxicity. To avoid this potential source of bias, a landmark analysis was used.
To investigate the potential association of the occurrence of toxicity and outcome 
following treatment with pazopanib, all analyses for the three types of toxicities have 
been performed on patients receiving the drug as well as on the patients in the phase III 
trial receiving placebo. As only a few of the patients receiving placebo did not experience 
progression/death before the landmark time point of 60 days and even a lower number of 
toxicities was observed in this patient group, unfortunately no real comparison could be 
made and no clear conclusions on a potential placebo-effect could be drawn.
The hypothesis that the occurrence of toxicity is related to efficacy of the drug and 
therefore outcome, prevails not only amongst physicians, but also amongst patients. Some 
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patients in daily clinical practice are concerned whether their treatment with pazopanib is 
effective if they do not experience any side-effects or toxicity. The results of this study may 
provide reassurance to the treating physicians as well as these patients that the absence of 
toxicity does not imply that there will be no benefit of treatment with pazopanib.
Conclusion
The occurrence of pazopanib-induced proteinuria, hypothyroidism or cardiotoxicity in 
patients with advanced STS treated with pazopanib did not have a significant predictive 
effect and was not associated with outcome. These toxicities can therefore not be used as 
predictor for pazopanib activity in these patients.
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Supporting Table S1. Overview of study details of the EORTC 62043 and 62072 trials.
EORTC 62043 trial EORTC 62072 trial
Type of trial Phase II Phase III
Design Single arm Randomized (2:1), double blind, 
placebo-controlled
Drug Pazopanib 800mg daily Pazopanib 800mg daily or placebo
Inclusion criteria Locally advanced/metastatic STS 
Ineligible to chemotherapy or 
failure to no more than two prior 
cytotoxic agents (sequentially as 
single agents or one combina-
tion regimen)
Metastatic non-adipocytic STS 
Failure to standard chemotherapy 
(including an anthracycline) in a met-
astatic/locally advanced setting, with 
a maximum of 4 previous lines or two 
lines of combination regimens
Primary outcome Progression-free survival at 12 
weeks
Progression-free survival
Secondary outcome Response rate







ClinicalTrial.gov number NCT00297258 NCT00753688
Reference Sleijfer et al., JCO, 2009 van der Graaf et al., Lancet, 2012
Supporting Table S2. Overview of the three pazopanib-induced toxicities in the 333 eligible patients.
Hypothyroidism Proteinuria Total
(N=333)No Yes
No Cardiotoxicity (any grade) 145 57 202
No 85 30 115
Yes 60 27 87
Yes Cardiotoxicity (any grade) 77 54 131
No 45 19 64




Supporting Table S3. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival























No 194 (75.5) 186 (75.6) 1.00 .953 237 (76.2) 182 (74.6) 1.00 .196
Yes 63 (24.5) 60 (24.4) 1.01 (0.75, 1.36) 74 (23.8) 62 (25.4) 1.22 (0.90, 1.64)
Performance status
0 145 (56.4) 139 (56.5) 1.00 .400 165 (53.1) 123 (50.4) 1.00 .001
1 112 (43.6) 107 (43.5) 0.89 (0.69, 1.16) 146 (46.9) 121 (49.6) 1.53 (1.18, 1.99)
Gender
Male 101 (39.3) 98 (39.8) 1.00 .028 126 (40.5) 106 (43.4) 1.00 .114
Female 156 (60.7) 148 (60.2) 0.74 (0.56, 0.97) 185 (59.5) 138 (56.6) 0.81 (0.62, 1.05)
Tumor grade
Low 24 (9.3) 19 (7.7) 1.00 .002 28 (9.0) 16 (6.6) 1.00 .017
Intermediate 87 (33.9) 85 (34.6) 2.34 (1.43, 3.82) 105 (33.8) 85 (34.8) 2.00 (1.18, 3.37)




106 (41.2) 104 (42.3) 1.00 .203 129 (41.5) 97 (39.8) 1.00 .011
Synovial 
sarcoma
50 (19.5) 47 (19.1) 0.77 (0.58, 1.03)  60 (19.3) 50 (20.5) 1.33 (0.98, 1.79)
Other 
sarcoma
101 (39.3) 95 (38.6) 0.93 (0.64, 1.34) 122 (39.2) 97 (39.8) 1.76 (1.21, 2.57)
Age at randomization
≤50 years 101 (39.3) 94 (38.2) 1.00 .089 122 (39.2) 93 (38.1) 1.00 .028
>50 years 156 (60.7) 152 (61.8) 1.27 (0.96, 1.67) 189 (60.8) 151 (61.9) 1.37 (1.03, 1.82)
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Supporting Table S4. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival























No 235 (91.4) 225 (91.5) 1.00 .937 285 (91.6) 223 (91.4) 1.00 .169
Yes 22 (8.6) 21 (8.5) 0.98 (0.62, 1.55) 26 (8.4) 21 (8.6) 1.38 (0.87, 2.19) 
Performance status
0 145 (56.4) 139 (56.5) 1.00 .408 165 (53.1) 123 (50.4) 1.00 <.001
1 112 (43.6) 107 (43.5) 0.90 (0.69, 1.16) 146 (46.9) 121 (49.6) 1.55 (1.20, 2.01) 
Gender
Male 101 (39.3) 98 (39.8) 1.00 .028 126 (40.5) 106 (43.4) 1.00 .121
Female 156 (60.7) 148 (60.2) 0.74 (0.56, 0.97) 185 (59.5) 138 (56.6) 0.81 (0.62, 1.06) 
Tumor grade
Low 24 (9.3) 19 (7.7) 1.00 .002 28 (9.0) 16 (6.6) 1.00 .015
Intermediate 87 (33.9) 85 (34.6) 2.34 (1.43, 3.83) 105 (33.8) 85 (34.8) 2.01 (1.20, 3.40) 




106 (41.2) 104 (42.3) 1.00 .203 129 (41.5) 97 (39.8) 1.00 .010
Synovial 
sarcoma
50 (19.5) 47 (19.1) 0.77 (0.58, 1.03) 60 (19.3) 50 (20.5) 1.78 (1.22, 2.59) 
Other 
sarcoma
101 (39.3) 95 (38.6) 0.93 (0.64, 1.34) 122 (39.2) 97 (39.8) 1.34 (0.99, 1.80) 
Age at randomization
≤50 years 101 (39.3) 94 (38.2) 1.00 .087 122 (39.2) 93 (38.1) 1.00 .031




Supporting Table S5. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival























No 32 (78.0) 32 (78.0) 1.00 .244 82 (81.2) 62 (82.7) 1.00 .324
Yes 9 (22.0) 9 (22.0) 1.78 (0.67, 4.69) 19 (18.8) 13 (17.3) 0.73 (0.39, 1.37)
Performance status
0 22 (53.7) 22 (53.7) 1.00 .128 48 (47.5) 33 (44.0) 1.00 .055
1 19 (46.3) 19 (46.3) 1.77 (0.85, 3.70) 53 (52.5) 42 (56.0) 1.58 (0.99, 2.54)
Gender
Male 15 (36.6) 15 (36.6) 1.00 .050 41 (40.6) 31 (41.3) 1.00 .564
Female 26 (63.4) 26 (63.4) 0.44 (0.19, 1.00) 60 (59.4) 44 (58.7) 0.86 (0.53, 1.42)
Tumor grade
Low 2 (4.9) 2 (4.9) 1.00 .016 3 (3.0) 2 (2.7) 1.00 .298
Intermediate 13 (31.7) 13 (31.7) 6.59 (1.10, 39.46) 25 (24.8) 17 (22.7) 2.18 (0.51, 9.35)




19 (46.3) 19 (46.3) 1.00 .011 42 (41.6) 31 (41.3) 1.00 .841
Synovial 
sarcoma
3 (7.3) 3 (7.3) 0.73 (0.34, 1.60) 11 (10.9) 7 (9.3) 0.89 (0.36, 2.21)
Other 
sarcoma
19 (46.3) 19 (46.3) 7.20 (1.60, 32.28) 48 (47.5) 37 (49.3) 1.11 (0.66, 1.88)
Age at randomization
≤50 years 19 (46.3) 19 (46.3) 1.00 .921 50 (49.5) 34 (45.3) 1.00 .123
>50 years 22 (53.7) 22 (53.7) 0.96 (0.43, 2.14) 51 (50.5) 41 (54.7) 1.52 (0.89, 2.60)
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Supporting Table S6. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival





















No 200 (77.8) 191 (77.6) 1.00 .210 247 (79.4) 198 (81.1) 1.00 .093
Yes 57 (22.2) 55 (22.4) 0.82 (0.61, 1.12) 64 (20.6) 46 (18.9) 0.75 (0.54, 1.05)
Performance status
0 145 (56.4) 139 (56.5) 1.00 .457 165 (53.1) 123 (50.4) 1.00 <.001
1 112 (43.6) 107 (43.5) 0.91 (0.70, 1.17) 146 (46.9) 121 (49.6) 1.62 (1.25, 2.10)
Gender
Male 101 (39.3) 98 (39.8) 1.00 .031 126 (40.5) 106 (43.4) 1.00 .157
Female 156 (60.7) 148 (60.2) 0.74 (0.57, 0.97) 185 (59.5) 138 (56.6) 0.82 (0.63, 1.08)
Tumor grade
Low 24 (9.3) 19 (7.7) 1.00 .002 28 (9.0) 16 (6.6) 1.00 .016
Intermediate 87 (33.9) 85 (34.6) 2.37 (1.45, 3.87) 105 (33.8) 85 (34.8) 2.01 (1.19, 3.39)




106 (41.2) 104 (42.3) 1.00 .186 129 (41.5) 97 (39.8) 1.00 .017
Synovial 
sarcoma
50 (19.5) 47 (19.1) 0.76 (0.57, 1.02) 60 (19.3) 50 (20.5) 1.34 (0.99, 1.80)
Other 
sarcoma
101 (39.3) 95 (38.6) 0.91 (0.63, 1.31) 122 (39.2) 97 (39.8) 1.70 (1.17, 2.48)
Age at randomization
≤50 years 101 (39.3) 94 (38.2) 1.00 .103 122 (39.2) 93 (38.1) 1.00 .034




Supporting Table S7. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival






















No 31 (75.6) 31 (75.6) 1.00 .557 85 (84.2) 64 (85.3) 1.00 .765
Yes 10 (24.4) 10 (24.4) 1.34 (0.51, 3.55) 16 (15.8) 11 (14.7) 0.90 (0.46, 1.78)
Performance status
0 22 (53.7) 22 (53.7) 1.00 .149 48 (47.5) 33 (44.0) 1.00 .059
1 19 (46.3) 19 (46.3) 1.75 (0.82, 3.76) 53 (52.5) 42 (56.0) 1.58 (0.98, 2.53)
Gender
Male 15 (36.6) 15 (36.6) 1.00 .057 41 (40.6) 31 (41.3) 1.00 .656
Female 26 (63.4) 26 (63.4) 0.38 (0.14, 1.03) 60 (59.4) 44 (58.7) 0.89 (0.53, 1.49)
Tumor grade
Low 2 (4.9) 2 (4.9) 1.00 .015 3 (3.0) 2 (2.7) 1.00 .242
Intermediate 13 (31.7) 13 (31.7) 5.51 (0.97, 31.47) 25 (24.8) 17 (22.7) 2.19 (0.51, 9.37)




19 (46.3) 19 (46.3) 1.00 .015 42 (41.6) 31 (41.3) 1.00 .886
Synovial 
sarcoma
3 (7.3) 3 (7.3) 0.81 (0.38, 1.73) 11 (10.9) 7 (9.3) 0.89 (0.36, 2.22)
Other 
sarcoma
19 (46.3) 19 (46.3) 7.01 (1.57, 31.23) 48 (47.5) 37 (49.3) 1.08 (0.64, 1.83)
Age at randomization
≤50 years 19 (46.3) 19 (46.3) 1.00 .640 50 (49.5) 34 (45.3) 1.00 .187
>50 years 22 (53.7) 22 (53.7) 1.19 (0.58, 2.44) 51 (50.5) 41 (54.7) 1.41 (0.85, 2.36)
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Supporting Table S8. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival




















Cardiotoxic Adverse Event (Grade 3-4)
No 242 (94.2) 231 (93.9) 1.00 .897 294 (94.5) 231 (94.7) 1.00 .801
Yes 15 (5.8) 15 (6.1) 0.97 (0.57, 1.64) 17 (5.5) 13 (5.3) 0.93 (0.52, 1.65)
Performance status
0 145 (56.4) 139 (56.5) 1.00 .403 165 (53.1) 123 (50.4) 1.00 <.001
1 112 (43.6) 107 (43.5) 0.90 (0.69, 1.16) 146 (46.9) 121 (49.6) 1.58 (1.22, 2.04)
Gender
Male 101 (39.3) 98 (39.8) 1.00 .027 126 (40.5) 106 (43.4) 1.00 .129
Female 156 (60.7) 148 (60.2) 0.74 (0.56, 0.97) 185 (59.5) 138 (56.6) 0.81 (0.62, 1.06)
Tumor grade
Low 24 (9.3) 19 (7.7) 1.00 .002 28 (9.0) 16 (6.6) 1.00 .013
Intermediate 87 (33.9) 85 (34.6) 2.35 (1.43, 3.84) 105 (33.8) 85 (34.8) 2.04 (1.21, 3.43)




106 (41.2) 104 (42.3) 1.00 .182 129 (41.5) 97 (39.8) 1.00 .009
Synovial 
sarcoma
50 (19.5) 47 (19.1) 0.76 (0.57, 1.02) 60 (19.3) 50 (20.5) 1.36 (1.01, 1.84)
Other 
sarcoma
101 (39.3) 95 (38.6) 0.91 (0.63, 1.31) 122 (39.2) 97 (39.8) 1.81 (1.23, 2.66)
Age at randomization
≤50 years 101 (39.3) 94 (38.2) 1.00 .048 122 (39.2) 93 (38.1) 1.00 .035
>50 years 156 (60.7) 152 (61.8) 1.34 (1.00, 1.79) 189 (60.8) 151 (61.9) 1.37 (1.02, 1.83)
Cardiac history
No 194 (75.5) 186 (75.6) 1.00 .303 233 (74.9) 182 (74.6) 1.00 .539




Supporting Table S9. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival




















Cardiotoxic Adverse Event (Any grade)
No 151 (58.8) 144 (58.5) 1.00 .380 190 (61.1) 155 (63.5) 1.00 .120
Yes 106 (41.2) 102 (41.5) 1.12 (0.87, 1.46) 121 (38.9) 89 (36.5) 0.81 (0.63, 1.06)
Performance status
0 145 (56.4) 139 (56.5) 1.00 .415 165 (53.1) 123 (50.4) 1.00 <.001
1 112 (43.6) 107 (43.5) 0.90 (0.69, 1.16) 146 (46.9) 121 (49.6) 1.57 (1.21, 2.03)
Gender
Male 101 (39.3) 98 (39.8) 1.00 .027 126 (40.5) 106 (43.4) 1.00 .121
Female 156 (60.7) 148 (60.2) 0.74 (0.56, 0.97) 185 (59.5) 138 (56.6) 0.81 (0.62, 1.06)
Tumor grade
Low 24 (9.3) 19 (7.7) 1.00 .001 28 (9.0) 16 (6.6) 1.00 .023
Intermediate 87 (33.9) 85 (34.6) 2.40 (1.46, 3.95) 105 (33.8) 85 (34.8) 1.93 (1.14, 3.26)




106 (41.2) 104 (42.3) 1.00 .222 129 (41.5) 97 (39.8) 1.00 .013
Synovial 
sarcoma
50 (19.5) 47 (19.1) 0.77 (0.58, 1.04) 60 (19.3) 50 (20.5) 1.33 (0.98, 1.80)
Other 
sarcoma
101 (39.3) 95 (38.6) 0.92 (0.63, 1.32) 122 (39.2) 97 (39.8) 1.76 (1.20, 2.58)
Age at randomization
≤50 years 101 (39.3) 94 (38.2) 1.00 .056 122 (39.2) 93 (38.1) 1.00 .019
>50 years 156 (60.7) 152 (61.8) 1.33 (0.99, 1.78) 189 (60.8) 151 (61.9) 1.42 (1.06, 1.91)
Cardiac history
No 194 (75.5) 186 (75.6) 1.00 .273 233 (74.9) 182 (74.6) 1.00 .570
Yes 63 (24.5) 60 (24.4) 0.84 (0.61, 1.15) 78 (25.1) 62 (25.4) 1.10 (0.80, 1.50)
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Supporting Table S10. Complete results of the multivariable Cox regression models for PFS and OS of patients 




Multivariable Cox model of
progression-free survival






















Cardiotoxic Adverse Event (Any grade)
No 36 (87.8) 36 (87.8) 1.00 .301 93 (92.1) 68 (90.7) 1.00 .988
Yes 5 (12.2) 5 (12.2) 0.52 (0.15, 1.79) 8 (7.9) 7 (9.3) 1.01 (0.41, 2.46)
Performance status
0 22 (53.7) 22 (53.7) 1.00 .261 48 (47.5) 33 (44.0) 1.00 .034
1 19 (46.3) 19 (46.3) 1.54 (0.73, 3.25) 53 (52.5) 42 (56.0) 1.76 (1.04, 2.96)
Gender
Male 15 (36.6) 15 (36.6) 1.00 .012 41 (40.6) 31 (41.3) 1.00 .801
Female 26 (63.4) 26 (63.4) 0.29 (0.11, 0.76) 60 (59.4) 44 (58.7) 0.93 (0.55, 1.59)
Tumor grade
Low 2 (4.9) 2 (4.9) 1.00 .004 3 (3.0) 2 (2.7) 1.00 .218
Intermediate 13 (31.7) 13 (31.7) 10.01 (1.42, 70.42) 25 (24.8) 17 (22.7) 2.12 (0.49, 9.17)




19 (46.3) 19 (46.3) 1.00 .021 42 (41.6) 31 (41.3) 1.00 .964
Synovial 
sarcoma
3 (7.3) 3 (7.3) 7.92 (1.72, 36.51) 11 (10.9) 7 (9.3) 0.94 (0.38, 2.35)
Other 
sarcoma
19 (46.3) 19 (46.3) 1.02 (0.44, 2.34) 48 (47.5) 37 (49.3) 1.05 (0.62, 1.77)
Age at randomization
≤50 years 19 (46.3) 19 (46.3) 1.00 .703 50 (49.5) 34 (45.3) 1.00 .114
>50 years 22 (53.7) 22 (53.7) 1.17 (0.53, 2.60) 51 (50.5) 41 (54.7) 1.57 (0.90, 2.76)
Cardiac history
No 27 (65.9) 27 (65.9) 1.00 .203 68 (67.3) 51 (68.0) 1.00 .234










































































































































































































































































































































































































































































































































































Although it is already being recognized for years that soft tissue sarcoma (STS) is not 
one disease, but a collective term for a heterogeneous group of individual and distinct 
mesenchymal tumors, most STS are still treated similarly. This applies to early and localized 
stages as well as to the more locally advanced and metastasized setting.
Importance of soft tissue sarcoma biology
Currently, the classification of the World Health Organization is used to categorize these 
tumors into subtypes, primarily based on morphology [1]. As outlined in especially chapter 
2 and chapter 4, there still can be quite some heterogeneity on a molecular level even within 
one STS subtype, implying that the assessment of morphology alone might not be the most 
accurate diagnostic method and that other factors – such as mutational status – should also 
be taken into account. This intra-STS subtype heterogeneity might also partially explain the 
negative clinical trials, including STS subtype-specific trials [2-5] or subgroup analyses [6, 7], 
trials studying a histology-driven choice of treatment [8], and trials investigating targeted 
therapies [9, 10]. It is clear that the histology of a specific STS subtype often cannot be used 
to predict responsiveness to a certain drug, and it is likely that a particular genetic aberration 
or profile is better associated with response to that drug. For example, sensitivity to imatinib 
in GIST: not all GISTs are sensitive to imatinib, only those with a KIT exon 11 mutation [11] and 
to a lesser extent a KIT exon 9 mutation [12]. Patients with PDGFRA-mutated [13] or wild-type 
[14] GIST generally do not respond to imatinib. This hypothesis might be translated to other 
targeted therapies such as anti-PDGFRA or anti-PD1 agents.
Additionally, in an attempt to identify patients possibly sensitive for targeted 
therapies such as olaratumab or pembrolizumab, the PDGFRA or PD-L1 expression is 
usually determined by immunohistochemistry [15, 16], rather than identifying a specific 
genetic alteration predictive of response to these agents. The mere presence of a protein, 
as detected by immunohistochemistry, does not automatically predict response to a drug 
targeting that protein. Perhaps only specific alterations in the protein lead to sensitivity for 
a drug. Therefore, immunohistochemistry might not be the most optimal method to identify 
biomarkers predictive of response in STS, taking again sensitivity for imatinib in GIST as an 
example. All KIT-mutated, most PDGFRA-mutated and some wild-type GISTs express CD117 
and/or DOG-1 [17]. These immunohistochemical biomarkers do not distinguish between the 
different (exon) mutations and thereby sensitivity to imatinib, and an mutation analysis is 
needed to make this distinction. 
We advocate that treatment or eligibility for inclusion into clinical trials should not be 
solely based on STS subtype as classified by the WHO, but also on specific genomic alterations 
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of these tumors. By identifying targetable mutations or signatures in each individual STS 
patient, we will be able to better select patients who could benefit from personalized 
treatment and from inclusion in clinical trials with these specific agents. Examples include 
patients with homologous recombination deficient tumors who could benefit from platinum-
based therapy [18], with BRAF-mutated tumors who could benefit from treatment with 
dabrafenib [19] or with an ESR1 mutation who could benefit from treatment with fulvestrant 
[20].
Heterogeneity amongst liposarcomas
The results of multiple studies in this thesis and in literature show that even within one STS 
subtype substantial heterogeneity can exist. This confirms that STS, and even liposarcoma, 
is not a single entity and that we should pursue a subtype-specific and maybe even a site-
specific treatment approach, illustrated by chapter 6 and chapter 7.
Approximately half of all the liposarcoma patient have the well-differentiated 
subtype (well-differentiated liposarcoma, WDLPS). Especially in this liposarcoma subtype, 
tumor localization is of importance [21]. Based on prognosis, essentially two groups can 
be distinguished: retroperitoneal WDLPS and non-retroperitoneal WDLPS. Patients with 
retroperitoneal WDLPS have a poorer prognosis and ultimately die of disease because 
of local control issues, while patients with non-retroperitoneal WDLPS generally have 
an excellent prognosis and seldom die of disease. This indicates that local control is of 
crucial importance in retroperitoneal WDLPS and that local treatment options should be 
reconsidered in this specific patient group. This includes the extent of resection (resection 
with or without uninvolved adjacent organs) and radiotherapy. Despite improving local 
control, we are currently reluctant in giving radiotherapy to any WDLPS patient, because of 
its toxicity, varying effectivity and missing effect on survival. However, retroperitoneal WDLPS 
might be the exception in which improved local control could lead to improved survival. 
At present, this hypothesis is being evaluated in the phase III STRASS trial. The preliminary 
results of this trial – randomizing between neoadjuvant radiotherapy plus surgery or surgery 
alone [22] – showed that neoadjuvant radiotherapy improved the abdominal recurrence-
free survival in the liposarcoma subgroup. At present, the final results are pending and 
will have to show whether the improved abdominal recurrence-free survival has led to an 
improvement in overall survival.
Regarding the non-retroperitoneal WDLPS, also called atypical lipomatous tumors 
(ALTs), we believe that we might be 'over-treating' these patients, opposite to the possible 
'under-treatment' of retroperitoneal WDLPS, as outlined in chapter 8. We feel that an active 
surveillance approach might be appropriate, safe and justified in selected cases, especially 




radical resection cannot be achieved. Additionally, we hypothesize that the (health-related) 
quality of life of patients treated with active surveillance is equal or even better compared to 
that of surgically treated patients. However, these parameters (feasibility, safety and quality 
of life) need yet to be evaluated in a prospective clinical trial before implementation into 
daily clinical practice is possible, but these observations highlight again the need to tailor 
treatment based on both liposarcoma/STS subtype and tumor localization. 
Besides a minimally invasive treatment approach in non-retroperitoneal WDLPS (i.e. 
active surveillance), we also searched for a minimally invasive method for diagnosing WDLPS 
in chapter 5, using radiomics. Radiomics is a type of artificial intelligence through which 
additional data is extracted from medical imaging which is not visible with the human eye, 
such as data regarding shape, texture, intensity, etc. Subsequently, these features are linked 
to the clinical data to create a diagnostic algorithm. Big data, machine learning and other 
forms of artificial intelligence are increasingly used in oncology and are expected to have 
a major impact on cancer care and research. Artificial intelligence enables the integration 
of different types of data, such as genomic data, imaging data and clinical data and allows 
for the discovery of hidden patterns and links. In general, this might lead to, for example, 
new drug discoveries [23] or being able to predict the response to treatment [24-26]. In 
non-retroperitoneal WDLPS specifically, examples of possible radiomics applications include 
predicting which patients will develop local recurrent disease after primary resection, who 
will have progressive disease (i.e. tumor growth) or in whom dedifferentiation will occur. 
Based on these radiomics models, treatment for non-retroperitoneal WDLPS could be 
tailored and individualized.
Surgical treatment of localized STS
The rarity, heterogeneity and complexity of STS highlight the need for centralization of STS 
care. Many studies have shown that centralization of sarcoma care has a beneficial effect 
on multiple outcomes, including survival [27-34]. Therefore, in an attempt to improve 
centralization of STS care in the Netherlands, six hospitals have been designated as centers 
of expertise by the Netherlands Federation of University Medical Centers (NFU), of which 5 
are also member of the European Reference Network for rare adult cancer (ERN-EURACAN). 
Additionally, in 2012 a standardization report on the multidisciplinary cancer care, defining 
the conditions a hospital needs to fulfill in order to deliver good cancer care, was published 
in the Netherlands, which is updated annually [35].
Two nationwide studies, in the time periods 2006-2011 [36] and 2006-2015 (chapter 
9), have shown that centralization in the Netherlands is increasing but is still in need of 
improvement. However, it should be realized that centralization is not only a result of the 
expertise centers recruiting STS patients, but mostly relies on the alertness and willingness 
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of physicians and patients in the general hospitals to refer/be referred to an expertise center. 
Creating more awareness for this rare group of diseases is therefore an important element 
in pursuing centralization of STS care and improving the outcomes of these patients.
Systemic treatment of metastatic STS
Despite the increase in available systemic treatment options for advanced/metastatic STS 
(chapter 11), there has been only a minimal increase in survival of patients with synchronous 
metastases (chapter 12) and most probably also for patients with metachronous metastases, 
given all the trials with a negative outcome reported in literature [6, 7, 10, 37-40]. These 
negative results and only minimal increase in survival stress that there is an unmet need for 
novel agents and targets. Identifying possible new targets for treatment and accompanying 
effective agents is obviously easier said than done, although new techniques such as 
whole genome sequencing – becoming more widely available and affordable – and artificial 
intelligence – used to discover hidden patterns and links – might be game changers in the 
STS field and cancer research in general.
Apart from identifying new targets and effective drugs, it is of importance to identify 
which patients will benefit from systemic treatment with these drugs. All kinds of predictive 
biomarkers have been tested and include, for example, specific genetic aberrations [41], 
expression levels of microRNAs [42], PD-L1 expression [43] or drug-induced toxicity (chapter 
13) [44, 45]. However, most of these biomarkers lack reliability, validity, sensitivity and/or 
specificity, and have insufficient predictive power. So unfortunately, for most drugs no solid 
biomarkers predictive of response exist (yet).
Future perspectives
Traditionally, all STS subtypes were combined to achieve adequate patient numbers in clinical 
trials, which has led to a 'one size fits all' treatment approach. Based on the results in this 
thesis, but also other studies reported in literature, it is time to conclude that one size does 
not fit all. Examples include the results of chapter 2, chapter 6 and chapter 7, in which we 
show that STS and even liposarcoma is not a single entity, that treatment should be tailored to 
a specific STS/liposarcoma subtype and may be even tailored to a specific tumor localization. 
Additionally, we suggest that treatment or inclusion into clinical trials should not be solely 
based on STS subtype as classified by the WHO, but also on the genomic aberrations present 
in these tumors, since with WGS a substantial number of patients were identified who could 
benefit from personalized targeted treatment. A switch to at least a histology-driven choice 
of treatment, but preferably personalized treatment, will be crucial to further improve the 




An example of a subtype-specific as well as a tumor localization-specific treatment for 
patients with localized STS is suggested in chapter 8. In this chapter, active surveillance is 
introduced for patients with non-retroperitoneal WDLPS/ALT. Recently, we have set up a 
prospective trial in which we aim to work towards a minimally invasive approach of ALTs 
(MINIMALIST trial). This trial will combine the evaluation of a minimally invasive diagnosis 
(prospective validation of the radiomics model developed in chapter 5) and the assessment 
of the feasibility and safety of a minimally invasive treatment approach (i.e. active surveillance 
as suggested in chapter 8). Currently, the MINIMALIST trial is open for accrual in the Erasmus 
MC Cancer Institute and the first patients are being included.
In the advanced/metastatic stage, ideally a clinical trial in which STS patients are 
randomized between treatment according to the standard lines of systemic treatment for 
metastatic STS (as defined in international guidelines) and treatment according to their 
histology plus genomic alterations should define the role of personalized treatment in 
this stage. As a consequence of these subtype-specific, tumor localization-specific and/or 
personalized trials, it will become even harder and more complicated to perform research 
in these rare tumors, stressing the need and importance of more intensive national and 
international collaborations as well as of better registration of sarcomas in (inter)national 
cancer registries.
Lastly, artificial intelligence will be increasingly used. Besides differentiating lipomas 
from WDLPS and thereby ultimately omitting a biopsy, already multiple other applications 
of radiomics in non-retroperitoneal WDLPS can be thought, let alone all other possible 
applications in other STS subtypes. The three possible radiomics applications mentioned 
earlier (to predict the risk of local recurrence, tumor growth and dedifferentiation) could help 
to further tailor and personalize treatment. In case of high risk of local recurrent disease, 
two different treatment approaches might be thought of: (1) more extended surgery or 
neoadjuvant/adjuvant therapy might be needed to lower the risk of recurrence, or (2) these 
patients might be candidate for treatment with active surveillance (i.e. patient selection), 
since the tumor will recur anyway. Radiomics could also help patient selection for active 
surveillance with regards to tumor growth: patients in whom no/minimal tumor growth is 
predicted might also be good candidates for an active surveillance approach. Lastly, in case 
of high risk of dedifferentiation, treatment might be intensified by extended resection or by 
adding radiotherapy, thereby trying to lower the risk of an unfavorable outcome.
 Overall, it can be concluded that there is still a lot to gain in the knowledge of soft 
tissue sarcomas and that the gaps of the mosaic are not all filled in.
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This thesis consists of four parts. In part I we strived to gain more insight into the biology of 
soft tissue sarcomas (STS) and searched for new actionable targets for therapy. In part II, 
one of the most frequently observed STS subtypes, liposarcoma, was further examined. This 
includes the diagnosis and the outcomes of patients with different liposarcoma subtypes 
and different tumor localizations. Part III evaluated the surgical treatment of localized STS, 
on a nation-wide level as well as for a small subgroup of patients treated in the Erasmus MC 
Cancer Institute. Lastly, part IV focuses on the systemic treatment of metastatic STS. A short 
overview is given of the currently available therapies and therapies in the pipeline, followed 
by an evaluation of the survival as a result of the changes in treatment strategies.
Part I – Expanding the insight into the biology of soft tissue sarcomas
In chapter 2, the genomic landscape of metastatic STS (mSTS), including new targets for 
therapy, is described. Samples of metastatic STS were collected and analyzed by whole genome 
sequencing. Metastatic leiomyosarcomas on average had a higher tumor mutational burden 
(TMB) than the metastatic gastrointestinal stromal tumors (mGIST) or other mSTS. Kataegis 
was observed in 35 of the 122 samples and chromothripsis in 24 of the 122 samples. All 
known COSMIC mutational signatures were present and no clear differences in contributing 
signatures were seen between the different STS subtypes. In 86% of the samples at least one 
actionable target could be identified for which an FDA-approved or investigational agent is 
available. Examples include sorafenib for KIT-mutated GIST, trastuzumab for ERBB2-mutated 
leiomyosarcoma, imatinib for KIT-mutated angiosarcoma or fulvestrant for ESR1-mutated 
leiomyosarcoma and ESR1-mutated endometrial stromal cell sarcoma. Additionally, six mSTS 
samples had a TMB ≥10 and might benefit from treatment with checkpoint inhibitors. This 
study gives an important insight into the biology of mSTS and shows that whole genome 
sequencing can serve as a valuable tool to identify clinically relevant and targetable molecular 
aberrations. It thereby improves patient management and treatment decision making, even 
or especially after multiple lines of treatment.
Chapter 3 describes the association between the overexpression of miR-26a and miR-
3913, located in the 12q13-15 region, and the proliferation of well-differentiated liposarcoma 
(WDLPS) and dedifferentiated liposarcoma (DDLPS), characterized by amplification of the 
12q13-15 region. Both microRNAs were indeed overexpressed in WDLPS and/or DDLPS. 
Inhibition of these microRNAs led to decreased cellular proliferation, and inhibition of miR-
3913 also induced apoptosis in WDLPS cell lines. Additionally, miR-26a appeared to target the 
tumor suppressor PTEN. So, miR-26a and miR-3913 overexpression, most probably due to 
pathognomonic amplification of 12q13-15, seemed to promote liposarcoma development by 




that non-protein coding genes, like microRNAs, may also play an role in sarcomagenesis of 
WDLPS and DDLPS.
In chapter 4, the microRNA expression and DNA methylation patterns of paired 
primary and recurrent WDLPS were compared. The aim was to detect differences in 
microRNA expression levels and DNA methylation profiles, thereby identifying processes 
involved in recurrence. However, no distinction between primary and recurrent WDLPS could 
be made based on differentially expressed microRNAs or differentially methylated regions 
and no common drivers for recurrence could be identified. The differences, especially in DNA 
methylation patterns, were very heterogeneous and variable between patients.
Part II – Heterogeneity within the liposarcoma spectrum
In chapter 5, a new and non-invasive method to differentiate between WDLPS and lipomas 
was investigated. It can be difficult to distinguish between these two tumor types based on 
imaging, and an invasive biopsy is needed for pathological examination. Radiomics is a form 
of artificial intelligence which enables the extraction of imaging features from MRI scans and 
links them to pathological characteristics of a tumor, such as the mutational status. In this 
case, the MDM2 amplification status was used to discriminate WDLPS from lipomas: MDM2 
amplification is present in WDLPS, but absent in lipomas. The radiomics model based on T1-
weighted imaging features scored a mean AUC of 0.83, sensitivity of 0.68 and a specificity of 
0.84. These scores were compared to the scores of three trained radiologists, who scored 
an AUC of 0.74/0.72/0.61, a sensitivity of 0.74/0.91/0.64, and a specificity of 0.55/0.36/0.59, 
respectively. From these results we concluded that radiomics is a promising, non-invasive 
method to differentiate between WDLPS and lipomas. However, further optimization and 
validation is needed before radiomics can be used in daily clinical practice.
Chapter 6 evaluated the role of primary tumor localization in the local recurrence-free 
survival, the distant metastasis-free survival and the disease-specific survival of patients with 
liposarcoma. Patients with a retroperitoneal, intrathoracic or scrotal liposarcoma developed 
a local recurrence more often than patients with a tumor in the extremity, trunk or head-and-
neck region, but no differences in the development of metastases were observed. Patients 
with a retroperitoneal or intrathoracic liposarcoma had a poorer disease-specific survival, 
despite the observation that there were no differences in the development of metastatic 
disease. While most cancer patients die due to metastatic disease, these data suggest that 
these patients die of local disease and that for each tumor localization a different treatment 
approach might be preferable.
In chapter 7, we elaborated on liposarcomas in the extremity, the most common 
primary tumor localization. There were clear differences in recurrence patterns and survival 
between the different liposarcoma subtypes, indicating that extremity liposarcoma is not 




– including resection with wide margins and radiotherapy – led to excellent local control 
in extremity WDLPS, while a more conservative approach – with marginal excision and no 
radiotherapy – led to more local recurrences. However, this did not lead to an improved 
distant metastasis-free survival or disease-specific survival. Therefore, the benefits of wide 
excision and radiotherapy should be carefully balanced against the disadvantages and 
toxicity/morbidity.
Part III – Evaluation of the surgical treatment of localized soft tissue 
sarcoma
As a result of the observations in chapter 7, the treatment and outcomes of patients with 
extremity WDLPS were further examined in chapter 8. These patients rarely developed 
distant metastasis and seldom died due to their tumor. Death of disease only occurred after 
dedifferentiation of the tumor upon recurrence, which occurred sporadically. On the other 
hand, two patients died of treatment-related causes, so we wondered whether we might 
be ‘over-treating’ these patients. Therefore, we analyzed a small group of patients in whom 
deliberately an active surveillance approach was chosen. In this small cohort of patients, 
we concluded that active surveillance, also called wait-and-see or watchful waiting, is an 
appropriate and adequate treatment option in selected cases. This especially applies for 
elderly patients, patients with multiple or severe comorbidities and/or patients in whom a 
radical resection is not possible. However, the follow-up of this patient cohort is still short, and 
the feasibility and safety of active surveillance as treatment option for non-retroperitoneal 
WDLPS needs to be assessed and explored in a larger prospective clinical trial.
Chapter 9 of this thesis focuses on the centralization of soft tissue sarcoma surgery 
in the Netherlands. Because of the rarity of STS, it is estimated that a general practitioner 
only sees one patient with an STS every 20 years and a surgeon in a general hospital only 
once every 4 years. This, in combination with the heterogeneity amongst the STS subtypes 
and the fact that benign soft tissue tumors are 100x more prevalent, makes diagnosing and 
treating these tumors challenging and highlights the urgency for centralization. However, 
centralization in the Netherlands was limited until 2011 and in need of improvement. This 
study showed that centralization of STS surgery improved over time, although it is still highly 
fragmented across the country. A survival benefit was observed for patients with high-grade 
and deep-seated STS who were treated in a high-volume hospital (≥20 resections per year) 
compared to patients treated in low-volume hospitals (<10 resections per year). Additionally, 
unplanned resection and re-resections were less often performed in high-volume hospitals 
than in low-volume hospitals. Therefore, we plea for further centralization of STS care.
In chapter 10, the unplanned resections are further analyzed using data from the 




timely recognition of malignant STS can be challenging. It is not unusual that an STS is initially 
considered as benign and excised without proper diagnostic work-up and inadequate 
surgical margins. These unplanned resections are also called ‘whoops’ resections. Unplanned 
resection occurred in 17% of all primary STS resections. These tumors were generally smaller 
(≤5cm), more often located superficially and in the upper extremity, and pre-operative 
imaging was missing more often. Most unplanned resections resulted in residual disease, 
and patients more often needed to undergo a re-resection or radiotherapy. After an 
unplanned resection, patients were often referred to/discussed with a sarcoma expertise 
center, especially when there was residual tumor. To prevent unplanned resections, more 
awareness and education is needed. However, unplanned resections of small and superficial 
STS are unlikely to be completely preventable, given the high incidence of benign soft tissue 
tumors, and are partially ‘all in the game’. 
Part IV – Evaluation of the systemic treatment of metastatic soft 
tissue sarcoma
In chapter 11, a short overview of the currently available systemic therapies and the new 
therapies in the pipeline for metastatic STS is given. Despite the heterogeneity in terms 
of pathophysiology and sensitivity to chemotherapy, the first-line treatment is similar 
for almost all STS subtypes and consists of doxorubicin. Doxorubicin is mostly given as 
monotherapy, but can be combined with ifosfamide. At the time of writing this chapter, 
olaratumab was conditionally added to doxorubicin, based on a phase II trial showing an 
improvement in overall survival of almost a year. However, in the meantime, the preliminary 
results of the phase III trial have been presented; the benefit of the combination therapy 
could not be confirmed. Consequently, the conditional approval has been withdrawn. In 
second-line treatment and beyond, a histology-driven choice of treatment is much more 
common. Examples include trabectedin in (myxoid) liposarcomas and leiomyosarcomas, 
eribulin in liposarcomas, taxanes in angiosarcomas and gemcitabine-based regimens in 
leiomyosarcomas. Notwithstanding the expanding treatment options, the survival of patients 
with metastatic STS remains poor and there is an urgent need for new treatment strategies. 
Currently, all kinds of new drugs are tested, including immunotherapies, that have shown 
to be effective in other cancer types (such as ipilimumab, nivolumab and pembrolizumab).
Chapter 12 describes the change in overall survival of STS patients with metastatic 
disease at time of diagnosis (synchronous metastasis), which concerns nearly 15% of all 
newly diagnosed STS patients. Predilection sites of the metastases are the lungs, liver, bones 
and lymph nodes. These patients have a poor median overall survival, approximately 6 
months, which was slightly improving over de years. The median overall survival of these 




compare two treatment regimens (medians of 12-24 months). Possible explanations include: 
1) a considerable part of the patients in our study did not receive any treatment (due to 
contra-indications, unfitness or patients’ own wish); 2) the patients in this study probably 
were less fit than the patients included in clinical trials who need to meet strict eligibility 
criteria; 3) we only included patients with synchronous metastasis, while clinical trials mostly 
include patients who develop metastatic disease at a later point in time (metachronous 
metastasis). Patients with synchronous metastasis might represent a different and perhaps 
more aggressive subgroup of STS compared to patients with metachronous metastasis. 
In conclusion, the survival of STS patients with synchronous metastasis only improved 
minimally from 1989 until 2014, whereby the need for novel treatment strategies once again 
is emphasized.
Lastly, in chapter 13 it is investigated whether there is an association between 
pazopanib-induced toxicity and survival of patients with metastatic STS. This study was based 
on the hypothesis that the occurrence of toxicity is related to the anti-tumor activity of the 
drug, and that toxicity therefore could serve as a biomarker of efficacy. Such a biomarker is 
needed, because the response rate to pazopanib is low (<10%) and most patients therefore 
unnecessary receive this drug, along with its side-effects and toxicity. On the other side, there 
is also a small subgroup with an exceptionally good and long-lasting response to pazopanib. 
Three toxicities were studied: proteinuria, hypothyroidism and cardiotoxicity. There was no 
difference in progression-free survival or overall survival between patients with or without 
one of the toxicities. Therefore, these three toxicities cannot be used as a biomarker for 











Dit proefschrift bestaat uit vier delen. In deel I wordt gepoogd meer inzicht te krijgen in de 
biologie van wekedelen sarcomen, waarbij ook gezocht is naar nieuwe aangrijpingspunten 
voor therapie. In deel II is één van de meest voorkomende subtypes van het wekedelen 
sarcoom, het liposarcoom, onder de loep genomen. Dit omvat onder andere de diagnostiek 
en de uitkomsten van de verschillende subtypes en lokalisaties. Deel III evalueert de 
chirurgische behandeling van het gelokaliseerde wekedelen sarcoom, zowel op nationaal 
niveau voor alle wekedelen sarcomen als voor een kleine subgroep van patiënten behandeld 
in het Erasmus MC Kanker Instituut. Ten slotte focust deel IV zich op de evaluatie van de 
systemische behandeling van het gemetastaseerd wekedelen sarcoom. Eerst wordt er een 
overzicht van alle huidige therapieën gegeven, gevolgd door een evaluatie van de overleving 
ten gevolge van de veranderingen in de systemische behandeling.
Deel I – Biologie van wekedelen sarcomen
In hoofdstuk 2 hebben we met behulp van Whole Genome Sequencing (WGS) de genomische 
afwijkingen in gemetastaseerd wekedelen sarcomen in kaart gebracht. Leiomyosarcomen 
hadden gemiddeld een hoger aantal mutaties (tumor mutational burden, TMB) dan gastro-
intestinale stromale tumoren (GIST) en andere wekedelen sarcomen. Kataegis (kleine 
gebieden met hypermutaties) werd gezien in 35 van de 122 samples en chromothripsis 
(waarbij een chromosoom (deels) verpulverd wordt in kleine stukjes) in 24 samples. Alle 
bekende mutatiesignaturen, zoals beschreven in de ‘Catalogue Of Somatic Mutations In 
Cancer’ (COSMIC), waren aanwezig in de sarcomen en er waren geen duidelijke verschillen 
in bijdragende signaturen tussen de verschillende subtypes van de wekedelen sarcomen. In 
86% van de patiënten werd een ‘actionale target’ geïdentificeerd, een genetische afwijking 
waarvoor reeds geregistreerde medicatie of een middel in ontwikkeling beschikbaar is. 
Voorbeelden ontdekt in de data zijn: sorafenib voor GIST met een KIT mutatie, trastuzumab 
voor leiomyosarcomen met ERBB2 mutatie, imatinib voor een angiosarcoom met een KIT 
mutatie en fulvestrant voor leiomyosarcoom en endometrium stromacel sarcoom met een 
ESR1 mutatie. Verder waren er 6 patiënten met een TMB ≥10 die mogelijk baat kunnen 
hebben van behandeling met checkpoint inhibitors. Hiermee geeft deze studie een belangrijk 
inzicht in de biologie van het wekedelen sarcoom en laat zien dat WGS een waardevol 
instrument is om klinisch relevante moleculaire afwijkingen te identificeren. Daarmee kan 
WGS de behandeling en uitkomsten van patiënten verbeteren, zelfs of misschien juist nadat 
patiënten al meerdere lijnen therapie gehad hebben.
Hoofstuk 3 beschrijft de associatie tussen de overexpressie van 2 microRNA’s, miR-
26a en miR-3913, en de progressie van goedgedifferentieerde en gededifferentieerde 




genen kunnen reguleren en beïnvloeden. Het goedgedifferentieerde en gededifferentieerde 
liposarcoom worden beiden gekenmerkt door amplificatie van chromosoom 12q13-15, 
waarop ook zowel miR-26a als miR-3913 gelokaliseerd zijn. Beide microRNA’s bleken tot 
overexpressie te komen in goedgedifferentieerde en/of gededifferentieerde liposarcomen. 
Remming van miR-26a en miR-3913 leidde tot verminderde cellulaire proliferatie, waarbij 
remming van miR-3913 ook apoptose induceerde in goedgedifferentieerde liposarcoom-
cellijnen. Daarbij leek miR-26a de tumor suppressor PTEN te reguleren. Concluderend 
lijkt overexpressie van miR-26a en miR-3913, meest waarschijnlijk veroorzaakt door de 
kenmerkende amplificatie van 12q13-15, de ontwikkeling van liposarcomen te stimuleren 
door proliferatie te stimuleren en – in mindere mate – apoptose te remmen. Dit suggereert 
dat ook niet-eiwit coderende genen, zoals microRNA’s, een rol kunnen spelen in de 
ontwikkeling van goedgedifferentieerde en gededifferentieerde liposarcomen. 
In hoofdstuk 4 hebben we tumor samples van primaire goedgedifferentieerde 
liposarcomen vergeleken met samples van recidief goedgedifferentieerde liposarcomen. 
Dit waren gepaarde samples, wat inhoudt dat de samples van de primaire en recidief 
liposarcomen afkomstig van dezelfde patiënten waren. Dit hebben we gedaan op microRNA 
en DNA methylatie niveau, waarbij DNA methylatie een epigenetisch proces is waarmee de 
expressie van genen gereguleerd kan worden. Het doel was om verschillen, en daarmee 
processen betrokken bij recidivering, te ontdekken. Echter bleek dat er geen onderscheid 
gemaakt kon worden tussen primaire en recidief goedgedifferentieerde liposarcomen op 
basis van microRNA expressie en DNA methylatie patronen. De verschillen, met name in DNA 
methylatie patronen, waren erg heterogeen en variabel tussen de verschillende patiënten. Er 
konden geen gemeenschappelijke patronen geïdentificeerd worden, en daarmee ook geen 
aanwijzingen naar een specifiek proces dat betrokken zou zijn bij de recidivering van deze 
tumoren. 
Deel II – Heterogeniteit binnen de liposarcomen
In dit deel worden de liposarcomen verder onder de loep genomen. In hoofdstuk 5 hebben 
we gezocht naar een non-invasieve methode om goedgedifferentieerde liposarcomen 
te kunnen onderscheiden van lipomen. Deze twee tumoren kunnen op een MRI-scan er 
nagenoeg hetzelfde uitzien en daarom wordt er vaak een invasief biopt afgenomen. Dit 
biopt wordt vervolgens door de patholoog bekeken om de juiste diagnose te kunnen 
stellen. Radiomics is een vorm van kunstmatige intelligentie waarbij beeldkarakteristieken 
uit een MRI-scan gelinkt kunnen worden aan pathologische kenmerken, zoals bijvoorbeeld 
de mutatiestatus. In dit geval is dat amplificatie van het MDM2-gen: dit is aanwezig in 
goedgedifferentieerde liposarcomen, maar afwezig in lipomen. Het radiomics model 




een sensitiviteit van 0.68 en een specificiteit van 0.84. Deze scores zijn vergeleken met 
de scores van 3 radiologen. Respectievelijk scoorden zij een AUC van 0.74/0.72/0.61, 
sensitiviteit van 0.74/0.91/0.64 en een specificiteit van 0.55/0.36/0.59. Hieruit concludeerden 
we dat radiomics een veelbelovende en non-invasieve methode is om goedgedifferentieerde 
liposarcomen van lipomen te onderscheiden. Echter is verdere optimalisatie en validatie 
nodig is voordat het radiomics model bruikbaar is in de dagelijkse klinische praktijk.
Hoofdstuk 6 evalueert de rol van tumorlokalisatie in de lokaal recidief-vrije overleving, 
afstandsmetastase-vrije overleving en ziekte-specifieke overleving van patiënten met 
een liposarcoom. Hieruit bleek dat patiënten met een liposarcoom dat retroperitoneaal, 
scrotaal of intra-thoracaal gelokaliseerd was vaker een lokaal recidief ontwikkelden dan 
patiënten met een liposarcoom in één van de ledematen, de romp of het hoofd-halsgebied. 
Er werden geen verschillen gevonden in de ontwikkeling van afstandsmetastasen tussen 
de verschillende tumorlokalisaties. Patiënten met een retroperitoneaal of intra-thoracaal 
liposarcoom hadden een slechtere ziekte-specifieke overleving, ondanks dat deze patiënten 
even vaak metastasen ontwikkelden. Waar de meeste kankerpatiënten overlijden aan 
gemetastaseerde ziekte, suggereert deze data, in combinatie met het vaker ontwikkelen 
van een lokaal recidief, dat patiënten met een retroperitoneaal/intra-thoracaal liposarcoom 
overlijden aan lokale ziekte. Mogelijk moet de behandeling voor het liposarcoom per tumor 
lokalisatie aangepast worden.
In hoofdstuk 7 wordt nader ingegaan op de liposarcomen gelokaliseerd in een 
ledemaat, de meest voorkomende lokalisatie van het liposarcoom. Er waren duidelijke 
verschillen in recidivering en overleving tussen de vier liposarcoom subtypes. Verder bleek 
dat bij patiënten met een goedgedifferentieerd liposarcoom een agressievere behandeling 
– bestaande uit ruime resectie en (neo)adjuvante radiotherapie – tot uitstekende lokale 
controle leidde, terwijl een meer conservatieve behandeling – met een marginale resectie 
zonder (neo)adjuvante therapie – resulteerde in meer lokale recidieven. Echter bleek ook 
dat dit uiteindelijk geen effect had op de ziekte-specifieke overleving van deze patiënten. De 
voordelen van ruime resectie en radiotherapie dienen daarom zorgvuldig afgewogen tegen 
de nadelen en toxiciteit hiervan.
Deel III – Chirurgische behandeling van het gelokaliseerde wekedelen 
sarcoom
Naar aanleiding van de resultaten uit hoofdstuk 7, zijn de behandeling en uitkomsten van 
patiënten met een goedgedifferentieerd liposarcoom in een ledemaat nader onderzocht in 
hoofdstuk 8. Het bleek dat deze patiënten maar zelden afstandsmetastasen ontwikkelden 
en zelden overleden aan de ziekte. Dit gebeurde alleen wanneer de patiënt een lokaal recidief 




bleek ook dat er patiënten overleden waren aan de behandeling. Daarop vroegen we ons 
af of we deze patiënten niet aan het overbehandelen zijn. Met deze reden hebben we een 
kleine groep patiënten geanalyseerd die onder controle werden gehouden zonder actieve 
behandeling (active surveillance). Hieruit kon geconcludeerd worden dat active surveillance 
in bepaalde patiënten een goede en gerechtvaardigde behandeloptie lijkt te zijn. Dit geldt 
met name voor oudere patiënten, patiënten met (meerdere) comorbiditeiten en/of patiënten 
waarbij de tumor ongunstig gelokaliseerd ligt waardoor een radicale resectie niet haalbaar is. 
Echter is de follow-up van deze groep patiënten nog kort en dient de haalbaarheid en veiligheid 
van active surveillance als behandeling voor non-retroperitoneale goedgedifferentieerde 
liposarcomen nog op grotere schaal in een prospectieve studie uitgezocht te worden.
Hoofdstuk 9 van dit proefschrift richt zich op de centralisatie van wekedelen chirurgie 
in Nederland. Gezien de zeldzaamheid van wekedelen sarcomen, wordt er geschat dat 
een huisarts maar 1x in de 20 jaar een patiënt met een wekedelen sarcoom ziet en een 
algemeen chirurg in een perifeer ziekenhuis 1x in de 4 jaar. De zeldzaamheid, in combinatie 
met het bestaan van vele verschillende subtypes en het feit dat goedaardige wekedelen 
tumoren 100x zo vaak voorkomen, maakt het diagnosticeren en behandelen van wekedelen 
sarcomen zeer uitdagend. Dit roept logischerwijs de noodzaak tot centralisatie op en 
daarom zijn in Nederland een aantal expertisecentra aangewezen. Dit onderzoek liet zien 
dat de centralisatie van wekedelen chirurgie verbeterd was in de afgelopen 10 jaar, alhoewel 
er nog steeds veel ruimte voor verbetering is. Daarnaast zagen we dat patiënten met een 
hooggradig en diep-gelegen sarcoom een betere overleving hadden wanneer ze geopereerd 
waren in een hoog-volume ziekenhuis (≥20 operaties per jaar) ten opzichte van patiënten die 
in een laag-volume ziekenhuis geopereerd waren (<10 operaties per jaar). Verder vonden 
er minder vaak ongeplande resecties en re-resecties plaats in hoog-volume ziekenhuizen. 
Derhalve pleiten wij voor verdere centralisatie van de zorg voor wekedelen sarcomen. 
In hoofdstuk 10 worden de ongeplande resecties verder uitgelicht met data uit 
de Nederlandse Kankerregistratie. Gezien goedaardige wekedelen tumoren veel vaker 
voorkomen dan kwaadaardige wekedelen sarcomen, kan het tijdig herkennen van een 
sarcoom lastig zijn. Het is niet ongebruikelijk dat een wekedelen sarcoom initieel voor een 
goedaardige tumor wordt aangezien en verwijderd wordt zonder adequate diagnostiek 
voorafgaand aan de operatie en zonder de juiste chirurgische marges. Deze ongeplande 
sarcoomresecties worden daarom ook wel ‘whoops’ resecties genoemd. In 17% van alle 
primaire sarcoom operaties was er sprake van een ongeplande resectie. Deze wekedelen 
sarcomen waren over het algemeen kleiner (≤5cm), oppervlakkig gelegen, gelokaliseerd in 
de arm en er was vaker geen beeldvorming verricht voorafgaand aan de operatie. Na de 
meeste ongeplande resecties was er sprake van resterende ziekte. De patiënten moesten 




na een ongeplande resecties vaker verwezen naar of besproken met een sarcoom 
expertisecentrum, met name als er resterende ziekte was. Om deze ongeplande resecties te 
voorkomen is meer onderwijs en bewustwording nodig. Echter zullen ongeplande resecties 
van oppervlakkige en kleine wekedelen sarcomen nooit helemaal voorkomen kunnen worden 
vanwege de hoge incidentie van goedaardige wekedelen tumoren en zijn deze resecties voor 
een deel ‘all in the game’.
Deel IV – Systemische behandeling van het gemetastaseerde 
wekedelen sarcoom
In hoofdstuk 11 wordt een kort overzicht van zowel de huidige behandelstrategieën als nieuwe 
behandelingen die momenteel onderzocht worden voor het gemetastaseerd wekedelen 
sarcoom gegeven. Ondanks de heterogeniteit met betrekking tot de pathofysiologie en 
de wisselende gevoeligheid voor chemotherapie, is de eerstelijns therapie voor vrijwel alle 
subtypes van het wekedelen sarcoom hetzelfde. Deze bestaat uit doxorubicine, vaak als 
monotherapie, maar soms in combinatie met ifosfamide. Ten tijde van het schrijven van dit 
hoofdstuk was olaratumab (conditioneel) toegevoegd aan de eerstelijnstherapie, gebaseerd 
op de resultaten van een fase II studie waarbij de algehele overleving bijna een jaar toenam. 
Echter zijn de eerste resultaten van de fase III trial inmiddels bekend; er was geen verschil 
in overleving tussen de groep met de combinatietherapie en de groep met doxorubicine 
monotherapie. Derhalve is de voorwaardelijke goedkeuring voor olaratumab inmiddels weer 
ingetrokken. In de tweede lijn wordt wel steeds vaker naar subtype-specifieke behandelingen 
gekeken. Voorbeelden zijn trabectedine in (myxoid) liposarcomen en leiomyosarcomen, 
eribuline in liposarcomen, taxanen in angiosarcomen en gemcitabine in leiomyosarcomen. 
Ondanks dat er steeds meer behandelopties bij zijn gekomen, blijft de overleving van 
patiënten met gemetastaseerd wekedelen sarcoom slecht en is onderzoek naar nieuwe 
therapieën nodig. Onder andere immunotherapieën – zoals ipilimumab, nivolumab of 
pembrolizumab – die reeds gebruikt worden bij andere kankersoorten, worden momenteel 
getest in patiënten met een wekedelen sarcoom.
Hoofdstuk 12 beschrijft de verandering in de overleving van patiënten met een 
wekedelen sarcoom dat bij diagnose reeds gemetastaseerd is (synchrone metastasen). 
Ongeveer 15% van de patiënten heeft bij diagnose al afstandsmetastasen, waarbij de 
voorkeurslokalisaties de longen, lever, botten en lymfeklieren waren. Deze patiënten hebben 
een slechte algehele overleving, mediaan ca. 6 maanden, al was er een verbeterende trend 
over de tijd zichtbaar. De mediane overleving van deze groep patiënten ligt een stuk lager 
dan de overleving die in andere klinische studies beschreven wordt (ca. 12-24 maanden), 
waarin verschillende chemotherapie-regimes onderzocht wordt. Hier zijn een aantal 




behandeling gehad hebben (niet mogelijk of eigen wens/keuze); 2) de patiënten in deze 
studie zijn waarschijnlijk minder fit dan de patiënten die meedoen aan een klinische studie, 
waarbij er vaak strenge in- en exclusiecriteria gehandhaafd worden; 3) in deze studie zitten 
alleen patiënten met synchrone metastasen, terwijl in de andere studies vooral patiënten 
zitten die pas later metastasen ontwikkeld hadden (metachrone metastasen). De patiënten 
die zich met synchrone metastasen presenteren, hebben mogelijk een agressievere 
vorm van het wekedelen sarcoom, en daardoor een slechtere prognose. Al met al is de 
overleving van patiënten met synchrone metastasen maar minimaal toegenomen van 1989 
tot 2014, waarmee opnieuw het belang en de noodzaak van het ontwikkelen van nieuwe 
behandelstrategieën benadrukt wordt.
Tenslotte wordt er in hoofdstuk 13 onderzocht of er een associatie bestaat tussen 
door pazopanib-geïnduceerde toxiciteit en de overleving van patiënten met gemetastaseerd 
wekedelen sarcoom. Deze onderzoeksvraag is gebaseerd op de hypothese dat het optreden 
van toxiciteit gerelateerd is aan de anti-tumor werking van het middel, en dat toxiciteit daarom 
gebruikt kan worden als biomarker voor de werkzaamheid van het middel. Een dergelijke 
biomarker is nodig, omdat het aantal patiënten dat respondeert op pazopanib heel laag ligt 
(<10%), en dus een groot gedeelte van de patiënten onnodig deze medicatie krijgt, inclusief 
bijwerkingen en toxiciteit. Echter is er ook een subgroep van patiënten die uitzonderlijk goed 
reageert op pazopanib en een langdurige respons heeft. In deze studie is gekeken naar 3 
toxiciteiten: proteïnurie, hypothyreoïdie en cardiotoxiciteit. Er bleek geen verschil te zijn in 
progressie-vrije overleving of algehele overleving tussen patiënten met of zonder één van 
deze toxiciteiten. Deze toxiciteiten kunnen daarom niet gebruikt worden als biomarker voor 
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De parallel met het mozaïek heeft niet alleen betrekking op de inhoud van dit proefschrift, 
maar ook op alle de mensen die belangrijk zijn geweest voor het tot stand komen van dit 
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ik nu soms nog steeds niet weet wat ik kan verwachten, met als toppunt vanuit het niets 
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geroepen werd en de grappen tijdens de tumorwerkgroep missen. Noemenswaardig vind ik 
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Femke, Bodine, Daan, Koen, Ruben, Louwrens en Florence. Bedankt dat jullie mij in het 
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Tenslotte, Anne-Rose, bedankt voor het overnemen van het stokje, ik weet zeker dat de 
MINIMALIST bij jou in goede handen is en een succes wordt!
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Beste collega’s en kinderartsen van de Kindergeneeskunde uit het Haaglanden 
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 Lieve paranimfen, bedankt dat jullie hier vandaag naast mij staan en mij voorzien 
van mentale support. Lieve Milea, mijn mede-wekedelen onderzoeker en wekedelen maatje. 
Het bleek ontzettend moeilijk voor sommige mensen (met name een bepaalde 2-meter lange 
professor, maar ik zal geen namen noemen)  om onze namen uit elkaar te houden en zijn we 
daarom maar omgedoopt tot M&M. Ook het aanmeten van onze ‘ghetto’ namen, Shaniqua 
en Shay’Nay’Nay, mocht niet baten. Vaak deelden we dezelfde frustraties en liepen we tegen 
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ben ik dan ook op jou dat jij hier vlak voor mij stond! Lieve Noor, van 1e-jaars studiegroep-
genoten tot nog steeds goede vriendinnen jaren later en beide promovendi. Ook jij bedankt 
voor al je steun, voor alle koffies en lunches/etentjes waarbij we ons onderzoeksleed konden 
delen. Hopelijk blijven we dit voortzetten tijdens onze assistententijd. Ik kijk uit naar de dag 
dat jij hier staat!
Lieve vriendinnen, Noor, Lindsay, Linsey, Roxanna, Luciënne en Eva, ook jullie 
bedankt voor alle gezelligheid, afleiding en ontspanning de afgelopen jaren. Bedankt voor 
jullie vriendschap. Lindsay, van huisgenoot tot goede vriendin en mede-promovendus bij 
dezelfde professor, ook jij heel erg bedankt voor alle steun en toeverlaat de afgelopen jaren. 
Ik kijk uit naar jouw promotie!
Lieve tennismaatjes, met name Fred en Caroline, ook bij jullie heb ik de afgelopen 
jaren regelmatig even mijn hoofd leeg kunnen maken en heb ik met veel plezier met jullie op 
de baan gestaan, waarvoor ik jullie wil bedanken.
Lieve familie, opa & oma’s, Shirley, maar in het bijzonder lieve papa en mama, zonder 
jullie had ik hier niet gestaan. Woorden kunnen niet omschrijven hoe dankbaar ik jullie ben. 
Jullie hebben mij altijd onvoorwaardelijk gesteund en altijd in mij geloofd. Jullie hebben mij 
altijd aangemoedigd om mijn eigen weg te kiezen en ik kan altijd bij jullie terecht. Ik weet niet 
hoe ik jullie hier ooit genoeg voor kan bedanken, ik hou van jullie.
Lieve Roderik, mijn laatste dankwoord is voor jou. Ook al werd het aangaan van een 
relatie tijdens mijn promotietijd mij ten strengste verboden door beide professoren en houd 
ik mij normaal netjes aan de regels, deze ‘regel’ heb ik maar al te graag aan mijn laars gelapt. 
Ook jij hebt mij vanaf begin af aan altijd gesteund en me alle vrijheid gegeven om dit te 
kunnen bereiken, waardoor ik mijzelf nu dan toch echt slimmer dan jij mag noemen. De 
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afgelopen jaren hebben we al een aantal mooie reizen mogen maken, ik hoop dat we dat 
we de komende jaren blijven doen. Ik had deze tijd nooit met iemand anders willen delen, 
bedankt voor je onvoorwaardelijke steun en liefde. Ik ben gek op je.

